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Bladder cancer is an important public health issue, because of its high incidence, 
especially in high income countries, and the high medical care costs resulting 
from the frequent tumour recurrences necessitating repeated interventions.1, 2 
The majority of malignant tumours arising in the urinary bladder are epithelial in 
origin, and approximately 90% correspond to histologically defined “urothelial 
cell carcinoma” (UCC).3 Tobacco use is the most important modifiable risk 
factor for bladder cancer.4 Other well-established risk factors are occupational 
exposures to carcinogens like aromatic amines and polycyclic aromatic 
hydrocarbons (PAHs)5, family history6 and specific low-penetrance genetic 
susceptibility variants, such as in NAT2 and GSTM17. However, the occurrence 
of bladder cancer is not fully explained by these risk factors. Other etiological 
factors still need to be identified. 
Dietary habits are recognized to be important modifiable risk factors influencing 
cancer risk and prevention. During the past decades there has been considerable 
interest in the role of fruit and vegetables in the prevention of bladder cancer. 
Fruit and vegetables contain vitamins, minerals and other bioactive compounds 
with anticarcinogenic activity, and could therefore play a role in the prevention 
of bladder cancer. In 2007, the World Cancer Research Fund (WCRF) and the 
American Institute of Cancer Research (AICR) concluded that the evidence for 
an association between fruit and vegetable consumption and bladder cancer 
is limited.8 The weak protective or null associations in epidemiological studies 
may be explained by the fact that most studies had a relatively short follow-up 
period, included relatively few participants and thereby lacked power to detect 
associations. Inconsistent results may also partly be due to the fact that most 
studies assessed ranking of fruit and vegetable consumption through dietary 
questionnaires. Methods for assessing diet are prone to measurement error and 
have difficulty in accurately quantifying the amount of intake. Thus, accurate 
assessment of consumption of foods is difficult and small effects may be 
missed.9, 10 Even small effects, however, can have large impact on public health 
leading to preventive dietary recommendations on a population scale. 
Biomarkers, as indicators of dietary intake or nutritional status, offer an 
important opportunity for improving measurement of exposure as they do not 
rely on self-reports of food intake. Therefore, random measurement errors of 
the dietary biomarkers are not likely to be correlated with those of the dietary 
assessment method.11, 12 As fruits and vegetables are the primary source of 
dietary carotenoids and vitamin C, blood levels of these nutrients have been 
considered as useful biomarkers of fruit and vegetable consumption despite 
individual variability in absorption, availability and metabolism.13, 14 At least 40 
different carotenoids are present in the human diet15, but major carotenoids 
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circulating in plasma include: α-carotene, α-carotene, α-cryptoxanthin, lycopene, 
lutein and zeaxanthin.16 In addition to their antioxidative properties, α- and 
α-carotene and α-cryptoxanthin can be metabolized to retinol and thereby 
induce epithelial cell differentiation.17 Vitamin C and tocopherols are important 
components of the antioxidant defence system and have been hypothesized to 
act synergistically because vitamin C may regenerate the antioxidant activity of 
tocopherols.18, 19 Fruit and vegetables are also rich sources of folate, and blood 
levels of folate are another biomarker for the intake of these food items.20, 21 
Folate, in combination with homocysteine and vitamins B2, B6 and B12, is 
involved in DNA synthesis, DNA methylation and DNA repair.22 Currently, the 
relationships between circulating levels of the specific components and bladder 
cancer risk have been examined in only a small number of epidemiological 
studies, mostly case-control studies, and often with small sample sizes.23-28 
With regard to other dietary factors, it is postulated that the intake of fluid 
may influence the risk of bladder cancer through several proposed mechanisms. 
Bladder cancer may be related to prolonged contact time of carcinogens with the 
urothelium. Higher fluid intake may play a protective role by diluting the urine 
or increasing the frequency of urination.29 However, an opposite mechanism 
was proposed to explain the postulated increase in bladder cancer risk. A high 
intake of fluids could increase the risk if fluids contain contaminants that are 
bladder carcinogens. Bladder wall extension associated with a high intake of 
fluids or a lower miction frequency may allow the carcinogens in the urine 
to come into contact with the deeper layers of the bladder urothelium.30 An 
international panel of experts, coordinated by WCRF/AICR, concluded in 2007 
that evidence for an association of total fluid intake in relation to bladder cancer 
risk is limited.8 
Besides nutritional factors that may influence bladder cancer risk, the use of hair 
dyes has been suggested as a risk factor for bladder cancer. Components of hair 
dyes include aromatic amines.31 Occupational exposure to hair dyes has been 
associated with an increased bladder cancer risk.32 This has raised concerns that 
personal hair dye use may also increase the risk of bladder cancer. Despite the 
majority of the epidemiological studies reporting null associations, the use of 
personal hair dyes still leads to discussions about its impact on human health.33
Urothelial cell carcinoma of the bladder represents a heterogeneous group 
of tumours characterized by different molecular pathways. The low grade, 
papillary tumours are characterized by activating mutations in the HRAS and 
FGFR3 oncogenes and chromosome 9 aberrations; the high grade solid tumours 
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are characterized by structural and functional defects in the TP53 and RB 
tumour suppressor genes.34, 35 The prognosis of UCC depends on the stage and 
grade of the tumour.36 Because of the variation in histopathology and clinical 
behaviour, stratification into different bladder cancer subgroups according to 
stage and grade may help in identifying risk factors involved in different UCC 
pathways. Despite the different molecular aberrations and related differences 
in prognosis, scarce data exist about a different aetiology between low-grade 
and high-grade tumours. To date, no epidemiological studies on nutritional 
blood levels distinguished UCC by tumour aggressiveness. 
AIMS AND OUTLINE OF THE THESIS
This thesis focuses on a better understanding concerning the risk factors for 
urothelial carcinomas of the bladder from an epidemiological perspective. We 
studied the role of specific nutritional biomarkers, dietary and lifestyle habits in 
the aetiology of UCC.
The main objective of this thesis was to study the association between 
prediagnostic blood concentrations of carotenoids (α- and α-carotene, 
α-cryptoxanthin, lycopene, lutein and zeaxanthin), vitamin C, retinol, 
tocopherols (α- and α-tocopherol) and nutrients involved in the one-carbon 
metabolism (folate, homocysteine, vitamin B6 and vitamin B12) and the 
subsequent risk of UCC. In addition, reliability of repeated measurements of 
nutritional biomarkers was investigated. Furthermore, we studied the relation 
between fruit and vegetable consumption, fluid intake and the use of hair dyes 
on the development of UCC.
The research described in this thesis is mostly carried out within the European 
Prospective Investigation into Cancer and Nutrition (EPIC), comprising more 
than half a million people recruited in 23 centres in 10 European countries 
(Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, 
and the United Kingdom). This large multi-centre prospective cohort study was 
designed to investigate the relation between prediagnostic food, nutritional 
status, various lifestyle and environmental factors and the subsequent 
development of cancer.37, 38 In addition, case-control data of the Nijmegen 
Bladder Cancer Study (NBCS) were used.39, 40 
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Chapter 2 provides an overview of the epidemiology and genetic susceptibility to 
bladder cancer. Chapter 3 describes the association between fruit and vegetable 
consumption and the risk to develop UCC, stratifying for aggressive and non-
aggressive UCC. In chapters 4 to 6 the associations between circulating levels 
of carotenoids and vitamin C (Chapter 4), folate and other B-vitamins (Chapter 
5), retinol and tocopherols (Chapter 6) and the subsequent development of UCC 
are presented. Chapter 7 evaluates the reliability of blood concentrations of 
antioxidants and markers of one-carbon metabolism. In Chapter 8 the relation 
between fluid intake and the risk of UCC is reported. The association between 
personal hair dye use and the risk of bladder cancer is described in Chapter 9. In 
Chapter 10, the main findings of this thesis are discussed. 
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ABSTRACT 
The incidence of bladder cancer varies considerably among countries; the 
highest incidence rates are in Western communities. The variation in occurrence 
can partly be explained by differences in registration and coding practices of pTa 
tumours. Factors that modify the occurrence of bladder cancer are smoking 
and exposure to many kinds of carcinogenic substances in the workplace. 
Evidence also exists for radiotherapy to the pelvis, infection with Schistomsoma 
haematobium, and certain medications as risk factors for bladder cancer. Despite 
enormous efforts, other important environmental or lifestyle factors that clearly 
and consistently increase or decrease the risk of bladder cancer have not been 
identified. Bladder cancer in first-degree relatives doubles the risk of bladder 
cancer; this increased risk might be due to high-penetrance susceptibility genes 
in a small subset of families, but most of this risk is probably caused by common 
lower-penetrance DNA variants that influence risk through one or more 
different cancer pathways. In the next 2 years genome-wide association scans 
will probably yield important new information on such variants. This might also 
facilitate new studies on lifestyle factors restricted to groups of susceptible 
people. In the future, it will also be necessary to pay more attention to potential 
risk factors for different types of bladder cancer, more specifically low grade 
vs. high grade cancer. The ultimate goal is to build a risk-prediction model by 
integrating environmental and genetic factors that can project individualized 
probabilities of developing bladder cancer.
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INTRODUCTION
Worldwide, bladder cancer is the seventh most common malignancy in men 
and the 17th in women. In 2002, approximately 357,000 new cases of bladder 
cancer were diagnosed, while 145,000 patients died from the disease.1 In 
Europe and the USA, bladder cancer accounts for 5-10% of all malignancies 
among males2. The age-adjusted incidence rates of bladder cancer (Figure 1)3 
are particularly high in Southern Europe, Northern Africa, North America and 
Western Europe; incidence rates are low in Japan, Korea and China. Part of 
the differences between countries is caused by differences in registration or 
reporting of (low-grade) pTa tumours. Unfortunately, this makes the comparison 
between countries very difficult. 
Figure 1. Age-standardized (world) incidence rates (per 100,000) of bladder cancer 3
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Age-standardized (world) mortality rates vary from 2-10 per 100,000 males and 
0.5-4 per 100,000 females. Bladder cancer is three to four times more common 
among males than among females.1 The excess of bladder cancer in males is 
largely but possibly not fully explained by gender differences in smoking habits 
and occupation (the two strongest risk factors for bladder cancer). African-
Americans have a lower incidence of bladder cancer, but a higher mortality 
than Caucasians. African-Americans are being diagnosed with more aggressive 
and more advanced tumors.4 Non-urothelial bladder cancer also is found more 
commonly in African- Americans, and this might adversely affect survival. 
Not all survival differences between African-Americans and Caucasians 
can be explained by differences in stage at presentation. Also racial biologic 
variations and within-race individual differences might modify various phases of 
carcinogenesis, such as the capacity to convert pro-carcinogens to carcinogens, 
to detoxify carcinogens, and to repair DNA. 
RISK FACTORS 
Tobacco 
The most well established risk factor for bladder cancer is cigarette smoking, 
although the association is not as strong as that for smoking and respiratory 
tract cancers. Compared to those who have never smoked cigarettes, people 
who have ever smoked cigarettes have two to four times the risk of bladder 
cancer5-7; 30-50% of all bladder cancer is caused by cigarette smoking.5, 6 
Bladder cancer risk tends to increase with both increasing duration and 
increasing intensity of cigarette smoking5, 8. Stopping smoking decreases 
the risk of bladder cancer immediately, and by 30% after 1-4 years and 60% 
after 25 years.8 Smokers of unfiltered cigarettes have a 35-50% higher risk of 
bladder cancer than to smokers of unfiltered cigarettes.5 The risk associated 
with smoking ‘black tobacco’ cigarettes is higher than that of ‘white tobacco’ 
cigarettes, although studies disagree about the level of this difference in risk.9-11 
4-aminobiphenyl has been suggested to be the most important carcinogen in 
cigarette smoke, but other factors such as α-naphtylamine, benzene, cadmium, 
chromium, radon, vinyl chloride, nickel and > 60 other carcinogenic substances 
are also important. Worldwide, time trends in bladder cancer follow trends in 
smoking behaviour, comparable to time trends in lung cancer but with a longer 
delay. In most Western communities the bladder cancer incidence and mortality 
in men has decreased in the last decade. In Europe, bladder cancer age-
standardized mortality rates declined about 16% in men and 12% in women in 
the last decade.12 
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OCCUPATION 
It has been estimated that occupational exposures could account for as much 
as 20% of all bladder cancer.13 Exposure to α-naphtylamine, 4-aminobiphenyl 
and benzidine, principally among workers in the textile dye and rubber tyre 
industry, are the only specific agents that have been unequivocally associated 
with bladder cancer, with extremely high relative risks (RRs).5,14 Currently these 
specific chemicals are banned from the workplace and contribute minimally 
to the current incidence of bladder cancer in Western countries. However, 
there remain many other strong candidates for bladder carcinogens, e.g. ortho-
toluidine, which is still used in the manufacture of dyes, rubber, pharmaceuticals, 
and pesticides.5, 14, 15 
Elevated risks are commonly reported among painters (exposure to possible 
carcinogenic constituents of paints, e.g. benzidine, polychlorinated biphenyls, 
formaldehyde, and asbestos and solvents like benzene, dioxane, and methylene 
chloride). A recent meta-analysis showed an increased risk (RR 1.17; 95%CI: 
1.11-1.23) of bladder cancer among painters.16 An increased risk was also found 
among leather workers and shoe makers, although the responsible agent is still 
unknown. A moderately increased risk of bladder cancer (odds ratio, OR 1.11; 
95%CI: 1.04-1.18) was reported in aluminum-, iron- and steelworkers, which 
might be the result of exposure to aromatic amines and polycyclic aromatic 
hydrocarbons in coal-tar pitch volatiles.17 
Many studies have assessed the relation between bladder cancer and diesel 
exhaust exposure, and evidence is accumulating that diesel exhaust moderately 
increases the risk of bladder cancer. An increased bladder cancer risk was 
detected among drivers of trucks (OR 1.17; 95%CI: 1.06-1.29) and buses (1.33; 
95%CI: 1.22-1.45).18 There seems to be a positive trend in risk with increasing 
duration of employment. Although an increased risk of bladder cancer has been 
reported for many other occupations, findings for most of these occupations 
are not consistent.19,20
DRINKING WATER QUALITY AND TOTAL FLUID INTAKE 
Chlorinated drinking water
In the USA, Canada and many other countries, but not in Western Europe, 
drinking water is disinfected with chlorine. During the chlorination process, 
chlorine reacts with organic compounds in water, resulting in halogenated 
organic compounds (mainly trihalomethanes such as chloroform and 
bromoform). Bioassays and in vitro studies suggest that some of these 
halogenated compounds are mutagenic or carcinogenic. However, a study from 
Australia found that the trihalomethane concentration in chlorinated drinking 
water was not related to DNA damage in bladder cells.21 
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Several studies22-24 on chlorinated drinking water and bladder cancer all reported 
increased risks. The (smoking adjusted) RRs varied from 1.4 to 2.2 for both 
sexes combined (exposure time varied from 20 to >60 years). In most studies 
the risks tend to increase with duration of exposure. Despite this, a report from 
the International Agency for Research on Cancer in 199925 concluded that there 
was inadequate evidence that the individual chlorination by-products such 
as chloroform and other trihalomethanes were carcinogenic. Although some 
studies had associated chlorinated drinking water intake with cancer, it was 
argued that single compounds could not be evaluated because these compounds 
occur in mixtures. A report of the WHO26, published in 2000, concluded that 
the evidence was insufficient to determine whether observed associations were 
causal or to determine which specific by-product or contaminant plays a role.
Villanueva et al.27 reported two pooled analyses, in which primary data from 
six case-control studies with individual-based exposure assessments were 
pooled. These studies used trihalomethanes as a marker for the total mixture of 
chlorination by-products. The average trihalomethane levels in the studies was 
10-30 µg/L. Exposure to trihalomethanes was associated with an excess risk 
among ever-exposed men (OR 1.32; 95%CI: 1.10–1.59). The risk increased with 
increasing exposure. There was no detectable increased risk among women. In 
conclusion, exposure to chlorinated drinking water might increase the risk of 
bladder cancer. The observed risks are relatively small, but if there is a great 
risk then the attributable risk will be considerable, because of the size of the 
exposed population. 
Arsenic in drinking water
Several large studies have evaluated the association between the ingestion of 
arsenic in drinking water and the risk of bladder cancer. Several studies were 
reported from the endemic area of Taiwan. Between 1930 and the mid-1960s, 
the population in this region was exposed to highly contaminated well-water 
(arsenic levels of 170-800 µg/L; the current regulation is a maximum of 10 
µg/L in Taiwan). These studies showed a clear dose-response relationship with 
bladder cancer.28 Bangladesh and West Bengal have a chronic problem with very 
high concentrations of arsenic in drinking water, which in some sources exceed 
2000-4000 µg/L.29 Arsenic levels in drinking water in the USA and Europe are 
much lower than those reported in regions of Asia. Overall, no clear association 
was found between low-intermediate exposure to arsenic in drinking water and 
the risk of bladder cancer.
Total fluid intake
High consumption of fluids might reduce the exposure to carcinogens by 
diluting the urine and reducing the contact time through increased frequency 
of urination. Results from fluid intake studies are inconsistent30-33, but there is 
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a tendency towards a reduced risk with high intake of fluids, regardless of type. 
Confounding might be caused by a possible harmful effect of chlorinated or 
arsenic-containing drinking water. A recent pooled analysis based on six case-
control studies found an increased risk between tap-water and bladder cancer 
but none for fluid intake other than tap-water.32 These findings suggest that 
contaminants in tap-water might be responsible for the excess risk. Confounding 
might also be caused by a possible harmful effect of coffee, as well as a possible 
beneficial effect of fruit and vegetable juices.
MEDICAL HISTORY 
Chronic urinary tract infection is associated with the development of bladder 
cancer, especially invasive squamous cell carcinomas (SCC).34-36 This type of 
cancer can occur in patients with spinal-cord injury in whom chronic cystitis is 
inevitable. This might be the result of formation of nitrites and nitrosamines by 
bacterial flora, and/or the inflammatory process, which leads to an increased cell 
proliferation, providing more opportunities for spontaneous DNA replication 
errors. 
Heavy consumption of phenacetin-containing analgesics increases the risk of 
renal pelvis and ureteric urothelial cell carcinoma, but has only a marginal effect 
on bladder cancer risk.37, 38 Because of its carcinogenic properties, the drug 
was initially banned from general use in the 1960s and 70s in most Western 
countries. The ban was later revoked is some countries but its legal use (the 
drug is being used as a cutting agent for cocaine) is highly restricted because of 
the dangers it poses. 
Cyclophosphamide, an alkylating agent that is used in the treatment of malignant 
neoplasms, increases the risk of bladder cancer (mainly urothelial cell carcinoma) 
with a clear dose-response relation.39 It is acutely toxic to the bladder mucosa 
and produces cellular abnormalities in the epithelium. Most cyclophosphamide-
induced tumours present as muscle-infiltrating lesions at the time of diagnosis, 
with a relatively short latency period (6-13 years). Of four known metabolites 
of cyclophosphamide, acrolein and phosphamide mustard bind to DNA, and 
acrolein is known to be responsible for its bladder toxicity. Radiotherapy is also 
a known risk factor for bladder cancer. Kaldor et al.40 reported a case-control 
study of tumours of the bladder in women who had previously been treated for 
ovarian cancer. The risk of bladder tumours was greater for patients who had 
been treated with radiotherapy or chemotherapy (thiotepa and melphalan) than 
in those treated with surgery. Moreover, the risk seemed to be much higher 
in patients who received both. In another study, Neugut et al.41 also found an 
increased risk of bladder cancer (RR 1.5; 95%CI: 1.1-2.0) several years after 
radiotherapy for prostate carcinoma. 
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Schistosomiasis (Bilharsia)
SCC of the urinary bladder has been associated with Schistosoma haematobium 
infection for many years. The epidemiologic association is based both on case-
control studies42, 43 and on the close correlation of bladder cancer incidence with 
the prevalence of S. haematobium infection within different geographic areas. 
S. haematobium is found throughout much of Africa and the Middle East.43, 44 
The life cycle of the S. haematobium requires water-borne transmission of 
infection between man and snail. Individuals with chronic schistosomiasis may 
eventually develop SCC, probably as a result of a higher amount of carcinogenic 
nitroso compounds in the urine and/or a depressed immunocompetence of 
infected patients. 
FRUIT AND VEGETABLES
In observational studies a high consumption of vegetables and fruit has been 
associated with a decrease in risk of almost all cancers, including bladder 
cancer45-47, although data are inconsistent. A role of diet in bladder carcinogenesis 
is plausible since most substances and metabolites, including (pre)-carcinogens, 
are excreted by the urinary tract. A possible biologic mechanism is that several 
antioxidants (vitamin A, C, E, retinol, selenium and folate) detoxify free radicals 
and thereby decrease the cancer risk. 
In 1997, an international panel concluded that there was significant evidence 
that a high intake of vegetables decreased the risk of bladder cancer, although 
observational studies of fruits and vegetable consumption are inconclusive.48 
In a meta-analysis of Steinmaus et al.,49 increased risks of bladder cancer were 
associated with diets low in fruit intake (RR 1.4; 95%CI: 1.08-1.83), and with diets 
of low vegetable intake (RR 1.16; 95%CI: 1.01-1.34). These results suggest that 
a diet high in fruits and vegetables may help to prevent bladder cancer. In a more 
recent meta-analysis, there was an inverse association for fruit consumption but 
vegetable intake was not related to bladder cancer risk.46 In 2005, the Nurses’ 
Health Study evaluated the effect of fruits and vegetables, carotenoids, folate, 
vitamin A, C, E on the risk of bladder cancer. In this prospective study there 
were no associations between any of the fruits, vegetables or vitamin intake and 
bladder cancer risk among women.50 The 2007 World Cancer Research Fund/
American Institute of Cancer Research51 report on the relation between food, 
nutrition, physical activity and the prevention of cancer concluded that there is 
limited evidence of a protective effect of fruit and vegetables on bladder cancer 
risk.
Although fruits and vegetables are sources of many vitamins, minerals and 
other bioactive compounds which may prevent cancer, plant foods can also 
contain carcinogenic pesticides. When pesticides are used to increase crop 
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yield, residues or traces sometimes remain. The inconsistent results of studies 
assessing the effect of fruits and vegetables on the risk of bladder cancer 
might be confounded by a harmful effect of pesticides in fruits and vegetables. 
However, the evidence of the carcinogenic effect of pesticides comes from 
animal studies only. A recent study52 found no association between pesticide 
exposure and bladder cancer risk. There is no epidemiological evidence that 
these small amounts of pesticides can increase cancer risk.51 
To elucidate the role of diet in cancer, large-scale, structurally supported 
prospective cohort studies are required, preferably with multi-centre 
multinational participation to increase variation in exposure. The European 
Prospective Investigation on Nutrition and Cancer (EPIC) cohort data offers 
a unique opportunity to conduct large prospective cohort analyses on a wide 
variety of risk factors. Analyses in the EPIC cohort on serum biomarkers for 
fruits and vegetables consumption in relation to bladder cancer are ongoing. 
OTHER DIETARY RISK FACTORS 
Several other possible risk factors have been suggested, e.g. coffee and alcohol 
consumption. However, evidence is very inconsistent.31, 53, 54 The positive 
findings in some studies might be the result of residual confounding by smoking 
(several case control studies did not adjust for smoking habits) or chance. 
Evidence for an increase in bladder cancer risk because of the use of artificial 
sweeteners55, 56 and a high total fat intake is insufficient.49 Drinking of black tea 
has been associated with a slightly decreased risk of bladder cancer, although 
the evidence is also inconsistent.33, 57 Physical activity was associated with an 
increase in bladder cancer in two large cohort studies.58, 59 
HAIR DYES 
The risk of bladder cancer through the use of hair-colouring products has been 
studied since the late 1970s but received a lot of interest the last few years. 
Some hair dyes contain aromatic amines such as 4-aminobiphenyl, of which 
small amounts might be absorbed percutaneously.60 Occupational exposure 
to hair dyes by hairdressers, barbers and beauticians has been suggested to 
moderately increase the risk of bladder cancer.61 Two cohort studies from the 
USA (the Nurses Health Study and the American Cancer Society CSP-II study) 
found no association between personal use of permanent dyes and bladder 
cancer. Also, several case-control studies found no evidence that use of hair 
dyes was associated with bladder cancer risk.62-64 However, in a study from 
California, Gago-Dominguez et al.64 reported that women who used permanent 
hair dyes at least once a month had twice the risk of bladder cancer relative to 
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non-users. They further showed that genetic variations in arylamine activation 
and detoxification pathways, especially N-acetyltransferase (NAT)-2, -1, and 
cytochrome (CYP) 1A2, modify the relationship between permanent hair dyes 
and bladder cancer in women.65 These results were not confirmed in the large 
case-control study from Spain.62 It is therefore difficult to arrive at a definitive 
conclusion on the role of hair dyes in the causation of bladder cancer. 
FAMILIAL BLADDER CANCER 
Familial bladder cancer is a fairly rare phenomenon compared to the familial 
occurrence of many other tumour sites. Nevertheless, numerous striking case-
reports described familial clustering of bladder cancer. Several of these show an 
extremely early age at onset, suggesting a genetic component.66 Epidemiological 
studies from the Netherlands and Spain showed that the risk of bladder cancer is 
doubled in the case of a first-degree relative with bladder cancer.67, 68 The cause 
of this familial clustering is still speculative but several lines of evidence suggest 
a contributing genetic factor. There is probably large heterogeneity in risk, with 
the cause in some high-risk families being a rare but highly penetrant gene69, 
and in other families being the combined effects of several more common but 
less-penetrant genes. It is expected that genome-wide association studies will 
report their findings within the next 2 years. Such findings might also direct the 
search for genetic causes in families with bladder cancer. 
GENETIC POLYMORPHISMS 
As summarized above, bladder cancer is primarily a disease induced by 
environmental carcinogens. However, there is also a clear genetic component 
to the aetiology of bladder cancer, as evidenced by the familial association of 
bladder cancer. Identification of low-penetrance genetic predisposition loci 
provides additional strong evidence for a genetic component of bladder cancer. 
Although the relative risks are modest, genetic polymorphisms might account 
for a large fraction of all bladder cancers because of their high prevalence in the 
population. Because there is a good understanding of the pathways and genes 
involved in carcinogen metabolism and host defence mechanisms, numerous 
studies evaluated associations between genetic polymorphisms in these 
pathways and bladder cancer risk. There are a few consistent associations, 
but most of the reported genetic associations have not been supported by 
replication in independent populations. We will not enumerate all the genetic 
variants that have been evaluated, but only summarize the most consistent 
associations and data from larger studies. 
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CARCINOGEN METABOLISM GENES
In general, the metabolism of carcinogens consists of two phases, phase I and II. 
Phase I enzymes, mainly CYP450, typically activate carcinogens, whereas phase 
II enzymes generally detoxify carcinogens. The balance between phase I and II 
enzymes often determines the accumulation of toxic reactive intermediates. 
There are about 60 human CYP genes arranged in 18 families and 42 
subfamilies.70 Human CYP genes are highly polymorphic. For example, CYP2D6 
has >100 variant alleles and CYP2C9 has 37 different variant alleles. Numerous 
studies have investigated various CYP gene polymorphisms and bladder cancer 
risk, including CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6 and CYP2E171, 
72; however, none of the genotypes showed consistent associations with 
bladder cancer risk. There are many reasons for this, including small sample 
sizes, weak correlations between genotypes and phenotypes, redundancy in 
enzyme functions and overlap in enzyme substrates, and variable frequencies 
of the polymorphic alleles in different ethnic populations. 
NADPH quinine oxidoreductase-1 (NQO1) is a cytosolic enzyme that catalyses 
two- or four-electron reductions of quinoid compounds into less toxic 
hydroquinones. A non-synonymous single-nucleotide polymorphism (nsSNP), 
Pro187Ser, has been widely studied in many cancer types. Several case-control 
studies of bladder cancer with small sample sizes (<300 cases) have produced 
contradictory results72,73, but a meta analysis of six studies among Caucasians 
suggested a modestly increased risk for the variant genotypes (OR 1.20; 95%CI: 
1.00– 1.43).73 
Glutathione S-transferases (GSTs) are a group of Phase II detoxification enzymes 
that catalyse the conjugation of glutathione to a wide variety of xenobiotics and 
carcinogenic compounds. At least seven mammalian GST families (α, µ, α, π, α, α 
and α) have been identified and several functional polymorphisms in GST family 
genes have been closely assessed in cancer-association studies.74 The largest 
case-control study to date (1150 cases and 1149 controls) reported that the 
null genotype of GSTM1 was associated with a significantly increased bladder 
cancer risk.75 A meta-analysis of 28 studies (5072 cases and 6466 controls) 
produced a summary odds ratio of 1.5 (95%CI: 1.3–1.6).75 The Ile105Val variant 
of GSTP1 might have a modest effect on bladder cancer risk, as suggested in a 
recent meta-analysis.76 Other common polymorphisms, such as the GSTT1 null 
genotype and the Val224Ile variant of GSTM3, appear to have a minimal effect 
on bladder cancer risk.75 
NATs catalyse the metabolic activation of aromatic and heterocyclic amine 
carcinogens by acetylation. NAT1 and NAT2 are two distinct NAT isozymes that 
exist in humans. The NAT1 and NAT2 genes have extensive polymorphisms 
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that stratify the population into rapid-, intermediate- and slow acetylator 
phenotypes.77 The association between NAT2 slow-acetylator genotype and 
increased bladder cancer risk is among the most consistent and robust, and has 
become a classical example of gene–environment interaction in the aetiology of 
sporadic cancer. The two largest case-control studies and a meta-analysis of 31 
studies (5091 cases and 6501 controls) showed that, compared with the NAT2 
rapid- or intermediate acetylators, NAT2 slow-acetylators had a 40% increased 
risk of bladder cancer.75,78 In addition, there was an interaction between NAT2 
genotype and smoking. The association of NAT1 slow-acetylator genotypes 
with bladder cancer is controversial and warrants further clarification.72,75,78 
Similarly, polymorphisms in many other phase II enzyme genes, including 
sulfotransferases, UDP-glucuronosyltransferases, myeloperoxidase, catechol-
o methyltransferase, manganese superoxide dismutase and glutathione 
peroxidase 1, are either contradictory or evaluated in only a few small studies72. 
Well-designed large studies are needed to clarify their roles in bladder cancer 
susceptibility. 
DNA REPAIR GENES
There are four major DNA repair systems in mammalian cells: nucleotide-
excision, base-excision, double-strand break and mismatch repair. Tobacco 
and environmental carcinogens might cause varied DNA damage that requires 
distinct repair pathways. Polymorphisms in DNA repair pathways, particularly 
in the first three systems, might be important in the aetiology of bladder cancer. 
There are many small case-control studies suggesting such roles72, but none 
of the commonly studied SNPs in DNA repair genes showed a consistent 
significant association with bladder cancer across large case-control studies 
published more recently.79–87 These latter studies had large samples and took a 
pathway-based approach to genotype a panel of SNPs with potential functional 
impact (e.g. nsSNPs and SNPs in promoter and untranslated regions). Meta-
analyses indicate that two XPD nsSNPs, Asp312Asn and Lys751Gln, might have 
modest effects on bladder cancer (García-Closas, personal communication). The 
same is true for the Thr214Met nsSNP in the XRCC3 gene (homozygous variant 
vs homozygous common genotype: OR 1.17; 95%CI: 1.00–1.36, from seven 
studies with 3086 cases and 3150 controls).87
OTHER PATHWAYS AND CANDIDATE GENES
In addition to carcinogen metabolism and DNA repair, there are numerous 
individual reports on candidate SNPs in cell cycle control79, apoptosis88, 
inflammatory response89, cell-adhesion molecules89,90, tumour microenviron-
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ment91, folate metabolism92,93, G proteins94, angiogenesis95, and other pathways 
in relation to bladder cancer risk72, but the individual results need replication 
in independent populations. In addition, the rapid advance of high-throughput 
genotyping technology has allowed large scale genotyping. García-Closas et 
al.95 genotyped 1433 SNPs in 386 genes in a large case-control study, and found 
that a SNP in VEGF was the most significant one. They further analysed 29 
additional SNPs in VEGF and found a few additional SNPs and two haplotype 
blocks encompassing the promoter and 5’ UTR associated with bladder cancer 
risk.95 We (X.W.) recently used the iSelect platform (Illumina, San Diego, CA, 
USA) and genotyped ˜10 000 SNPs in ˜1000 cancer-related genes in the Texas 
bladder cancer case-control study (data unpublished), and we will validate the 
top 10 promising loci in an independent population.
GENE-GENE AND GENE-ENVIRONMENT INTERACTION
The candidate-gene approach has given a few examples of true associations 
(e.g. GSTM1 and NAT2), but also produces numerous inconsistent results. 
The trend in cancer-association studies is to move beyond a limited candidate 
approach, and apply a pathway-based genotyping and analytical approach, and 
ultimately genome-wide association (GWA) studies. Several recent bladder 
cancer case-control studies examined the combined effect of multiple genes, 
as well as gene-gene and gene-environment interactions, using nonparametric 
data-mining tools, e.g. classification and regression tree (CART) and multifactor 
dimensionality reduction.79–83 Evaluating 44 SNPs in DNA repair and cell-
cycle genes, Wu et al.79 found a significant gene-dosage effect for increasingly 
elevated risks of bladder cancer with increasing numbers of high-risk alleles. 
CART analysis revealed potential higher-order gene-gene and gene-smoking 
interactions, and categorized a few higher-risk subgroups for bladder cancer 
based on distinct genotype and smoking combinations. Moreover, subgroups 
with a higher cancer risk also had higher levels of induced genetic damage. It 
is apparent that gene-environment interaction is important in bladder cancer 
aetiology, particularly NER genes and smoking interactions. However, from 
current reports, the interactions identified from various posthoc data-mining 
tools in different populations do not overlap.79–83 Unfortunately, validation of 
interactions is more demanding than that of individual associations and requires 
large sample sizes.
GWA STUDY OF BLADDER CANCER
Some cancer susceptibility loci cannot be identified by a candidate-gene 
approach, as recent GWA studies of other cancers suggest. High-resolution 
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GWA studies, with extensive replications of positive findings in other case and 
controls series, can map such susceptibility loci. For bladder cancer, there are at 
least three independent GWA studies ongoing, all using Illumina’s high-density 
SNP chips. We expect that there will be exciting results in the coming year or 
two.
PHENOTYPIC MARKERS AND BLADDER CANCER RISK
Although the vast majority of modern reports focus on genotypes, because of 
clear advantages in terms of easy sample collection, invariable genotype data 
and robust technology, phenotypic assays remain important. For most known 
genotypes, the functional impact is either not clear or not strong enough to be 
biologically relevant, contributing to the inconsistent results of genotypic data. 
Phenotypic assays measure the combined effects of multiple genes as well as 
environmental factors. Phenotypic markers are generally more consistent if the 
technical reproducibility is established, and require many fewer samples. 
Most of the phenotypic assays measure DNA damage level and DNA repair 
capacity. Schabath et al.96 applied the Comet assay to measure baseline, 
benzo[a]pyrene diol epoxide (BPDE)- and γ-radiation-induced DNA damage in 
peripheral blood lymphocytes (PBLs) of bladder cancer cases and controls. They 
found that higher levels of DNA damage at baseline (OR 1.84; 95%CI: 1.07–
3.15), after γ -radiation (OR 1.81; 95%CI: 1.04–3.14) and after BPDE treatment 
(OR 1.84; 95%CI: 1.69, 0.98–2.93) were all associated with increased risks 
of bladder cancer. Mutagen sensitivity is an established genetic predisposing 
factor for cancer.97 A recent large case-control study showed that high BPDE 
and γ-radiation sensitivity was associated with significantly increased bladder 
cancer risks (OR 1.48; 95%CI: 1.33–1.64 and 1.92; 1.71–2.15, respectively).98 
Lin et al.99 developed a modified host-cell reactivation assay to measure DNA 
repair capacity for DNA damage induced by 4 -aminobiphenyl, an aromatic 
amine and known bladder carcinogen, and found that poor DNA repair capacity 
was associated with a 3.42-fold increased bladder cancer risk. 
Another consistent phenotypic marker is telomere length in PBLs. Three 
independent studies showed that constitutive telomere shortening is a 
cancer-susceptibility factor for bladder cancer. Wu et al.100 provided the first 
epidemiological evidence that telomeres in PBLs of cases were significantly 
shorter than those of controls for four different types of cancer, including lung, 
head and neck, bladder, and kidney cancer. Dichotomized at the 75th percentile 
value of telomere length in controls, individuals with shorter telomeres were 
associated with a significantly increased risk of these cancers (OR 4.51; 95%CI: 
2.31–8.81). Broberg et al.101 showed that the risk of bladder cancer was 
significantly increased with decreasing telomere length, with an odds ratio of 4.5 
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for the shortest quartile compared to the longest quartile of telomere length. In 
a recent prospective case-control study nested within the Health Professionals 
Follow-up Study and the Nurses’ Health Study, McGrath et al.102 showed that 
the OR for bladder cancer was 1.88 (95%CI: 1.05–3.36) for the shortest quartile 
compared to the longest quartile of telomere length.
RISK ASSESSMENT MODEL FOR BLADDER CANCER 
The ultimate goal is to build a risk-prediction model by integrating environmental 
and genetic factors that can project individualized probabilities of developing 
bladder cancer. As the first attempt, Wu et al.98 used epidemiological and genetic 
data from a large case-control study to build a prediction model for bladder 
cancer. The area under the curve (AUC) was used to evaluate the discriminatory 
ability of the models. Significant risk factors in the epidemiological model 
included pack-years smoked and exposures to diesel, aromatic amines, dry-
cleaning fluids, radioactive materials, and arsenic. This model yielded good 
discriminatory ability (AUC 0.70; 95%CI: 0.67–0.73). When mutagen sensitivity 
(BPDE and γ-radiation sensitivity) data were incorporated, the AUC increased 
to 0.80 (95%CI: 0.72–0.82). The enhanced epidemiological-genetic model with 
the addition of a single genetic component has excellent discriminatory ability, 
showing the promising future of cancer risk prediction by incorporating multiple 
genetic factors. Validation of this model in an external population is an essential 
next step towards its practical use in the clinical setting.
CONCLUSION 
Smoking and exposure to carcinogenic substances at the workplace are the 
main causes of bladder cancer. In theory, at least half of all the cases of bladder 
cancer can be prevented with smoking-cessation programmes and protection 
from occupational exposures. Pelvic radiation, S. haematobium infection, and 
specific medications are confirmed risk factors, but their contribution to bladder 
cancer occurrence is much smaller. Other than that, important environmental or 
lifestyle factors have not been clearly and consistently associated with bladder 
cancer risk. A Mendelian hereditary form of bladder cancer is unknown, although 
RB1 carriers seem to be at greater risk. However, susceptibility to bladder 
cancer is modified by common lower penetrance DNA variants in several cancer 
pathways. Only variants in NAT2 and deletions of GSTM1 have unequivocally 
been confirmed to be bladder cancer risk factors, but technical advances in 
this area of research will lead to the identification of dozens of other low 
penetrance bladder cancer genes in the next few years. Future epidemiological 
research needs to pay more attention to different forms of bladder cancer, 
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more specifically low- and high-grade cancer. Large international collaborations 
might be needed for sufficient power in such studies. The ultimate goal is to 
build a risk-prediction model by integrating environmental and genetic factors 
and that can project individualized probabilities of developing bladder cancer.
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ABSTRACT 
Background
Many epidemiological studies have examined fruit and vegetable consumption 
in relation to the risk of urothelial cell carcinoma (UCC) of the bladder, but results 
are inconsistent. The association between fruit and vegetable consumption and 
UCC risk may vary by bladder tumour aggressiveness. Therefore, we examined 
the relation between fruit and vegetable consumption and the risk of aggressive 
and non-aggressive UCC in the European Prospective Investigation into Cancer 
and Nutrition (EPIC).
Methods
After 8.9 years of follow-up, 947 UCC were diagnosed among 468,656 EPIC 
participants. Of these, 421 could be classified as aggressive UCC and 433 as 
non-aggressive UCC cases. At recruitment, fruit and vegetable consumption was 
assessed by validated dietary questionnaires. Multivariable hazard ratios were 
estimated using Cox regression stratified by age, sex and centre and adjusted 
for smoking status, duration and intensity of smoking, and energy intake.
Results
Total consumption of fruits and vegetables was not associated with aggressive 
UCC nor with non-aggressive UCC. A 25 g/day increase in leafy vegetables 
and grapes consumption was associated with a reduced risk of non-aggressive 
UCC (hazard ratio (HR) 0.88; 95% confidence interval (CI) 0.78–1.00 and HR 
0.87; 95%CI: 0.77–0.98, respectively), while the intake of root vegetables was 
inversely associated with risk of aggressive UCC (HR 0.87; 95%CI: 0.77–0.98).
Conclusion
Our study did not confirm a protective effect of total fruit and/or vegetable 
consumption on aggressive or non-aggressive UCC. High consumption of 
certain types of vegetables and of fruits may reduce the risk of aggressive or 
non-aggressive UCC; however chance findings cannot be excluded.
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INTRODUCTION 
Urothelial cell carcinoma (UCC) of the bladder represents a heterogeneous 
group of tumours developing through diαerent molecular pathways. The low 
grade, low stage papillary tumours are characterized by activating mutations 
in HRAS and FGFR3 and by chromosome 9 aberrations; the high grade solid 
muscle invasive tumours are characterized by structural and functional defects 
in TP53 and RB1.1–3
Because of the variability in histopathology, diαerent etiological factors may be 
involved in the pathogenesis of diαerent types of UCC. It has been suggested 
that risks associated with cigarette smoking and employment in a high-risk 
occupation, the most well-known risk factors for UCC,4 are higher for bladder 
tumours with a higher clinical stage and pathological grade.5,6 However, other 
studies did not find diαerent associations with stage-specific bladder cancer.7,8 
Consumption of fruits and vegetables has been suggested to decrease UCC 
risk.9,10 To date, only one cohort study has distinguished between invasive and 
non-invasive UCC and found that an inverse association between both fruit and 
vegetables was most pronounced in invasive UCC.11
The European Prospective Investigation into Cancer and Nutrition (EPIC) is 
a large cohort study, well suited to examine the role of fruit and vegetable 
consumption in relation to diαerent pathological features of UCC. Previously, 
Büchner et al.12 observed no eαect of fruit and vegetable consumption on 
bladder cancer risk within EPIC. We collected pathology information for all 
tumours and evaluated the role of fruit and vegetable consumption separately 
for aggressive and non-aggressive UCC.
MATERIAL AND METHODS
Study population and data collection
The rationale and methods of the EPIC study are described elsewhere.13 Briefly, 
EPIC is a cohort study of more than half a million people recruited by 23 centres 
in 10 European countries. At baseline, usual dietary intake during the year before 
recruitment was measured by country-specific validated dietary questionnaires 
designed to reflect local dietary patterns.13,14 Besides total fruit and vegetable 
consumption, subgroups of fruit (citrus-, hard-, stone fruit, grapes, berries) 
and vegetables (fruiting-, leafy-, and root vegetables, cabbages, mushrooms, 
onions and garlic) were investigated.12,15 Baseline information on other lifestyle 
variables was obtained from standardized questionnaires including questions 
on education, occupation, medical history, physical activity, and smoking.14
We excluded all prevalent cancer cases at recruitment (n=23,633), participants 
with missing follow-up data (n=3,448), participants with missing questionnaires 
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(n=16,037) and participants with a ratio of energy intake versus energy 
expenditure in the top and bottom 1% of the distribution were also excluded to 
reduce the effect of implausible dietary values (n=9,674). After these exclusions, 
the study cohort comprised 468,656 participants. The study was approved by 
the Internal Review Board of the International Agency for Research on Cancer 
(IARC, Lyon) and the local ethics commit- tees in the participating countries.
Outcome assessment 
Ascertainment of newly diagnosed cancer was described previously.12 For the 
current analysis, participants were followed from study entry until a diagnosis of 
first primary UCC (code C67 according to the ICD-Oncology third edition). Only 
urothelial cell ‘papillomas’ and carcinomas (morphology codes 812–813) were 
included in the analysis. Pathology reports of the UCC cases were collected 
from each centre. According to Kiemeney et al.16 we classified UCC with regards 
of risk of progression into aggressive and non-aggressive tumours. Individuals 
with a high-risk of progression (aggressive UCC) were defined as: stage T1 and 
higher or carcinoma in situ (CIS) or World Health Organisation (WHO) grade 3; 
tumours with a low-risk of progression (non-aggressive UCC) were defined as: 
stage Ta grade 1 or stage Ta grade 2.
Statistical methods
Cox proportional hazard models were used to evaluate the association of fruit 
and vegetable consumption with overall UCC risk, aggressive UCC and non-
aggressive UCC. In the analysis of aggressive UCC risk, participants with a non-
aggressive tumour were censored at time of diagnosis and vice versa. Age was 
used as the primary time variable in the models. Time at entry was defined 
as age at recruitment and exit time as age at diagnosis, age at death, age at 
emigration or age at end of follow-up, whichever came first. All analyses were 
stratified by age at recruitment (in one-year categories) to control for length 
of follow-up, by sex, and by centre to control for country effects, as follow-
up procedures and questionnaire design may slightly differ between countries. 
Cases diagnosed after the censoring date were considered as non-cases.
Fruit and vegetable consumption were analysed as categorical variables with 
EPIC-wide tertiles as cut-offs, and as continuous variables (increment of 100 
g/day). Subgroups of fruit and vegetables were analysed per 25 g/day increase. 
To calculate the P value for trend across tertiles, the median of each tertile 
was assigned to participants, and this variable was entered as a continuous 
term in the Cox models. All analyses were controlled for smoking status (never, 
former, current), duration of smoking (in years), lifetime intensity of smoking 
(cigarettes/day) and energy intake from fat and non-fat sources. Height, weight, 
consumption of red and processed meat, alcohol, physical activity, educational 
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level, were not included in the analysis as each factor did not noticeably 
affect risk estimates. Since smoking may modify the association with fruit 
and vegetable consumption, analyses were also stratified by smoking status. 
Joint effects were determined for tertiles of fruit and vegetable consumption 
in combination with smoking status in relation to UCC risk. The combined 
category of low consumption of fruit and/or vegetables with current smoking 
was chosen as reference. Statistical interaction on a multiplicative scale was 
tested by introducing a product term between fruit and vegetable consumption 
(continuous) and smoking status, sex, country, alcohol intake and BMI (Body 
Mass Index). For a subset of the cohort data on occupational history of 
the participants was available (n=203,400). We focused on the following 
carcinogenic exposures: heavy metals, aromatic amines, Polycyclic Aromatic 
Hydrocarbons and Environmental Tobacco Smoking. The scores were treated as 
dichotomous variables (yes versus no).
RESULTS 
During a mean follow-up of 8.9 years, 947 UCC were diagnosed among 468,656 
participants. Of these, 421 could be classified as aggressive UCC and 433 as 
non-aggressive UCC cases. 93 UCC cases could not be classified as aggressive 
or non-aggressive UCC because information on stage and grade was lacking. 
Participants who developed UCC were somewhat older, more likely to be men, 
heavier in weight and longer in stature, more likely to be current smokers, to 
be exposed to carcinogens at the job, more frequently of a lower educational 
level and reported lower consumption of fruits and vegetables, higher intakes of 
alcohol and red and processed meats compared to the total cohort at baseline. 
These differences were more pronounced in aggressive UCC cases (Table 1). No 
association was found between fruit consumption and aggressive UCC (hazard 
ratio (HR) highest versus lowest tertile 1.01; 95% confidence interval (CI) 
0.76–1.35) nor for non-aggressive UCC (HR highest versus lowest tertile 0.88; 
95%CI: 0.66–1.18) (Table 2). We observed no significant association between 
vegetable consumption and aggressive UCC (HR highest versus lowest tertile 
0.91; 95%CI: 0.68–1.23) nor for non-aggressive UCC (HR highest versus lowest 
tertile 0.83; 95%CI: 0.61–1.12) (Table 2). When joint effects of smoking status 
and fruit and vegetable consumption were evaluated for total UCC, smoking 
was the dominant risk factor in all levels of fruit and of vegetables.
Although the interaction on a multiplicative scale was not statistically significant, 
lowest risks were obtained among never and former smokers with highest 
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Table 1. Baseline characteristics of EPIC participants.1 
Total cohort
(n=468,656)
All urothelial 
cell carcinomas2
(n=947)
Men
(n=140,629)
Women
(n=328,027)
Men
(n=667)
Women
(n=280)
Country
France6 - 64,256 - 27
Italy 13,791 30,497 68 38
Spain 15,144 24,845 77 13
United Kingdom 22,060 51,645 108 44
The Netherlands 9,763 26,422 28 31
Greece 10,034 14,343 13 2
Germany 21,536 27,867 75 33
Sweden 22,079 26,225 134 43
Denmark 26,222 28,673 164 39
Norway6 - 33,254 - 10
General characteristics
Age at recruitment (y) 52.2 ± 10.1 50.8 ± 9.8 59.0 ± 8.0 58.4 ± 7.3
Height (cm) 174.7 ± 7.3 162.3 ± 6.7 173.8 ± 7.3 161.8 ± 6.5
Weight (kg) 80.9 ± 12.0 65.7 ± 11.7 81.4 ± 11.9 66.2 ± 11.3
BMI (kg/m2) 26.5 ± 3.6 25.0 ± 4.4 26.9 ± 3.8 25.3 ± 3.9
Physically active (%)7 50 47 54 51
Smoking status
Never smokers (%) 33 57 13 42
Former smokers (%) 37 23 42 24
Lifetime number of  
cigarettes (cig/day)
12.1 ± 11.3 6.7 ± 7.8 11.2 ± 10.6 7.3 ± 8.1
Smoking duration (y) 19.9 ± 12.1 15.1 ± 10.9 25.5 ± 13.9 21.1 ± 13.1
Age at start smoking (y) 17.6 ± 5.1 18.5 ± 6.8 16.9 ± 4.8 20.3 ± 8.5
Time since quitting smoking (y) 14.9 ± 10.8 14.3 ± 10.2 14.1 ± 11.4 14.5 ± 11.5
Current smokers (%) 30 20 45 34
Lifetime number of  
cigarettes (cig/day)
14.1 ± 9.4 11.7 ± 6.8 14.0 ± 9.8 13.0 ± 6.8
Smoking duration (y) 32.0 ± 11.4 27.9 ± 10.4 38.9 ± 9.7 36.6 ± 11.1
Age at start smoking (y) 18.1 ± 6.2 19.9 ± 7.1 17.3 ± 5.2 19.4 ± 7.7
Exposure to carcinogens at the job (%)8
Heavy metals 24 2 31 3
Aromatic amines 17 1 21 2
Polycylic Aromatic 
Hydrocarbons (PAH)
4 6 5 7
With environmental tobacco 
smoking exposure
16 12 18 17
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Aggressive urothelial 
cell carcinomas3 5
(n=421)
Non-aggressive urothelial 
cell carcinomas4 5
(n=433)
Men
(n=328)
Women
(n=93)
Men
(n=282)
Women
(n=151)
Country
France6 - 6 - 14
Italy 33 15 28 19
Spain 56 6 17 7
United Kingdom 49 17 37 19
The Netherlands 13 16 15 15
Greece 6 1 4 1
Germany 36 5 33 13
Sweden 63 17 65 26
Denmark 72 8 83 29
Norway6 - 2 - 8
General characteristics
Age at recruitment (y) 59.0 ± 7.7 60.1 ± 6.9 58.8 ± 8.2 57.4 ± 6.9
Height (cm) 173.7 ± 7.1 161.3 ± 6.0 174.1 ± 7.5 161.9 ± 6.6
Weight (kg) 81.6 ± 12.3 66.3 ± 12.7 81.2 ± 11.8 66.5 ± 10.4
BMI (kg/m2) 27.0 ± 3.6 25.5 ± 4.6 26.8 ± 4.0 25.3 ± 3.4
Physically active (%)7 55 61 50 43
Smoking status
Never smokers (%) 14 38 12 38
Former smokers (%) 40 29 40 22
Lifetime number of  
cigarettes (cig/day)
11.1 ± 10.6 7.8 ± 9.1 10.8 ± 11.4 5.9 ± 6.7
Smoking duration (y) 25.4 ± 14.1 24.9 ± 14.3 25.4 ± 13.9 17.8 ± 12.6
Age at start smoking (y) 17.2 ± 4.4 20.5 ± 8.7 16.9 ± 5.2 20.3 ± 8.5
Time since quitting smoking (y) 14.2 ± 11.6 11.7 ± 10.2 13.7 ± 11.0 16.2 ± 12.4
Current smokers (%) 47 33 48 40
Lifetime number of  
cigarettes (cig/day)
13.6 ± 10.3 13.7 ± 8.4 14.6 ± 9.4 12.7 ± 5.9
Smoking duration (y) 39.1 ± 9.6 38.3 ± 12.6 39.1 ± 9.4 35.7 ± 10.6
Age at start smoking (y) 17.7 ± 5.1 19.2 ± 8.8 17.1 ± 5.2 19.7 ± 7.4
Exposure to carcinogens at the job (%)8
Heavy metals 33 - 30 2
Aromatic amines 20 10 21 -
Polycylic Aromatic  
Hydrocarbons (PAH)
4 5 6 6
With environmental tobacco 
smoking exposure
16 5 23 24
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Table 1. Continued
Total cohort
(n=468,656)
All urothelial 
cell carcinomas2
(n=947)
Educational level (%)
None 4 5 5 3
Primary school 30 24 40 36
Technical/professional school 24 22 23 24
Secondary school 13 24 9 20
University degree 27 23 20 14
Not specified 2 2 3 3
Diet 
Total energy (kcal/d) 2423 ± 668 1941 ± 540 2386 ± 597 1916 ± 531
Energy from fat (kcal/d) 868 ± 304 698 ± 244 841 ± 278 675 ± 233
Energy from non-fat (kcal/d) 1555 ± 439 1243 ± 353 1544 ± 402 1241 ± 359
Calibrated fruit consumption  
(median g/day) 9
162 (99,266) 195 (146,260) 143 (85,250) 184 
(134,253)
Citrus fruit (g/day) 9 30 (14,58) 37 (25,53) 27 (12,56) 37 (20,55)
Hard fruit (g/day) 9 64 (36,107) 69 (47,96) 59 (29,101) 65 (43,92)
Stone fruit (g/day) 9,10,13 13 (6,32) 26 (16,43) 12 (4,25) 23 (14,39)
Grapes (g/day) 9,10,13,14 7 (2,17) 11 (6,17) 7 (3,14) 11 (6,17)
Berries (g/day) 9 4 (1,7) 7 (3,12) 4 (1,7) 7 (3,12)
Calibrated vegetable  
consumption (median g/day)9
157 (123,202) 169 (131,206) 144 
(110,184)
146 
(114,188)
Leafy vegetables (g/day)9,10 13 (9,24) 18 (10,32) 10 (7,19) 15 (10,25)
Fruiting vegetables (g/day)9 62 (47,87) 73 (50,94) 53 (40,75) 59 (43,83)
Root vegetables (g/day) 9 14 (9,21) 19 (11,28) 14 (10,22) 16 (10,26)
Cabbages (g/day) 9 17 (11,23) 16 (13,22) 18 (12,26) 17 (12,24)
Mushrooms (g/day) 9,10,13 3 (2,5) 3 (2,4) 3 (2,6) 3 (2,4)
Onions/garlic (g/day)9,10,11,12 12 (8,17) 8 (6,11) 11 (7,16) 8 (6,11)
Alcohol (g/day) 21.0 ± 23.7 8.1 ± 11.7 23.2 ± 25.5 8.7 ± 14.0
Red meat (g/day) 58.9 ± 42.4 39.2 ± 31.2 61.8 ± 39.0 41.8 ± 29.0
Processed meat (g/day) 42.4 ± 39.5 27.3 ± 25.1 44.2 ± 36.7 27.5 ± 23.0
1. Mean ± SD, unless otherwise stated. 
2. The group “urothelial cell carcinomas” includes transitional cell papillomas and carcinomas (morphology 
codes 812 and 813, and behaviour coded as ‘uncertain whether benign or malignant’, ‘carcinoma in situ’ and/
or as ‘malignant’), but excludes inverted papillomas (8121/1). 
3. The category “aggressive urothelial cell carcinomas” includes T1 or higher, all CIS or all WHO 1973 grade 
3 carcinomas (including Ta grade 3)
4. The category “non-aggressive urothelial cell carcinomas” includes Ta grade 1 or Ta grade 2 carcinomas.
5. Ninety tree urothelial cell carcinomas cannot be classified as aggressive or non-aggressive urothelial cell 
carcinomas, because of lacking information on stage and/or grade.
6 The French and the Norwegian cohorts consist of women only.
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Total cohort
(n=468,656)
All urothelial 
cell carcinomas2
(n=947)
Educational level (%)
None 7 4 3 3
Primary school 40 43 43 33
Technical/professional school 24 17 21 27
Secondary school 10 18 10 21
University degree 16 14 22 13
Not specified 3 4 1 3
Diet 
Total energy (kcal/d) 2351 ± 582 1917 ± 502 2436 ± 619 1906 ± 521
Energy from fat (kcal/d) 820 ± 266 670 ± 230 869 ± 292 673 ± 233
Energy from non-fat (kcal/d) 1531 ± 396 1247 ± 334 1567 ± 413 1233 ± 357
Calibrated fruit consumption 
(median g/day) 9
154 (86,263) 188 (138,266) 130 (83,211) 180 (130,228)
Citrus fruit (g/day) 9 29 (12,56) 38 (27,59) 25 (12,51) 35 (16,54)
Hard fruit (g/day) 9 62 (31,108) 67 (40,93) 53 (29,92) 63 (42,91)
Stone fruit (g/day) 9,10,13 13 (5,34) 22 (13,38) 11 (4,21) 20 (13,39)
Grapes (g/day) 9,10,13,14 7 (3,15) 11 (6,16) 6 (2,11) 10 (6,16)
Berries (g/day) 9 4 (1,7) 6 (3,10) 3 (1,6) 6 (3,11)
Calibrated vegetable  
consumption (median g/day)9
146 
(111,184)
148 
(107,185)
139 
(105,179)
140 (113,185)
Leafy vegetables (g/day)9,10 11 (7,25) 16 (9,26) 10 (7,15) 13 (9,22)
Fruiting vegetables (g/day)9 54 (41,81) 59 (40,84) 51 (39,71) 57 (43,82)
Root vegetables (g/day) 9 14 (10,20) 10 (6,15) 15 (10,22) 16 (10,27)
Cabbages (g/day) 9 18 (13,26) 18 (13,24) 18 (11,25) 17 (12,25)
Mushrooms (g/day) 9,10,13 3 (2,4) 2 (1,3) 2 (1,4) 2 (1,4)
Onions/garlic (g/day)9,10,11,12 11 (7,17) 8 (6,11) 11 (7,16) 8 (7,10)
Alcohol (g/day) 24.7 ± 26.0 9.0 ± 17.0 22.3 ± 24.9 8.4 ± 12.0
Red meat (g/day) 60.3 ± 35.7 40.4 ± 24.2 66.6 ± 41.7 44.6 ± 31.7
Processed meat (g/day) 43.5 ± 38.9 26.9 ± 23.2 47.6 ± 34.7 28.9 ± 24.0
7. Cambridge Physical Activity Index incorporates occupational and non-occupational physical activity. 
8. Information on exposure to carcinogens at the job is not available for Umea (Sweden), Norway, Naples 
(Italy), Utrecht (The Netherlands) and France. 
9. Median intake (25 and 75 percentile) 
10. Norway excluded because of missing data. 
11.France excluded because of missing data. 
12.United Kingdom excluded because of missing data.
13.Umea excluded because of missing data. 
14.Denmark excluded because of missing data.
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consumption of fruits and of vegetables, while no difference in risk estimates 
was observed among current smokers with a high or low consumption of 
fruits and of vegetables (data not shown). Separating prognostic risk groups, 
increased fruit and of vegetable consumption also decreased the risk of both 
aggressive and non-aggressive UCC among never and former smokers, but the 
strongest inverse associations with fruits and with vegetables were suggested 
for non-aggressive UCC (Figure 1 and 2). There was no heterogeneity between 
sex, geographic region, alcohol intake and BMI on the effect of total fruit or 
vegetable consumption on UCC risk (P for interaction > 0.05). Associations 
between fruit and vegetable consumption and UCC remained similar when 
occupational history was added to the model. Exclusion of the first 2 years of 
follow-up did not change the results (data not shown).
In the analysis of subgroups of fruit and vegetables, no association was found 
between consumption of citrus fruit, stone fruit, berries, fruiting vegetables, 
cabbages, mushrooms and garlic and onions and UCC risk (Table 3). We 
observed a decreased risk of an increment of grapes with 25 g/day on non-
aggressive UCC (calibrated HR 0.68; 95%CI: 0.47–1.00) and in the analysis of 
the categorical intake variable (HR highest versus lowest tertile 0.67; 95%CI: 
0.48–0.94, P-trend=0.04, Table 4). We did find a decreased risk with increments 
of25 g/day of root vegetables for aggressive UCC (observed HR 0.87; 95%CI: 
0.77–0.98, calibrated HR 0.70; 95%CI: 0.50–0.97) (Table 3). Comparing the 
highest tertile with the lowest tertile, we also observed an association between 
root vegetables and aggressive UCC (HR 0.71; 95%CI: 0.52–0.96; P-trend=0.02, 
Table 4). Higher consumption of leafy vegetables was inversely associated with 
non-aggressive UCC (observed HR for 25 g/day increase in intake 0.88; 95%CI: 
0.78–1.00, calibrated HR 0.58; 95%CI: 0.38–0.88) (Table 3). This association 
was also observed in the analysis of the categorical intake variable (HR highest 
versus lowest tertile 0.54; 95%CI: 0.36–0.82; P-trend=0.003, Table 4). The 
interaction of smoking status and subgroups of fruits and vegetables was not 
statistically significant (P for interaction > 0.05) (data not shown).
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Figure 2. Relation of non-aggressive urothelial cell carcinoma risk with consumption of vegeta-
bles and smoking status (never, former, current). Bars represent the hazard ratios of the joint 
effect of tertiles of vegetable consumption with smoking status. Statistically significant inverse 
association of each separate bar compared with the reference bar (low vegetable consumption in 
current smokers) are marked in bold. Analyses were controlled for duration of smoking (in years), 
and lifetime intensity of smoking (cigarettes/day). P = 0.54 for interaction of tertiles of vegetable 
consumption with smoking status. 
Figure 1. Relation of non-aggressive urothelial cell carcinoma risk with consumption of fruit and 
smoking status (never, former, current). Bars represent the hazard ratios of the joint effect of 
tertiles of fruit consumption with smoking status. Statistically significant inverse associations of 
each separate bar compared with the reference bar (low fruit consumption in current smokers) 
are marked in bold. Analyses were controlled for duration of smoking (in years), and lifetime 
intensity of smoking (cigarettes/day). P = 0.35 for interaction of tertiles of fruit consumption 
with smoking status. 
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DISCUSSION
In this large prospective study, we found no association between total fruit and/
or vegetable consumption and the risk of non-aggressive or aggressive UCC. 
Suggestions of inverse associations were observed between several subgroups 
of fruits and vegetables and risk of UCC; between root vegetables and aggressive 
UCC; and between leafy vegetables, grapes and non-aggressive UCC.
Case–control studies have mainly observed inverse associations between fruit 
and vegetable consumption and bladder cancer risk.18–23 However, these studies 
may have suαered from recall bias by disease-related changes in (the reporting 
of) dietary habits. This problem is overcome in prospective cohort studies. Thus 
far, seven cohort studies have investigated fruit and vegetable consumption in 
relation to bladder cancer risk.9,12,24–28 Three of these studies reported a weak 
inverse association between bladder cancer risk and consumption of fruits and 
vegetables.9,27,28 The four other cohort studies12,24–26 found no association, 
which is in line with our findings. An international panel of experts concluded 
that the evidence for an association between fruit and vegetable consumption 
and bladder cancer is limited.29 The weak protective or null associations in 
epidemiological studies may be explained by the fact that most studies had 
a relatively short follow-up period, included relatively few participants and 
thereby lacked power to detect real associations.
Inconsistencies between studies may also arise because the relation with fruit 
and vegetables was not stratified by bladder tumour aggressiveness. It has been 
recognized that bladder tumours vary in natural history and stratification into 
diαerent UCC subgroups according to stage and grade may help in identifying 
risk factors involved in diαerent UCC pathways. While the eαect of fruit and 
vegetables on the risk of bladder cancer has been extensively studied, thus 
far only The Netherlands Cohort Study27 investigated fruit and vegetable 
consumption in relation to stage-specific UCC risk. This study reported that an 
inverse association between both vegetables and fruit was more pronounced in 
invasive UCC than in non-invasive UCC. However, the authors did not present 
the risk estimates and the pathological features for each prognostic subgroup 
of UCC were not specified. It is diαcult to compare this study with our results 
because of possible diαerences in classification systems for bladder tumour 
aggressiveness.
For specific types of fruits and vegetables, the present study suggests an inverse 
association between the consumption of root vegetables, leafy vegetables, 
and grapes and the risk of UCC. Although several case-control studies and 
cohort studies reported an inverse association with grapes,27,30,31 leafy 
vegetables30,32 and root vegetables,27,30–33 as far as we know, there are no 
previous studies that evaluated the eαect of subgroups of fruit and vegetable 
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consumption separately for aggressive and non-aggressive bladder cancer. 
Diαerent mechanisms have been proposed to account for the potential 
protective eαect of subgroups of fruits and vegetables on bladder cancer, 
such as antioxidant and other mechanisms.34–36 While there is a biologically 
plausible role for some subgroups of fruit and vegetables in relation to bladder 
cancer, it is unclear why the risk of UCC diαered according to bladder tumour 
aggressiveness. Even though results suggest inverse associations, this should 
be interpreted with caution because we conducted multiple comparisons and 
residual confounding cannot be excluded. It has been postulated that smokers 
may benefit more from the consumption of fruit and vegetables than non-
smokers. The high antioxidant content of fruit and vegetables may reduce or 
prevent the oxidative damage caused by cigarette smoking. In contrast, our joint 
analyses show an inverse association between fruit or vegetables and UCC risk, 
in particular non-aggressive UCC, among non-smokers. So, if there is an eαect 
of fruit or vegetables, it is more clearly seen in non-smokers. No eαect was 
observed among current smokers with a high or a low consumption of fruit 
and vegetables. As smoking is the predominant risk factor for the development 
of UCC, these findings should further reinforce recommendations for smoking 
prevention and cessation. Despite the large cohort size, there is limited power to 
evaluate joint eαects of smoking status and subgroups of fruits and vegetables 
because the number of cases becomes small when stratified by smoking status 
and chance findings cannot be excluded.
The strengths of our study include its large-scale and multi-centre prospective 
study design and the possibility to distinguish non-aggressive from aggressive 
urothelial bladder cancers. A limitation of our study was that the food frequency 
questionnaire was only used during enrolment and was not repeated during 
follow-up. Although it is not expected that most middle-aged participants, 
the majority of the EPIC study participants, substantially change their dietary 
habits over the years,37 a single food frequency questionnaire may not perfectly 
capture long-term intake. Besides that, changes in diet and lifestyle habits may 
not have a direct eαect on disease risk because of the relatively long latency 
period of cancer. Diet long before enrolment is perhaps more of influence. In 
the present study, although widening confidence intervals, calibrated risks for 
fruits and vegetables became somewhat stronger supporting the suggestion 
that a high consumption of several subgroups of fruit and vegetables may 
protect against UCC. Although the calibration method assumes that a single 24-
hour dietary recalls measures the diet on an aggregate level without large bias 
and that the measurement error of the 24-hour dietary recalls is independent 
of that of the dietary questionnaires, this assumption may not be fully met in 
practice, and the calibrated hazard ratios may still be aαected to some extent 
by  measurement error.17 Therefore, the hazard ratio estimates may be biased 
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toward the null value and the calibrated HR estimates should be interpreted 
with caution.38 Furthermore, dietary questionnaires measuring foods with 
bioactive compounds do not reflect the bioavailability of the nutrients from 
various foods, the level of absorption from the digestive tract, or individual 
diαerences in metabolism. Blood levels of these compounds and related 
genetic variation are expected to be better markers of true biological exposure 
than dietary intake assessments. Therefore, future analyses of diet and UCC 
risk should preferably include data on specific genetic polymorphisms and 
biomarkers of diet such as concentrations of antioxidant levels in blood. On 
the other hand, people do not consume single foods or nutrients, but meals 
that consist of certain combinations of foods and nutrients. Therefore, it is of 
interest to identify dietary patterns that are associated with UCC risk. Analyses 
to this respect are planned within EPIC.
In summary, our study did not confirm a protective eαect of total fruit and/or 
vegetable consumption on aggressive or non-aggressive UCC. High consumption 
of certain subtypes of vegetables and fruits may reduce the risk of aggressive or 
non-aggressive UCC, although chance findings cannot be excluded.
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ABSTRACT
Background
Published associations between dietary carotenoids and vitamin C and bladder 
cancer risk are inconsistent. Biomarkers may provide more accurate measures 
of nutrient status.
Objective
We investigated the association between plasma carotenoids and vitamin C and 
risk of urothelial cell carcinoma (UCC) in a case-control study nested within the 
European Prospective Investigation into Cancer and Nutrition.
Design
A total of 856 patients with newly diagnosed UCC were matched with 856 cohort 
members by sex, age at baseline, study centre, date and time of blood collection, 
and fasting status. Plasma carotenoids (α- and α-carotene, α-cryptoxanthin, 
lycopene, lutein, and zeaxanthin) were measured by using reverse-phase HPLC, 
and plasma vitamin C was measured by using a colorimetric assay. Incidence 
rate ratios (IRRs) were estimated by using conditional logistic regression with 
adjustment for smoking status, duration, and intensity.
Results
UCC risk decreased with higher concentrations of the sum of plasma carotenoids 
(IRR for the highest compared with the lowest quartile 0.64; 95%CI: 0.44-0.93, 
P-trend=0.04). Plasma b-carotene was inversely associated with aggressive 
UCC (IRR 0.51; 95%CI: 0.30-0.88, P-trend=0.02). Plasma lutein was inversely 
associated with risk of nonaggressive UCC (IRR 0.56; 95%CI: 0.32, 0.98, 
P-trend=0.05). No association was observed between plasma vitamin C and 
risk of UCC.
Conclusions
Although residual confounding by smoking or other factors cannot be excluded, 
higher concentrations of plasma carotenoids may reduce risk of UCC, in 
particular aggressive UCC. Plasma lutein may reduce risk of nonaggressive 
UCC. 
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INTRODUCTION 
During the past decades, there has been considerable interest in the role of 
antioxidants in the prevention of cancer. Carotenoids and vitamin C received 
much attention, particularly because they may prevent DNA damage by 
neutralizing free radicals and oxidants.1 Dietary intake of carotenoids and vitamin 
C may reduce risk of bladder cancer.2 However, results from prospective studies 
are inconsistent. This inconsistency may partly be due to misclassification of 
self-reported vegetable and fruit consumption, which is the primary source of 
dietary carotenoids and vitamin C.3 Only a few studies used circulating blood 
concentrations of carotenoids or vitamin C, which reflect both dietary and 
supplemental intakes.4–7 A case-control study4 in the United States and a nested 
case-control study5 in Japanese-American men showed inverse associations 
between bladder cancer risk and several individual carotenoid concentrations. 
Two prospective studies showed no association between circulating carotenoids 
and bladder cancer risk.6, 7 Contradictory results may also be explained because 
urothelial cell carcinoma (UCC)6 of the bladder is often considered to be one 
disease although it represents a heterogeneous group of tumours with different 
prognoses that develop through different molecular pathways. Low-grade 
papillary tumours are characterized by activating mutations in the HRAS and 
FGFR3 oncogenes and chromosome 9 aberrations; high-grade papillary and 
solid tumours are characterized by structural and functional defects in the TP53 
and RB tumour-suppressor genes.8, 9 
We examined the association between prediagnostic plasma carotenoids and 
vitamin C concentrations and risk of prognostic subgroups of UCC in a case-
control study nested within the European Prospective Investigation into Cancer 
and Nutrition (EPIC).
SUBJECTS AND METHODS 
Study population and data collection
The design and methods of the EPIC study have been previously described in 
detail.10, 11 Briefly, the EPIC is a cohort study comprising more than one-half 
million people recruited in 23 centres in 10 European countries (Denmark, 
France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the 
United Kingdom). Study participants were aged between 25 and 70 y and were 
recruited between 1992 and 2000, mainly from the general population. Eligible 
subjects were invited to participate in the study, and subjects who consented 
completed standardized questionnaires on their diet, lifestyle, and medical 
history at enrollment.10–12 Usual dietary intake during the year before recruitment 
was measured by using country-specific validated diet questionnaires designed 
to reflect local dietary patterns.10,11 Intakes of dietary α-carotene (the only 
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dietary carotenoid currently available in the EPIC database) and vitamin C were 
estimated by using standardized country-specific food composition tables.12 
Data on the use of dietary supplements (yes compared with no) were collected 
for ~80% of the cohort.
In each of the participating centres, blood samples of ≥20 mL were drawn 
at baseline from consenting participants (74% of all respondents donated 
samples). Study centres collected and stored blood samples according to a 
standardized protocol.10 After blood donation, samples were stored at 5–10αC, 
protected from light, and transported to local laboratories for processing and 
dividing into aliquots. Exceptions were the EPIC-Oxford (United Kingdom) and 
EPIC-Norway centres, where blood samples were collected from a network 
of general practitioners and transported to a central laboratory by post, and 
centres in Sweden, where blood was divided into aliquots ≤1 h after collection. 
In all countries, except in Denmark and Sweden, blood was separated into 
0.5-mL fractions (serum, plasma, red cells, and buffy coat for DNA extraction) 
and stored in heat-sealed straws in liquid nitrogen (-196αC). One-half of all 
aliquots were stored at the local study centre and the other one-half of aliquots 
were stored in the central EPIC biorepository at the International Agency for 
Research on Cancer (IARC, Lyon, France). In Denmark, blood fraction aliquots in 
1-mL tubes were stored at -150αC under nitrogen vapour. In Sweden, samples 
were stored in 1.8-mL tubes in -80αC freezers.10, 11
All participants gave written informed consent, and the study was approved 
by the Institutional Review Board of IARC and the local ethics committees in 
participating countries.
Nested case-control design and selection of participants
Incident cancer cases were identified through linkage to population-based 
cancer registries in Denmark, Italy (except Naples), the Netherlands, Norway, 
Spain, Sweden, and the United Kingdom or through a combination of methods 
including linkage to health insurance records, cancer and pathology registries, 
and active follow-up of study participants or their next of kin in France, 
Germany, Greece, and Naples (Italy). The follow-up ended between 2002 and 
2005 in different countries; individuals were censored at the end of follow-up, 
last known contact, cancer diagnosis, or death. Participants were followed from 
study entry until a first primary bladder cancer diagnosis (code C67 according 
to the International Classification of Diseases–Oncology, third edition,2000), 
death, emigration, or end of the follow-up period. Only urothelial cell papillomas 
and carcinomas (morphology codes 8120 and 8130) were included in the 
analyses. Pathology reports of UCC cases were collected from each centre. 
Stage T1 and higher, carcinoma in situ, or WHO grade 3 carcinomas were 
classified as aggressive UCCs, whereas stage Ta grades 1 or 2 were classified 
as nonaggressive UCCs.13 Ninety-two percent of the cases were classified 
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as aggressive or nonaggressive UCC. Each case was matched to one control 
subject by incidence density sampling from all cohort members alive and free of 
cancer at the time of diagnosis of cases (except for nonmelanoma skin cancer). 
Controls were randomly selected from the population at risk at the time of the 
index case occurrence. Under this design, a selected control could have served 
as a control for another case and may have become a case at a later time in 
follow-up. Matching criteria were sex, age at time of enrolment (±3 y), study 
centre, date of blood collection (±3 mo), time of day of blood collection (±2 h), 
and fasting status at the time of blood collection (<3, 3–6, and >6 h since last 
meal). Matched controls were unavailable for 11 cases, and these individuals 
were excluded from analyses. The current study included 856 pairs of first 
primary UCC cases and their matched controls.
Laboratory assays
Aliquots of plasma were extracted from the central biorepository at IARC and 
the local centres of Denmark and Sweden. The frozen plasma was shipped in dry 
ice to the National Institute for Public Health and the Environment (Bilthoven, 
Netherlands) for analysis. Samples were thawed shortly before analysis. Seven 
carotenoids (α- and α-carotene, α-cryptoxanthin, lycopene, lutein, zeaxanthin, 
and cantaxanthin) were simultaneously analysed with HPLC by using an HPLC 
column (250 x 4.6 mm, ChromSpher 5-µm C18; Varian Association) with 
detection at 450 nm. Echinenone was used as internal standard.14 Cantaxanthin 
concentrations were close or below the limit of detection for most samples 
and, therefore, were not used in the current study. Approximately 4.5% of 
concentrations of the other carotenoids were under the limit of detection (20 
nmol/L) and were set at the detection limit. For quality control, one control 
sample with concentrations similar to mean concentrations in controls was 
added to each batch of samples to assess interbatch reproducibility. There were 
25 batches. CVs for these quality-control samples were 14.6% for α-carotene, 
6.3% for α-carotene, 4.4% for α-cryptoxanthin, 10.1% for lycopene, 7.8% 
for lutein, and 10.5% for zeaxanthin. Plasma vitamin C concentrations were 
determined with an LX20-Pro autoanalyzer (Beckman-Coulter) by using a 
colorimetric assay.15 The CV for vitamin C was 4.7% at a vitamin C concentration 
of 28.3 mmol/L. The limit of sensitivity of the method was 2.5 mmol/L, and no 
peaks of vitamin C were under the limit of detection. To minimize the influence 
of batch-to-batch variation, cases were analysed in the same analytic batch as 
their matched controls. Laboratory technicians were blinded to the case-control 
status of samples, and biochemical analyses were done in one laboratory, with 
avoidance of between-laboratory method variability. Plasma carotenoids and 
vitamin C have been estimated to be stable for several years at different storage 
temperatures.16, 17
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Statistical analysis
ORs and 95% CIs for UCC risk in relation to plasma concentrations and dietary 
intakes were calculated by using conditional logistic regression models stratified 
by the case-control set. With an incidence density sampling design, the OR 
is an unbiased approximation of the incidence rate ratio (IRR).18 IRRs were 
calculated by using quartiles with cutoffs that were based on the distribution of 
carotenoids and vitamin C in control subjects. We derived probability values for 
a linear trend across quartiles from regression models by using median plasma 
concentrations within quartiles as a continuous variable, thereby taking the 
unequal distances of the quartiles into account.19 The data were also analysed 
as continuous variables. Plasma values of carotenoids and vitamin C were log2-
transformed to improve normality. The IRR of these log2-transformed variables 
corresponded to the reduction of UCC risk with the doubling of the plasma 
concentration or dietary intake.
All analyses were controlled for smoking status (never, former, or current), 
duration of smoking (years), and lifetime intensity of smoking (cigarettes/d). 
Energy intake (continuous), consumption of processed or red meat (continuous), 
alcohol intake (continuous), physical activity (inactive, moderately inactive, 
moderately active, or active), BMI (continuous), occupational history, and 
educational level (primary school or less, technical/professional school, 
secondary school, or university) were not included in the final analyses because 
none of these factors noticeably affected the α estimates of plasma variables. 
Additional analyses were performed by using nonaggressive and aggressive 
UCCs as separate endpoints.
Because smoking could have modified the investigated associations, joint 
effects were determined for tertiles of plasma carotenoids and vitamin C in 
combination with smoking status (never, former, or current) in relation to UCC 
risk. The combined category of low plasma carotenoids or vitamin C with current 
smoking was chosen as reference. We used tertiles of plasma carotenoids or 
vitamin C instead of quartiles to have enough power. The statistical interaction 
on a multiplicative scale was tested by introducing a product term between 
plasma carotenoids or vitamin C (continuous) and smoking status. Analyses of 
joint effects were controlled for duration of smoking (y) and lifetime intensity 
of smoking (cigarettes/d). Similar models were used to test for interactions with 
sex, alcohol intake, and BMI. To evaluate whether preclinical disease may have 
influenced results, analyses were repeated after exclusion of cases along with 
their matched controls who were diagnosed within 2 y after recruitment (n=134 
pairs). All statistical analyses were performed with SAS software (version 9.2; 
SAS Institute Inc). For all analyses, 2-sided P < 0.05 was considered statistically 
significant.
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RESULTS 
As expected, UCC cases were more likely to smoke. They were also slightly 
less educated, reported a higher intake of alcohol, and consumed less fruit and 
vegetables. Of 856 UCC cases, 405 cases were classified as aggressive and 384 
cases were identified as nonaggressive. Sixty-seven UCC cases could not be 
classified as aggressive or nonaggressive UCCs because information on stage 
and grade was not available (Table 1).
No significant associations were observed between concentrations of 
individual carotenoids, vitamin C, and risk of total UCC. The sum of carotenoids, 
however, showed an inverse association with total UCC (IRR for highest 
compared with lowest quartile 0.64; 95%CI: 0.44-0.93, P-trend=0.04). For 
the sum of carotenoids, inverse associations were quite similar for aggressive 
and nonaggressive UCC risk, but the reduction in risk of aggressive UCC was 
only significant for subjects in the highest quartile (IRR for highest compared 
with lowest quartile 0.53; 95%CI: 0.30-0.94, P-trend=0.05) (Table 2). Plasma 
α-carotene was inversely associated with aggressive UCC (IRR for highest 
compared with lowest quartile 0.51; 95%CI: 0.30-0.88, P-trend=0.02) but not 
with nonaggressive UCC. For nonaggressive UCC, inverse associations were 
observed for plasma lutein (IRR highest compared with lowest quartile 0.56; 
95%CI: 0.32-0.98, P-trend=0.05) (Table 2). These inverse associations persisted 
after exclusion of cases diagnosed during the first 2 y of follow-up (data not 
shown).
For dietary α-carotene, an inverse association was observed with total UCC 
risk (IRR for highest compared with lowest quartile 0.70; 95%CI: 0.50-0.97, 
P-trend=0.04). A higher intake of dietary α-carotene was borderline significantly 
inversely associated with nonaggressive UCC risk (IRR for higher compared with 
lowest quartile 0.61; 95%CI: 0.37-0.99, P-trend=0.09) but not with aggressive 
UCC risk (Table 3). In contrast, for plasma α-carotene, an inverse association was 
shown for aggressive UCC but not for nonaggressive UCC (Table 2). A higher 
intake of dietary vitamin C was not associated with UCC risk (Table 3).
When joint effects of smoking status and plasma carotenoids and vitamin C were 
evaluated, smoking was the dominant risk factor. Although the interaction of 
smoking status and plasma carotenoids was not significant (P-interaction=0.27), 
compared with the reference category (current smokers in the lowest tertile 
of plasma carotenoids), the lowest UCC risk was seen in current smokers with 
increasing plasma concentrations of carotenoids (IRR for highest compared with 
lowest plasma carotenoid concentrations 0.61; 95%CI: 0.38-0.99) (Table 4). 
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Table 1. Baseline characteristics of the study population of urothelial cell carcinoma cases and 
controls in the EPIC.1
Cases 
(n= 856)
Matched controls 
(n= 856)
Participating countries (n)
France 5 5
Italy 102 102
Spain 91 91
United Kingdom 103 103
The Netherlands 58 58
Greece 14 14
Germany 105 105
Sweden 173 173
Denmark 204 204
Norway 1 1
General characteristics
Men (n, %) 631 (74) 631 (74)
Women (n,%) 225 (26) 225 (26)
BMI (kg/m2) 26.6 ± 4.02 26.4 ± 3.8
Physically active (%)3 41 42
Age at recruitment (y) 58.5 ± 7.4 58.5 ± 7.4
Smoking status
Never smokers (%) 19 39
Former smokers (%) 36 35
Lifetime number of cigarettes (cig/day) 10.4 ± 10.0 10.1 ± 10.2
Smoking duration (y) 25.3 ± 13.8 21.6 ± 13.0
Age at start smoking (y) 17.8 ± 5.7 19.0 ± 6.6
Time since quitting smoking (y) 13.7 ± 11.5 17.1 ± 12.1
Current smokers (%) 45 26
Lifetime number of cigarettes (cig/day) 14.0 ± 9.3 11.8 ± 8.9
Smoking du ration (y) 38.6 ± 9.9 36.1 ± 11.6
Age at start smoking (y) 17.9 ± 5.9 19.5 ± 7.8
Exposure to carcinogens at the job (%)4
Heavy metals 11 11
Aromatic amines 9 8
Polycylic Aromatic Hydrocarbons (PAH) 8 6
With environmental tobacco smoking 
exposure
3 3
1 Controls were matched to cases by gender, age at baseline, study centre, date and time of 
blood collection, and fasting status. EPIC, European Prospective Investigation into Cancer and 
Nutrition.
2 Mean ± SD (all such values). 
3 Cambridge Physical Activity Index incorporates occupational and non to occupational physical 
activity. 
4 Data were not available for Umea (Sweden), Norway, Naples (Italy), Utrecht (The Netherlands) 
and France. 
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Table 1. Continued
Cases 
(n= 856)
Matched controls 
(n= 856)
Educational level (%)
None and primary school 45 40
Technical/professional school 24 28
Secondary school 11 10
University degree 18 20
Not specified 2 2
Diet 
Total energy (kcal/day) 2263.0 ± 661.7 2279.0 ± 710.4
Energy from fat (kcal/day) 782.7 ± 286.1 785.4 ± 295.8
Energy from non to fat (kcal/day) 1480.3 ± 443.3 1493.6 ± 479.6
Alcohol consumption (g/day) 19.2 ± 22.8 17.6 ± 21.5
Red meat (g/day) 55.3 ± 39.4 53.7 ± 45.2
Processed meat (g/day) 40.7 ± 35.3 40.3 ± 35.0
Total fruits (g/day) 195.6 ± 165.2 217.6 ± 187.5
Total vegetables (g/day) 172.7 ± 143.7 178.9 ± 125.7
Dietary vitamin C, mg/day 
(median, 5th - 95th percentile)
101.5 (40.0 - 232.1)5 102.7 (41.9 - 222.1)
Dietary β to carotene, μg/day 
(median, 5th - 95th percentile)
2110.6 (660.4 - 7296.0) 2307.9 (642.5 - 7932.9)
Plasma concentrations micronutrients 
(median, 5th to 95th percentile)
Vitamin C, μmol/L 33.7 (2.2 - 70.1) 36.6 (6.3 - 66.0)
α-carotene, nmol/L 84.7 (26.4 - 278.8) 94.3 (32.2 - 298.5)
β-carotene, nmol/L 400.2 (151.7 - 1201.4) 445.3 (167.0 - 1291.4)
Lycopene, nmol/L 346.3 (85.7 - 927.6) 370.3 (113.9 - 948.1)
β-cryptoxanthin, nmol/L 232.3 (51.0 - 1069.6) 244.5 (65.6 - 1017.3)
Zeaxthantin, nmol/L 77.9 (21.9 - 214.9) 78.6 (24.6 - 222.9)
Lutein, nmol/L 279.5 (112.9 - 766.3) 296.7 (123.4 - 790.6)
Sum of carotenoids, nmol/L 1551.7 (732.6 -3604.9) 1671.4 (816.2 - 3749.0)
Cases only
Age at diagnosis 63.2 ± 7.7 -
Time from blood draw to diagnosis (y) 4.6 ± 2.8 -
Urothelial cell carcinoma (n,%)6
Aggressive7 405 (47) -
Non-aggressive8 384 (45) -
Unknown9 67 (8) -
5 Median; 5th-95th percentile in parentheses (all such values)
6 Includes transitional cell papillomas and carcinomas (morphology codes 812 and 813, and beha-
viour coded as ‘uncertain whether benign or malignant’, ‘carcinoma in situ’ and/or as ‘malignant’), 
but excludes inverted papillomas (8121/1). 
7 Includes all stage T1 or higher, all CIS or all WHO 1973 grade 3 carcinomas (including Ta grade 3) 
8 Includes all stage Ta grade 1 or Ta grade 2 carcinomas. 
9 Sixty-seven urothelial cell carcinomas cannot be classified as aggressive or non-aggressive urot-
helial cell carcinomas because of a lack of information on stage and/or grade.
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In comparison with the reference category (current smokers in the lowest tertile 
of plasma vitamin C), a graded decrease in UCC risk with increasing plasma 
concentrations of vitamin C was shown in current smokers (IRR for highest 
compared with lowest plasma vitamin C concentrations 0.63; 95%CI: 0.41-0.97; 
P-interaction=0.007) (Table 4). These data suggest that smoking may modify the 
association between plasma carotenoids and vitamin C and risk of UCC. The 
associations between plasma carotenoids or vitamin C and risk of UCC were not 
modified by sex, alcohol intake, or BMI (data not shown).
DISCUSSION
In the current study, the sum of plasma carotenoids was inversely associated 
with UCC risk. Inverse associations were also observed for α-carotene and risk 
of aggressive UCC and between plasma lutein and risk of nonaggressive UCC. 
No association was observed between plasma vitamin C concentrations and 
UCC risk. Risk of UCC was reduced with increasing plasma concentrations of 
vitamin C in current smokers.
The relation between circulating carotenoids and bladder cancer risk has been 
previously investigated. A case-control study4 that included 84 cases showed 
that plasma lutein, α-carotene, α-cryptoxanthin, and lycopene were inversely 
associated with bladder cancer risk. However, results may have been biased by 
changes in blood concentrations after diagnosis. A nested case-control study of 
Japanese-American men with 111 incident cases of bladder cancer showed inverse 
associations between serum α-carotene and lutein plus zeaxanthin.5 Two other 
prospective studies observed no associations between α-carotene6, 7 and lycopene7 
and bladder cancer risk. These studies also had a very small sample size (10–
20 cases) and may have lacked power to detect any significant difference in 
risk. Randomized intervention trials that involved synthetic α-carotene20–22 or 
vitamin C23 supplements and examined bladder cancer as a secondary endpoint 
showed increased risks20 as well as no associations21–23. The null or harmful 
effect of α-carotene on bladder cancer risk in trials is inconsistent with the 
inverse association seen in our cohort. Although observational studies observe 
the effect of α-carotene in the general population, clinical trials can examine 
only a specific intervention, in a specific population, over a relatively short 
period of time. Also much higher doses of α-carotene were used than obtained 
from the diet. Despite the inconsistencies among trials, it is unlikely that the 
different pharmacologic doses of α-carotene that were used would prevent 
bladder cancer.
In our study, dietary α-carotene was borderline significantly inversely associated 
with UCC risk, whereas dietary vitamin C was not associated with UCC risk. 
The correlation coefficient between plasma concentrations and dietary intake 
Chapter 4
78
was only 0.20 for α-carotene and 0.16 for vitamin C. These weak correlations 
may be explained by errors in the food-composition table from which dietary 
α-carotene and vitamin C were derived and biases in the assessment of dietary 
intake. Other explanations may be related to the bioavailability of carotenoids 
and vitamin C that can vary substantially depending on the cooking method 
used or the metabolism of carotenoids and vitamin C that can affect their blood 
concentrations or because only a single plasma measurement was available. 
However, risk estimates of plasma concentrations and dietary intakes of 
α-carotene and vitamin C were quite similar despite the low correlations.
After separation of prognostic risk groups, our findings suggest an inverse 
association between plasma α-carotene and risk of aggressive UCC. For 
nonaggressive UCC, inverse associations were observed for plasma lutein. To 
our knowledge, only 2 previous studies evaluated the effect of carotenoids 
stratified by bladder tumour aggressiveness. The Alpha-Tocopherol Beta-
Carotene Prevention trial on α-carotene supplementation observed no 
difference in risk estimates for invasive and noninvasive bladder tumors.22 
The Netherlands Cohort Study reported that the inverse association between 
dietary intakes of α-cryptoxanthin did not differ according to bladder tumour 
aggressiveness.24 Although antioxidant properties of carotenoids have been 
suggested as the main mechanism that underlies their inverse association with 
epithelial cancers25, additional mechanisms have also been proposed. α- and 
α-carotene and α-cryptoxanthin can be converted into vitamin A, which is 
involved in cell differentiation and enhancement of the immunologic response. 
In addition, carotenoids stimulate gap junctional intercellular communication 
correlated with the growth inhibition of chemically transformed cells (26). 
Stivala et al.27 showed that α-carotene induces a cell-cycle delay in the G1 
phase in normal human fibroblasts. Aggressive, high-grade bladder tumours are 
characterized by defects in the RB tumour-suppressor gene, which prevents 
premature G1/S cell-cycle transition. This potential mechanism suggests that 
α-carotene can modulate aggressive bladder carcinogenesis through pathways 
related to cancer cell proliferation.
In the current study, plasma vitamin C or carotenoid concentrations in 
combination with smoking status suggest that there is a graded decrease in 
UCC risk in current smokers with a high concentration of plasma vitamin C or 
carotenoids. Thus, if an effect of plasma vitamin C or carotenoids exists, our 
study suggests that it is more prominent in current smokers. This finding is 
in line with the hypothesis that smokers may benefit more from vitamin C or 
carotenoids intake than non-smokers. The high antioxidant content of vitamin C 
or carotenoids may reduce the oxidative damage caused by cigarette smoking.28 
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However, the inverse associations observed should be interpreted with caution 
because we conducted multiple comparisons, and residual confounding by 
smoking could not be excluded.
Our results showed that the inverse associations remained unchanged when the 
results were adjusted for several lifestyle factors. However, inverse associations 
seen in observational studies may reflect other unmeasured lifestyle factors 
associated with both high plasma concentrations of carotenoids and low 
risk of bladder cancer. Thus, high plasma concentrations of carotenoids may 
just be a marker of a healthy lifestyle.29 In our study, participants with higher 
plasma concentrations of carotenoids tended to have a healthier lifestyle (data 
not shown). Higher concentrations of carotenoids may also be a marker of a 
concerted effect of multiple bioactive compounds in fruit and vegetables. The 
possibility was not supported by results from Büchner et al.30, 31 who showed 
no effect of quantity30 or variety31 in fruit and vegetable consumption on 
bladder cancer risk in the EPIC. However, the correlation between plasma 
markers and the variety of fruit and vegetable consumption was rather weak 
(data not shown), which makes interpretation difficult. The strengths of our 
study included its prospective design, the relatively large number of UCC 
cases, the wide range in plasma concentrations, and the collection of blood 
samples before cancer diagnosis. However, there were limitations in this study. 
Carotenoids are transported in blood as part of lipoprotein complexes, and 
plasma concentrations may depend on the type and amount of fat consumed. 
Optimally, plasma concentrations of carotenoids should be adjusted for blood 
lipids. Still, adjustment for plasma lipids measured in another EPIC study on 
gastric cancer that used the same biomarkers did not result in any appreciable 
changes in risk estimates.32 The use of supplements such as α-carotene or 
vitamin C could also affect plasma concentrations. In our study, no substantial 
change in risk estimates was observed by simple adjustment for dietary 
supplement use (yes compared with no). Unfortunately, information about the 
type of supplement and frequency of use was not available in our study.
Our analyses were based on single measurements of plasma carotenoids and 
vitamin C concentrations. On this basis, we assumed that plasma concentrations 
were stable in persons during follow-up. Blood concentrations may differ over 
time because of day-to-day variation and long-term changes within persons, 
which may lead to an attenuation of associations. The repeatability of serum 
carotenoids has been previously been determined, and intraclass correlation 
coefficients over 1–4 y ranged from 0.5 to 0.7.33 This result suggests a moderate 
repeatability of measurements of plasma carotenoids and vitamin C. These 
measures should be reliable enough to detect moderate associations.
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In conclusion, this study provides some evidence for a protective role of 
plasma carotenoids in UCC development. Our results suggest that plasma 
α-carotene may be protective for aggressive UCC, whereas plasma lutein may 
be protective for nonaggressive UCC. Residual confounding by smoking or 
other factors cannot entirely be excluded, and confirmation of our results in 
other prospective settings is warranted.
GRANT SUPPORT
This work was supported by the European Commission: Public Health and 
Consumer Protection Directorate 1993-2004; Research Directorate-General 
2005-.”; Ligue contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de 
l’Education Nationale, Institut National de la Santé et de la Recherche Médicale 
(INSERM) (France); German Cancer Aid, German Cancer Research Center, 
Federal Ministry of Education and Research (Germany); Danish Cancer Society 
(Denmark); Health Research Fund (FIS) of the Spanish Ministry of Health, The 
participating regional governments and institutions (Spain); Cancer Research 
UK, Medical Research Council (United Kingdom); Hellenic Health Foundation, 
Stavros Niarchos Foundation and the Hellenic Ministry of Health and Social 
Solidarity; Italian Association for Research on Cancer, National Research 
Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), 
Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention 
Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund 
(WCRF), Dutch Cancer Society (KWF), Statistics Netherlands (The Netherlands); 
Swedish Cancer Society, Swedish Scientific Council, Regional Government of 
Skane (Sweden); Helga study - Nordforsk centre of excellence programme in 
food and nutrition (Norway). 
Plasma carotenoids and vitamin C and the risk of urothelial cell carcinomas
81
REFERENCES
1. Stebbing J, Hart CA. Antioxidants and cancer. Lancet Oncol 2011;12(11):996.
2. Steinmaus CM, Nunez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary 
variables. Am J Epidemiol 2000;151(7):693-702.
3. Key TJ. Fruit and vegetables and cancer risk. Br J Cancer 2011;104(1):6-11.
4. Hung RJ, Zhang ZF, Rao JY, et al. Protective effects of plasma carotenoids on the risk of 
bladder cancer. J Urol 2006;176(3):1192-7.
5. Nomura AM, Lee J, Stemmermann GN, Franke AA. Serum vitamins and the subsequent risk 
of bladder cancer. J Urol 2003;170(4 Pt 1):1146-50.
6. Knekt P, Aromaa A, Maatela J, Alfthan G, Aaran RK, Nikkari T, Hakama M, Hakulinen T, 
Teppo L. Serum micronutrients and risk of cancers of low incidence in Finland. Am J 
Epidemiol 1991;134(4):356-61.
7. Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-
carotene, retinol, and subsequent bladder cancer. Cancer Res 1989;49(21):6144-8.
8. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 
2005;5(9):713-25.
9. Knowles MA. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008;13(4):287-
97.
10. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective 
Investigation into Cancer and Nutrition. Int Epidemiol 1997;26 Suppl 1:S6-14.
11. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, 
Casagrande C, Vignat, J, et al. European Prospective Investigation into Cancer and Nutrition 
(EPIC): study populations and data collection. Public Health Nutr 2002;5(6B):1113-24.
12. Slimani N, Deharveng G, Unwin I, Southgate DA, Vignat J, Skeie G, Salvini S, Parpinel M, 
Moller A, Ireland J, et al. The EPIC nutrient database project (ENDB): a first attempt to 
standardize nutrient databases across the 10 European countries participating in the EPIC 
study. Eur J Clin Nutr 2007;61(9):1037-56.
13. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, Gudmundsson J, 
Jakobsdottir M, Bergthorsson JT, Sigurdsson A, et al. Sequence variant on 8q24 confers 
susceptibility to urinary bladder cancer. Nat Genet 2008;40(11):1307-12.
14. Steghens JP, van Kappel AL, Riboli E, Collombel C. Simultaneous measurement of 
seven carotenoids, retinol and alpha-tocopherol in serum by high-performance liquid 
chromatography. J Chromatogr B Biomed Sci Appl 1997;694(1):71-81.
15. Lee W, Roberts SM, Labbe RF. Ascorbic acid determination with an automated enzymatic 
procedure. Clin Chem 1997;43(1):154-7.
16. Al-Delaimy WK, van Kappel AL, Ferrari P, Slimani N, Steghens JP, Bingham S, Johansson 
I, Wallstrom P, Overvad K, Tjonneland A, et al. Plasma levels of six carotenoids in nine 
European countries: report from the European Prospective Investigation into Cancer and 
Nutrition (EPIC). Public Health Nutr 2004;7(6):713-22.
Chapter 4
82
17. Key T, Oakes S, Davey G, Moore J, Edmond LM, McLoone UJ, Thurnham DI. Stability 
of vitamins A, C, and E, carotenoids, lipids, and testosterone in whole blood stored at 4 
degrees C for 6 and 24 hours before separation of serum and plasma. Cancer Epidemiol 
Biomarkers Prev 1996;5(10):811-4.
18. Richardson DB. An incidence density sampling program for nested case-control analyses. 
Occup Environ Med 2004;61(12):e59.
19. Jansen MC, Bueno-de-Mesquita HB, Feskens EJ, Streppel MT, Kok FJ, Kromhout D. 
Quantity and variety of fruit and vegetable consumption and cancer risk. Nutr Cancer 
2004;48(2):142-8.
20. Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH. Effects of beta-carotene 
supplementation on cancer incidence by baseline characteristics in the Physicians’ Health 
Study (United States). Cancer Causes Control 2000;11(7):617-26.
21. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, 
Meyskens FL Jr, Valanis B, Williams JH Jr, et al. Risk factors for lung cancer and for 
intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer 
Inst 1996;88(21):1550-9.
22. Virtamo J, Edwards BK, Virtanen M, Taylor PR, Malila N, Albanes D, Huttunen JK, Hartman 
AM, Hietanen P, Maenpaa H, et al. Effects of supplemental alpha-tocopherol and beta-
carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland). 
Cancer Causes Control 2000;11(10):933-9.
23. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson 
JE, Sesso HD, Buring JE. Vitamins E and C in the prevention of prostate and total cancer in 
men: the Physicians’ Health Study II randomized controlled trial. JAMA 2009;301(1):52-62.
24. Zeegers MP, Goldbohm RA, van den Brandt PA. Consumption of vegetables and fruits 
and urothelial cancer incidence: a prospective study. Cancer Epidemiol Biomarkers Prev 
2001;10(11):1121-8.
25. Bertram JS, Bortkiewicz H. Dietary carotenoids inhibit neoplastic transformation 
and modulate gene expression in mouse and human cells. Am J Clin Nutr 1995;62(6 
Suppl):1327S-36S.
26. McCullough ML, Giovannucci EL. Diet and cancer prevention. Oncogene 2004;23(38):6349-
64.
27. Stivala LA, Savio M, Quarta S, Scotti C, Cazzalini O, Rossi L, Scovassi IA, Pizzala R, Melli 
R, Bianchi L, et al. The antiproliferative effect of beta-carotene requires p21waf1/cip1 in 
normal human fibroblasts. Eur J Biochem 2000;267(8):2290-6.
28. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants 
in oxidative stress-induced cancer. Chem Biol Interact 2006;160(1):1-40.
29. Dehghan M, Akhtar-Danesh N, Merchant AT. Factors associated with fruit and vegetable 
consumption among adults. J Hum Nutr Diet 2011.
Plasma carotenoids and vitamin C and the risk of urothelial cell carcinomas
83
30. Buchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, 
Raaschou-Nielsen O, Tjonneland A, Roswall N, Clavel-Chapelon F, et al. Consumption of 
vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation 
into Cancer and Nutrition. Int J Cancer 2009;125(11):2643-51.
31. Buchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, 
Tjonneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, et al. Variety in vegetable 
and fruit consumption and risk of bladder cancer in the European Prospective Investigation 
into Cancer and Nutrition. Int J Cancer 2011;128(12):2971-9.
32. Jenab M, Riboli E, Ferrari P, Sabate J, Slimani N, Norat T, Friesen M, Tjonneland A, Olsen 
A, Overvad K, et al. Plasma and dietary carotenoid, retinol and tocopherol levels and the 
risk of gastric adenocarcinomas in the European prospective investigation into cancer and 
nutrition. Br J Cancer 2006;95(3):406-15.
33. Al-Delaimy WK, Natarajan L, Sun X, Rock CL, Pierce JP. Reliability of plasma carotenoid 
biomarkers and its relation to study power. Epidemiology 2008;19(2):338-44.
Chapter 4
84


One-carbon metabolism 
biomarkers and risk of 
urothelial cell carcinomas: 
Results from the European 
Prospective Investigation into 
Cancer and Nutrition
5
Submitted
Chapter 5
88
ABSTRACT 
Background
Folate and other B-vitamins are involved in one-carbon metabolism affecting 
DNA methylation, nucleotide synthesis, and DNA repair. Low levels of 
B-vitamins may increase the risk of bladder cancer. This nested case-control 
study within the European Prospective Investigation into Cancer and Nutrition 
(EPIC) is the first prospective study that investigated associations between pre-
diagnostic serum folate, homocysteine, vitamins B6 and B12 and the risk of 
urothelial cell carcinomas of the bladder (UCC). 
Methods
824 patients with UCC were matched to 824 control participants by incidence 
density sampling. Matching factors were sex, age at baseline, study centre, 
date and time of day of blood collection, and fasting status. Levels of folate, 
homocysteine, vitamins B6 and B12 were measured in single pre-diagnostic 
serum samples. Odds ratios (OR) were estimated with conditional logistic 
regression with adjustment for smoking status, smoking duration and intensity. 
All statistical tests were two-sided.
Results
Lower concentrations of serum folate were borderline positively associated with 
UCC (IRR 1.37; 95%CI: 0.98-1.90, P-trend=0.05), in particular with aggressive 
UCC (IRR 1.69; 95% CI: 1.04-2.74, P-trend=0.04) and among current smokers 
(IRR 2.02; 95% CI: 1.07-3.82, P-trend=0.06). UCC risk was not associated with 
serum levels of homocysteine, and vitamins B6 and B12.
Conclusions
This study suggests that lower serum concentrations of folate are associated 
with increased UCC, in particular the risk of aggressive UCC and in current 
smokers. However, residual confounding by smoking cannot be excluded and 
these findings require confirmation with multiple measurements in future 
studies. 
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INTRODUCTION
There has been considerable interest in the association between folate, other 
B-vitamins and risk of several malignancies. Folate and related nutrients 
may influence cancer initiation and progression through their role in the 
one-carbon metabolism pathway, which is necessary for DNA synthesis, 
repair, and methylation.1 Folate plays an essential role in one-carbon transfer 
involving remethylation of homocysteine to methionine, which is a precursor 
of S-adenosylmethionine (SAM), the primary methyl group donor for most 
biological methylation reactions, including that of DNA. Vitamin B12 serves as 
an enzymatic cofactor in this conversion. Vitamin B2 acts as a cofactor in the 
methylenetetrahydrofolate reductase (MTHFR) reaction. MTHFR catalyses the 
formation of 5-methyltetrahydrofolate, the major circulatory form of folate in 
the body, and provides methyl groups for the conversion of homocysteine to 
methionine. Low levels of folate and vitamin B12 may reduce SAM production, 
resulting in aberrant DNA methylation and may thereby influence gene 
expression. Furthermore, folate in combination with vitamin B6 and vitamin B12 
are essential cofactors for the de novo biosynthesis of purines and thymidylate. 
Altered folate metabolism causes ineffective DNA synthesis and diminished 
levels of these vitamins may result in misincorporation of uracil into DNA, 
leading to chromosome breaks and disruption of DNA repair.2, 3 The importance 
of these processes in cell growth and development has led to the investigation 
of folate intakes on cancer development. It has been proposed that folate may 
affect bladder carcinogenesis because of its role in the synthesis of nucleic acids 
and in DNA methylation. Dysregulation of the one-carbon metabolic pathway 
could disrupt these processes and increase cancer risk.1
Epidemiological evidence regarding the role of folate and other B-vitamins 
in relation to bladder cancer risk has mainly been limited to studies on self-
reported intake. Three case-control studies found that higher intake of dietary 
folate4, 5, foods fortified with folate4, folic acid supplements4, dietary vitamin 
B65 and dietary vitamin B125, 6, were inversely associated with bladder cancer 
risk. Null associations were seen in two other case-control7-9 and four cohort 
studies10-13. Self-reported dietary intake of folate may be a less accurate measure 
of folate status than are blood folate concentrations, which reflect both dietary 
and supplemental intakes. Thus far, only one case-control study used circulating 
blood concentrations of folate. This study found an inverse association for 
higher plasma folate levels and bladder cancer risk.14 However, in case-control 
studies results may be biased by changes in blood levels after diagnosis. 
In addition to methods to assess folate status, the heterogeneous nature of 
bladder cancer may be another factor that contributes to inconsistent study 
results. Urothelial cell carcinoma (UCC), the most common morphological type 
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of bladder cancer, varies in natural history. Stratification into different subgroups 
according to stage and grade may help to identify risk factors involved in 
different UCC pathways. The low grade, papillary tumours are characterized 
by activating mutations in the HRAS and FGFR3 oncogenes and chromosome 
9 aberrations. The high grade papillary and solid tumours are characterized 
by structural and functional defects in the TP53 and RB tumour suppressor 
genes.15, 16 It has been suggested that associations with cigarette smoking 
and employment in a high-risk occupation, the most well-known risk factors 
for UCC17, are stronger for bladder tumours with a higher stage and grade.18-20 
However, other studies did not find different associations with stage-specific 
bladder cancer.21, 22 Previous findings from our group have shown that plasma 
concentrations of carotenoids23 and tocopherols (Ros et al. unpublished) may 
influence the risk of bladder tumours with a higher stage and grade. 
This nested case-control study within the European Prospective Investigation 
into Cancer and Nutrition (EPIC) is the first prospective study that investigated 
associations between pre-diagnostic serum compounds involved in one-carbon 
metabolism (folate, homocysteine, vitamin B6, vitamin B12) and the risk of UCC. 
METHODS 
Study population and data collection 
The design and methods of the EPIC study have been described in detail 
previously.24, 25 Briefly, EPIC is a cohort study comprising more than half a million 
people recruited in 23 centres in 10 European countries. Between 1992 and 
2000, standardized questionnaires on diet, lifestyle questionnaires, and medical 
history were collected at enrolment.24-26 Intakes of dietary folate, vitamins 
B2, B6 and B12 were estimated by using standardized country-specific food 
composition tables.26 Data on the use of vitamin or multivitamin supplements 
(yes versus no) was collected by dietary questionnaire for about 80% of the 
cohort. Information about the type of supplement and frequency of use was 
not available. Study centres collected and stored blood samples according to 
a standardized protocol.24 Biological samples (74% of all respondents donated 
samples) are stored at the International Agency for Research on Cancer (IARC, 
Lyon, France) in -196°C liquid nitrogen for all countries except Denmark (-150°C, 
nitrogen vapour) and Sweden (-80°C, freezers). While protected from light after 
blood donation, the blood samples from Oxford and Norway were exposed to 
ambient temperatures for up to 48h. As B-vitamin concentrations are partly 
degraded by such handling, the samples from these centres were excluded from 
the present analyses.24, 25 All participants gave written informed consent, and 
the study was approved by the Institutional Review Board of IARC and the local 
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ethics committees in the participating countries. 
Nested case control design and selection of participants 
Ascertainment of newly diagnosed bladder cancer patients is described 
previously.23 Participants were followed from study entry until a first primary 
bladder cancer diagnosis (code C67 according to the ICD–Oncology, third 
edition), at the end of follow-up (between 2002 and 2005 in different 
countries), last known contact date, cancer diagnosis, or death. Only urothelial 
cell papillomas and carcinomas (UCC morphology codes 8120 and 8130) 
were included in the analyses, as these comprise more than 90% of bladder 
tumours. Pathology reports of UCC cases were collected from each centre to 
obtain information on stage and differentiation grade of the tumour. Stage 
T1 (penetrated the basement membrane) and higher (grown into the muscle 
layer, fatty tissue or into nearby organs), carcinoma in situ, or WHO grade 3 
(poorly differentiated) carcinomas were classified as aggressive UCCs, whereas 
stage Ta (non-invasive papillary carcinoma) grades 1 or 2 (well and moderately 
differentiated) were classified as non–aggressive UCCs.27 92% of the cases 
could be classified as aggressive or non–aggressive UCC. 
Each case was matched to one control by incidence density sampling from 
all cohort members alive without a cancer diagnosis of any kind (except non-
melanoma skin cancer) at the time of diagnosis of the case. Controls were 
randomly selected from the population at risk at the time of diagnosis of the 
case. Under this design, a selected control may become a case at a later time 
during follow-up.28 Matching criteria were sex, age at time of enrolment (± 3 
years), study centre, date of blood collection (± 3 months), time of day of blood 
collection (± 2 hours) and fasting status at the time of blood collection (< 3, 
3-6, and > 6 hours since last meal). Matched controls were unavailable for 11 
cases and these individuals were excluded from analyses. Casesets including 
participants with missing blood samples (n=110), no information on follow-
up (n=6) or smoking history (n=16), from Oxford or Norway centre (n=49), or 
including cases with other morphology codes than 8120 and 8130 (n=78) were 
also excluded. The current study included 824 pairs of first primary UCC cases 
and their matched controls.
Laboratory assays
Aliquots of serum (plasma for Umeå, Sweden) were extracted from the central 
biorepository at IARC and the local centres of Denmark and Sweden. The 
frozen blood samples were shipped in dry ice to the National Institute for 
Public Health and the Environment (Bilthoven, The Netherlands) for analysis. 
Samples were thawed shortly before analysis. Samples were analysed for folate 
(vitamin B9) and vitamin B12 (cobalamin) by using an Access-2 immunoanalyzer 
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(Beckman-Coulter). Vitamin B6 (pyridoxal-5-fosfate) was determined by 
reversed-phase HPLC analysis with fluorescence detection using a kit of 
Chromsystems (Munich, Germany). Vitamin B2 (riboflavin) could not be assayed 
because of lack of sufficient amount of blood. The HPLC equipment was from 
Varian Association (Middelburg, the Netherlands) equipped with a fluorescence 
detector from Jasco (Separations, Hendrik-Ido-Ambacht, The Netherlands). 
Homocysteine concentrations were determined with an enzyme cycling assay 
(Dialab, Neudorf, Austria) on an LX20-Pro autoanalyzer (Beckman-Coulter, 
Woerden, The Netherlands). For quality control, one control sample with 
concentrations similar to the mean concentrations in controls was added to 
each batch of samples to assess interbatch reproducibility. There were 21 
batches. Coefficients of variation for these quality-control samples were 6.1% 
for folate, 3.4% for homocysteine, 3.5% for vitamin B6, and 7.2% for vitamin 
B12. To minimize the influence of batch-to-batch variation, cases were analysed 
in the same analytic batch as their matched controls. Laboratory technicians 
were blinded to the case-control status of the samples, and biochemical 
analyses were done in one laboratory, with avoidance of between-laboratory 
method variability. 
Statistical analysis
Odds ratios (OR) and 95% confidence intervals (95% CI) for UCC risk in 
relation to serum concentrations and dietary intakes were calculated by using 
conditional logistic regression models stratified by the case-control set. With an 
incidence density sampling design, the OR is an unbiased approximation of the 
incidence rate ratio (IRR).29 ORs were calculated by using quartiles with cutoffs 
that were based on the distribution of dietary intake and/or serum levels of 
folate, homocysteine, vitamins B2, B6 and B12 in control subjects. We derived 
probability values for a linear trend across quartiles from regression models by 
using median serum levels within quartiles as a continuous variable, thereby 
taking the unequal distances of the quartiles into account.30 The data were also 
analysed continuously with a risk equal to half of the serum concentrations or 
dietary intake using log2-transformed exposure variables.
All analyses were controlled for smoking status (never, former, current), 
duration of smoking (years), and lifetime intensity of smoking (cigarettes/day). 
Energy intake, consumption of processed or red meat, alcohol intake, physical 
activity, BMI, occupational history and educational level were not included 
in the final analyses because none of these factors affected the α estimates 
by more than 10%. For a subset of the cohort data on occupational history 
of the participants was available. We focused on the following carcinogenic 
exposures: heavy metals, aromatic amines, Polycyclic Aromatic Hydrocarbons 
and Environmental Tobacco Smoking. The scores were treated as dichotomous 
One-carbon metabolism biomarkers and risk of urothelial cell carcinomas
93
variables (yes versus no). The adjusted models were additionally adjusted for 
the other B-vitamins and homocysteine. As previous findings in the same study 
population suggest a reduced UCC risk with higher concentrations of the sum of 
plasma carotenoids23 and an increased UCC risk with plasma α-tocopherol (data 
not shown), the final models were further adjusted for these micronutrients. 
Plasma carotenoids and tocopherols were measured by using reverse-phase 
HPLC, which has been described in detail previously.23 Additional analyses were 
performed by using non–aggressive and aggressive UCC as separate endpoints. 
Because smoking may not only confound but also modify the association, 
joint effects were determined for tertiles of serum one-carbon metabolism 
biomarkers in combination with smoking status (never, former, current) in 
relation to UCC risk. The combined category of higher serum levels with never 
smoking was chosen as reference. We used tertiles of serum biomarkers 
instead of quartiles because of power considerations. Statistical interaction on 
a multiplicative scale was tested by introducing a product term between serum 
one-carbon metabolism biomarkers (continuous), and smoking status. Analyses 
of joint effects were controlled for duration of smoking, and lifetime intensity 
of smoking. Joint effects of one-carbon metabolism related nutrients were also 
conducted to evaluate whether the measured analytes (folate, homocysteine, 
vitamin B6 and vitamin B12) interacted with each other. Similar models were 
used to test for interactions with BMI, gender and alcohol intake. To evaluate 
whether preclinical disease may have influenced results, analyses were repeated 
after exclusion of cases along with their matched controls who were diagnosed 
within 2 years after recruitment (n=136 pairs). 
All statistical analyses were performed with SAS software (version 9.3, SAS 
Institute Inc). For all analyses, 2-sided P <0.05 was considered statistically 
significant.
RESULTS 
Baseline characteristics of cases diagnosed with UCC and their matched controls 
are shown in Table 1. UCC cases were more likely to smoke, were slightly less 
educated, reported a higher intake of alcohol and red and processed meat, and 
consumed less fruit and vegetables. 
Lower concentrations of serum folate were borderline associated with increased 
risk of UCC (OR for lowest vs. highest quartile 1.37; 95% CI: 0.98-1.90, 
P-trend=0.05). When stratified by prognostic subgroups of UCC, lower serum 
folate was positively associated with aggressive UCC (OR comparing the lowest 
with the highest quartile 1.69; 95%CI: 1.04-2.74, P-trend=0.04). Serum folate 
was not associated with non-aggressive UCC (OR lowest vs. highest quartile 
1.01; 95%CI: 0.61-1.67, P-trend=0.74).
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Table 1. Baseline characteristics of urothelial cell carcinoma cases and their matched controls.
Cases (n= 824) Controls1 (n= 824)
General characteristics
Men, n(%) 611 (74) 611 (74)
Women, n(%) 213 (26) 213 (26)
BMI (kg/m2) 26.6 ± 4.02 26.4 ± 3.8
Physical active3 (%) 42 43
Age at recruitment (y) 58.4 ± 7.4 58.4 ± 7.4
Smoking status
Never smokers (n, %) 156 (19) 316 (38)
Former smokers (n, %) 294 (36) 287 (35)
Lifetime number of cigarettes (cig/day) 10.2 ± 10.2 9.9 ±10.2
Smoking duration (y) 25.3 ± 13.6 21.8 ± 12.9
Age at start smoking (y) 17.9 ± 5.6 19.0 ± 6.6
Time since quitting smoking (y) 13.4 ± 11.4 16.8 ± 11.8
Current smokers (n, %) 374 (45) 221 (27)
Lifetime number of cigarettes (cig/day) 14.1 ± 9.3 11.7 ± 8.8
Smoking duration (y) 38.7 ± 10.0 36.1 ± 11.6
Age at start smoking (y) 17.9 ± 5.9 19.6 ± 7.9
Exposure to occupational carcinogens 
(n, %)4 
Heavy metals 168 (12) 159 (11)
Aromatic amines 132 (9) 115 (8)
Polycylic Aromatic Hydrocarbons (PAH) 115 (8) 94 (7)
Environmental tobacco smoke 37 (3) 38 (3)
Educational level (n, %)
None or primary school 387 (47) 338 (41)
Technical/professional school 200 (24) 230 (28)
Secondary school 90 (11) 86 (10)
University degree 142 (17) 159 (20)
Not specified 4 (1) 7 (1)
Serum concentrations micronutrients 
(median, 5th - 95th percentile)
Folate (nmol/L) 14.9 (7.2-31.4)5 16.0 (7.9-34.9) 
Homocysteine (μmol/L) 16.6 (9.4-26.3) 16.0 (8.7-25.6)
Vitamin B6 (μg/L) 37.5 (15.8-124.0) 40.1 (15.6-122.9)
Vitamin B12 (pmol/L) 275 (140-547) 270 (140-492)
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Table 1. Continued.
Cases (n= 824) Controls1 (n= 824)
Dietary factors 
Total energy (kcal/d) 2266.1 ± 665.4 2288.6 ± 716.3
Energy from fat (kcal/d) 784.9 ± 285.8 790.2 ± 296.9
Energy from non-fat (kcal/d) 1481.2 ± 446.2 1498.4 ± 484.5
Alcohol consumption (g/day) 19.2 ± 22.7 17.6 ± 21.4
Red and processed meat (g/day) 96.9 ± 56.7 95.2 ± 61.7
Fresh fruits (g/day) 195.5 ± 163.7 217.4 ± 189.9
Total vegetables (g/day) 169.5 ± 142.6 176.9 ± 125.2
Dietary folate intake (μg) 291.2 ± 106.9 302.6 ± 132.6
Dietary vitamin B2 (mg) 2.0 ± 0.63 2.04 ± 0.78
Dietary vitamin B6 intake (mg) 1.92 ± 0.80 1.91 ± 0.77
Dietary vitamin B12 intake (μg) 7.9 ± 6.0 7.4 ± 4.5
Cases only
Age at diagnosis 63.2 ± 7.7 -
Time from blood draw to diagnosis (y) 4.6 ± 2.8 -
Urothelial cell carcinomas (n,%)6
Aggressive7 390 (47) -
Non-aggressive8 374 (45) -
Unknown9 60 (8) -
1 Controls were matched to cases by sex, age at baseline, study centre, date and time of blood 
collection, and fasting status.
2 Mean ± SD (all such values).
3 Cambridge Physical Activity Index incorporates occupational and nonoccupational physical 
activity. 
4 Data were not available for Umea (Sweden), Norway, Naples (Italy), Utrecht (Netherlands), 
and France.
5 Median; 5th – 95th percentile in parentheses (all such values).
6 Includes urothelial cell papillomas and carcinomas (morphology codes 812 and 813, and be-
haviour coded as uncertain whether benign or malignant, carcinoma in situ, and/or malignant) 
but excludes inverted papillomas (8121/1).
7 Includes all stage T1 or higher, carcinoma in situ, or WHO 1973 grade 3 carcinomas (including 
Ta grade 3).
8 Includes all stage Ta grade 1 or Ta grade 2 carcinomas.
9 Sixty urothelial cell carcinomas could not be classified as aggressive or nonaggressive urothe-
lial cell carcinomas because of lack of information on stage or grade. 
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(Table 2) The associations of folate remained present after adjustment the final 
models one by one for each of the blood concentrations of homocysteine, 
vitamin B6, vitamin B12, α-tocopherol or the sum of carotenoids (data not 
shown). Serum concentrations of homocysteine, vitamin B6, or vitamin B12 
were not related to UCC risk (Table 2). These positive and null associations 
persisted after exclusion of cases diagnosed during the first two years of follow-
up (data not shown).
For dietary folate, a suggestive positive association was observed with UCC risk 
(OR lowest vs. highest quartile 1.30; 95%CI: 0.92-1.83, P-trend=0.11), while a 
statistically significant increased risk was seen for aggressive UCC (OR lowest 
vs. highest quartile 1.77; 95%CI: 1.03-3.03, P-trend=0.04). Intakes of dietary 
vitamin B2, vitamin B6 and vitamin B12 were not associated with UCC risk. 
(Table 3)
We further studied whether the associations between folate and UCC risk 
were modified by smoking status (Table 4). The reference group consisted 
of never smokers with the highest levels of folate. We observed a 2.02-fold 
(95%CI: 1.07-3.82) elevated risk of UCC for current smokers with lowest 
levels of folate, whereas in all other groups risks were not elevated. Although 
the interaction of smoking status and serum folate was only borderline 
significant (P-interaction=0.06), these data suggest that smoking may modify 
the association between serum folate and risk of UCC. Smoking status did not 
modify the associations between homocysteine, vitamin B6, and vitamin B12 
and risk of UCC. Interactions on a multiplicative scale between serum folate 
and other nutrients of the one-carbon metabolism (homocysteine, vitamin 
B6 and vitamin B12) were not significant (P-interaction > 0.05). Further, the 
associations between the four measured one-carbon metabolism biomarkers 
were not modified by alcohol intake, gender or BMI (P-interaction > 0.05). (data 
not shown)
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DISCUSSION 
In this large prospective study of blood levels of nutrients involved in the one-
carbon metabolism pathway and development of UCC, we observed that lower 
concentrations of serum folate were associated with an increased risk of UCC, 
in particular the risk of aggressive UCC. The positive association with lower 
serum folate concentrations was only apparent in current smokers. Serum 
homocysteine, vitamin B6, or vitamin B12 were not associated with UCC risk. 
In our study a suggestive positive association between a lower intake of dietary 
folate and risk of UCC was seen, whereas no evidence of an association was 
found for dietary vitamins B2, B6 and B12. Previous studies of the relation 
between dietary intake of B-vitamins and the risk of bladder cancer have 
yielded inconsistent results. A case-control study including 409 bladder cancer 
cases from the US found that higher intake of dietary folate, foods fortified with 
folate or folic acid supplements were inversely associated with bladder cancer.4 
A protective effect for higher dietary folate, vitamin B6 and vitamin B12 on 
bladder cancer development was also seen in a case-control study from Spain.5 
Recent results from a large US case-control study including 1,171 cases has 
shown that dietary vitamin B12, but not folate and vitamin B6, may be protective 
against bladder cancer.6 Dietary folate was not associated with bladder cancer 
in two other case-control studies6-8 and four cohort studies10-13 from the US and 
Europe. The association between circulating folate and bladder cancer risk has 
been investigated in one small case-control study. This case-control study from 
Taiwan with 171 cases of bladder cancer reported a decrease in risk associated 
with higher plasma folate concentrations.14
Bladder cancer is a complex disease with etiologic heterogeneity. Due to the 
relatively large number of cases in our study, we were able to analyse prognostic 
subgroups of UCC according to tumour aggressiveness. To our knowledge, 
previous studies on folate have limited their analyses to total bladder cancer, 
and therefore, any differences in associations according to stage and grade of 
bladder cancer may have been missed. In the current study, stronger associations 
for folate were found for aggressive UCC. Bladder carcinogenesis appears to 
occur via distinct molecular pathways and it is known that aggressive, high-
grade bladder tumours frequently show defects in the TP53 and RB tumour 
suppressor genes. In laboratory models, folate deficiency appears to induce 
p53 mutations. The p53 tumour suppressor gene appears to be susceptible 
to the DNA damaging and hypomethylating effects of folate deficiency 
resulting in decreased levels of p53 mRNA in a steady state condition.31 This 
potential mechanism suggests that folate can modulate aggressive bladder 
carcinogenesis through DNA methylation. Within the EPIC cohort, associations 
for plasma carotenoids23 and tocopherols(data not shown) were particularly 
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driven by aggressive UCC as well. However, the precise mechanisms underlying 
the association with aggressive bladder cancer risk remain undisclosed. Efficient 
one-carbon metabolism requires not only folate, but also vitamins B2, B6 and 
B12. These nutrients interact metabolically with folate in the one-carbon 
metabolism process, and may influence cancer risk.1 The current study found, 
however, no evidence for an association between blood concentrations and 
dietary intake of vitamins B6 and B12, and dietary vitamin B2 in relation to 
UCC risk. 
Smoking may affect B-vitamin status and reduce bioavailability of folate. 
Current smokers have lower circulating concentrations of folate, even after 
correction for folate intake. This suggests that smoking alters the systemic 
uptake or metabolism of folate.32, 33 The evidence of joint effects between 
folate concentrations and smoking is of particular interest. Previous findings 
suggest that the combined effects of smoking with decreased levels of folate 
can induce increased chromosomal damage. The higher proportion of cells with 
chromosome aberrations in cigarette smokers was attributed to lower folate 
levels in smokers compared with non-smokers.34, 35 Thus, DNA damage induced 
by smoking may be modulated by the folate metabolic pathway. In the present 
study, we noted a statistically significant two-fold increased risk of UCC only 
in current smokers with lowest levels of folate. Consistent results were seen 
in a case-control study from the US where joint effects of folate intake and 
smoking status showed that current smokers with lower folate intake tended 
to have a greater risk of bladder cancer compared with current smokers with 
higher folate intake.4 If an effect of serum folate exists, our study suggests that 
it is particularly prominent in smokers with lowest levels of folate. However, 
the observed associations should be interpreted with caution because we 
conducted multiple comparisons and because residual confounding by smoking 
cannot be excluded. 
Diets with a low intake of fruits and vegetables, which leads to insufficient folate 
intake and status, may reflect an unhealthy lifestyle.36 In our study, participants 
with lower serum concentrations of folate tended to have an unhealthy lifestyle 
as they smoked more frequently, were slightly more exposed to occupational 
bladder carcinogens, were less physical active, reported a higher intake of red 
and processed meat, and consumed less fruit and vegetables (data not shown). 
The possibility that the observed associations of serum folate with UCC risk 
may be explained by unhealthy behaviours is, however, unlikely as positive 
associations for folate remained unchanged when the results were adjusted for 
several lifestyle factors (data not shown). On the other hand, positive associations 
seen in observational studies may reflect other unmeasured lifestyle factors 
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associated with both low serum concentrations of folate and high risk of UCC. 
Further, it is possible that exposure to potential risk factors may have changed 
during follow-up which could lead to residual confounding. We could not take 
changes in dietary and lifestyle factors into account, as replicate measurements 
of these factors were not available in our study. Higher concentrations of folate 
may also be a marker of a concerted effect of multiple bioactive compounds 
in fruit and vegetables. Although folate sources are not restricted to fruit and 
vegetables, blood concentrations of folate may be a useful biomarker for the 
intake of fruit and vegetables in populations consuming unfortified foods.37 At 
the time of data collection, no European country had introduced mandatory folic 
acid fortification, although voluntary fortification is accepted in some countries, 
including France and the UK.38 The use of dietary supplements could also affect 
serum levels of micronutrients. However, no substantial change in risk estimates 
was observed by simple adjustment for dietary supplement use (yes vs. no) (data 
not shown). In a sub-sample of the EPIC cohort, the use of dietary supplements 
is asked in detail as part of single 24h recalls.39 This study indicates that folic 
acid supplements were not frequently consumed at the time of data collection. 
So, it seems that circulating folate is largely determined by natural folates from 
foods in the current study, and one might think the association with serum 
folate is merely driven by the association with dietary folate. This may explain 
the quite similar observed risk estimates of serum concentrations and dietary 
intakes of folate, despite the low correlation (0.21). 
The strengths of our study include its prospective design, a relatively large 
number of incident UCC cases, the wide range in blood concentrations of 
one-carbon metabolism related nutrients, and the collection of blood samples 
before cancer diagnosis. However, some limitations of the present study need 
to be discussed. In a subset of the cohort we were able to look at the influence 
of a history of high risk occupations in relation to UCC. However, we could 
not adjust our analyses fully for the role of occupation since we only could 
use a rather crude measurement of exposure. On the other hand, many of the 
carcinogens related to bladder cancer have been banned from the workplace for 
several decades. So, it is possible that the actual exposure to carcinogens within 
high risk occupations is reduced to a minimum. Further, our analyses were based 
on single measurements of nutrients involved in the one-carbon metabolism at 
baseline. On this basis, we assumed that serum levels were stable in persons 
during follow-up. Blood concentrations may differ over time because of day-
to-day variation and long-term changes within persons, which may lead to an 
attenuation of the associations. The stability of serum one-carbon biomarkers 
over time has been estimated in a subsample of the two Dutch cohorts within 
EPIC previously.40 Over 2 to 5 year, serum homocysteine and vitamin B12 
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were highly reliable biomarkers with intraclass correlation coefficients (ICC) of 
0.91 and 0.75 respectively. The ICC for serum folate was 0.45 and for vitamin 
B6 was 0.38. These measures should be reliable enough to detect moderate 
associations. In the present study, folate status is measured by determination 
of serum folate levels. Folate concentration in serum or plasma is an indicator 
of more recent folate intake, while red blood cell folate is considered to reflect 
average concentration over the erythrocyte life span (about 120 days).41, 42 As 
red blood cells are less subject to short-term dietary changes and reflect long-
term folate status, the observed associations for folate may be even stronger 
for red blood cell folate. 
In conclusion, the current study suggests that lower serum concentrations of 
folate may increase the risk of UCC, in particular the risk of aggressive UCC. This 
increased risk was only seen in current smokers. However, residual confounding 
by smoking cannot be excluded and confirmation with multiple measurements 
is warranted.  
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ABSTRACT
Background
Retinol and tocopherols play roles in various biological processes, such as gene 
expression, growth and immune function. The main role of tocopherols is its 
function as antioxidant, which have been hypothesized to influence cancer risk. 
Tocopherols may also act as pro-oxidants under conditions of increased oxidative 
stress. Epidemiological studies on blood levels of retinol and tocopherols and 
bladder cancer are limited and findings are inconclusive.
Methods
We prospectively investigated the association between plasma levels of retinol 
and tocopherols and the risk of urothelial cell carcinoma (UCC) in a case-control 
study nested within the European Prospective Investigation into Cancer and 
Nutrition (EPIC) cohort. 848 patients with UCC were matched to 848 controls 
by incidence density sampling. Matching factors were sex, age at baseline, study 
centre, date and time of blood collection, and fasting status. Odds Ratios (OR) 
were estimated with conditional logistic regression and adjusted for smoking 
status, duration and intensity of smoking. 
Results
Higher concentrations of plasma α-tocopherol were positively associated with 
UCC (OR highest vs. lowest quartile 1.63; 95%CI: 1.15-2.31, P-trend=0.003) 
and with the subgroup of ‘aggressive’ UCC (OR highest vs. lowest quartile 3.27; 
95%CI: 1.85-5.81, P-trend=0.0001). Plasma retinol and α-tocopherol were not 
significantly associated with UCC risk. 
Conclusions
These findings suggest that higher levels of plasma α-tocopherol may increase 
the risk of UCC, in particular aggressive UCC. Residual confounding by smoking 
or other factors cannot be excluded. This association requires confirmation 
in other large prospective studies, if possible with multiple measurements of 
blood levels. 
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INTRODUCTION
Retinol and tocopherols are fat-soluble nutrients that play important roles in 
metabolic and physiological processes1. Retinol, the physiologically active form 
of vitamin A obtained from animal products, plays an essential role in biological 
processes such as night vision, regulation of cell growth and differentiation, 
glycoprotein synthesis, epithelial cell integrity, immune cell maintenance and 
human growth hormone production. In addition, some data suggest that retinol 
may have an anti-oxidative function, but this remains to be clarified. Retinol, 
can also be produced endogenously from provitamin A carotenoids (α- and 
α-carotene, and α-cryptoxanthin from fruit and vegetables).1 Retinol has been 
shown to inhibit bladder carcinogenesis in animal models due to induction of cell 
growth and differentiation caused by changes in the expression of oncogenes 
that code for growth factors and growth factor receptors.2 
The main role of tocopherols in the body is as an anti-oxidant that protects 
cells from peroxyl radical induced oxidative damage. In addition to tocopherol’s 
function as an antioxidant, its role as an enhancer of the immune system, 
regulator of cell growth and inducer of tumour cell apoptosis may be crucial 
in its ability to inhibit carcinogenesis.3 In vitro and in vivo studies showed that 
α-tocopherol succinate induced apoptosis in human bladder cancer cells.4 
Although α-tocopherol is the predominant form of vitamin E in human blood 
and tissues, α-tocopherol has a greater anti-tumour and anti-inflammatory 
activity than α-tocopherol in several different animal models of colon, breast, 
and prostate cancer.5  Tocopherols may also behave as pro-oxidants when blood 
concentrations increase, especially under conditions of increased oxidative 
stress (e.g., cigarette smoking).6 The pro-oxidant activity of α-tocopherol is 
ascribed to the formation of tocopheroxyl radicals which can initiate processes 
of lipid peroxidation.7 Furthermore, α-tocopherol can be regenerated from the 
tocopheroxyl radical by other co-antioxidants, for example vitamin C. Such a 
recycling is expected to inhibit the pro-oxidant activity of α-tocopherols.8 
Observational studies of the association between blood concentrations of retinol 
and/or tocopherols and bladder cancer risk have shown inconsistent results. 
A case-control study from the US found that plasma retinol and α-tocopherol 
were inversely associated with bladder cancer risk.9 A null association was seen 
in another case-control study from the US.10 In contrast, small prospective 
studies conducted in the US and Finland suggest that blood levels of retinol11 
and α-tocopherol12,13 may be positively associated with bladder cancer risk. 
The heterogeneous nature of bladder cancer may be another factor that 
contributes to the inconsistent study results. Urothelial cell carcinoma (UCC), 
the most common morphological type of bladder cancer, varies in natural 
history. Stratification into different subgroups according to stage and grade may 
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help to identify risk factors involved in different UCC pathways. The low grade, 
papillary tumours are characterized by activating mutations in the HRAS and 
FGFR3 oncogenes and chromosome 9 aberrations. The high grade papillary and 
solid tumours are characterized by structural and functional defects in the TP53 
and RB tumour suppressor genes.14 It has been suggested that risks associated 
with cigarette smoking and employment in a high-risk occupation, the most 
well-known risk factors for UCC, are more pronounced for bladder tumours 
with a higher stage and grade.15-17 However, other studies did not find different 
associations with stage-specific bladder cancer.18,19 Previous findings from our 
group have shown that plasma concentrations of carotenoids20 may influence 
the risk of UCC with a higher stage and grade. To date, no epidemiological studies 
on blood levels of retinol and tocopherols distinguished UCC by aggressiveness. 
Given the inconsistent findings and the need to identify modifiable risk factors 
for UCC, we examined the association between pre-diagnostic plasma retinol 
and tocopherol concentrations and the risk of UCC in a case-control study 
nested within the European Prospective Investigation into Cancer and Nutrition 
(EPIC). 
SUBJECTS AND METHODS 
Study population and data collection 
The design and methods of the EPIC study have been described in detail 
previously.21,22 Briefly, EPIC is a cohort study, comprising more than half a 
million people recruited in 23 centres in 10 European countries (Denmark, 
France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the 
United Kingdom). Eligible subjects were invited to participate in the study, and 
subjects who consented completed standardized questionnaires on their diet, 
lifestyle, and medical history at enrolment.21-23 Usual dietary intake during the 
year before recruitment was measured by using country-specific validated diet 
questionnaires designed to reflect local dietary patterns.23 Intakes of dietary 
retinol and vitamin E were estimated by using standardized country-specific food 
composition tables. Dietary vitamin E includes several forms of tocopherols (α, 
α, α and α). Vitamin E derived from the food-composition table is a combination 
of these individual tocopherols. Data on the use of any vitamin or multivitamin 
supplements (yes versus no) was collected by self-reported questionnaire for 
about 80% of the cohort. 
In each of the participating centres, blood samples of ≥ 30mL were drawn at 
baseline from consenting participants (74% of all respondents donated samples). 
Study centres collected and stored blood samples according to a standardized 
protocol.21,22 After blood donation, samples were stored at 5–10°C, protected 
from light, and transported to local laboratories for processing and separation 
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into aliquots. Exceptions were the EPIC-Oxford (United Kingdom) and EPIC-
Norway centres, where blood samples were collected from a network of general 
practitioners and transported to a central laboratory by surface mail, and centres 
in Sweden, where blood was divided into aliquots ≤1 h after collection. In all 
countries, except in Denmark and Sweden, blood was separated into 0.5-mL 
fractions (serum, plasma, red cells, and buffy coat for DNA extraction) and stored 
in heat sealed straws in liquid nitrogen (-196°C). One-half of all aliquots were 
stored at the local study centre and the other one-half of aliquots were stored 
in the central EPIC biorepository at the International Agency for Research on 
Cancer (IARC, Lyon, France). In Denmark, blood-fraction aliquots in 1-mL tubes 
were stored at -150°C under nitrogen vapour. In Sweden, samples were stored 
in 1.8-mL tubes in -80°C freezers.21,22 All participants gave written informed 
consent, and the study was approved by the Institutional Review Board of IARC 
and the local ethics committees in the participating countries. 
Nested case control design and selection of participants 
Ascertainment of newly diagnosed bladder cancer patients has been described 
previously.24 Participants were followed from study entry until a first primary 
bladder cancer diagnosis (code C67 according to the ICD–Oncology, third 
edition), at the end of follow-up (between 2002 and 2005 in different countries), 
last known contact date, cancer diagnosis, or death. Only urothelial cell 
‘papillomas’ and carcinomas (morphology codes 8120 and 8130) were included 
in the analysis, further referred to as urothelial cell carcinomas (UCC). Pathology 
reports of the UCC cases were collected from each centre. Stage T1 and higher, 
carcinoma in situ, or WHO grade 3 carcinomas were classified as aggressive 
UCCs, whereas stage Ta grade 1 or 2 were classified as non–aggressive UCCs.25 
92% of the cases could be classified as aggressive or non–aggressive UCC. 
Each case was matched to one control by incidence density sampling from 
all cohort members alive without a cancer diagnosis of any kind (except non-
melanoma skin cancer) at the time of diagnosis of the case. Controls were 
randomly selected from the population at risk at the time of diagnosis of the 
case. Under this design, a selected control may become a case at a later time 
during follow-up.26 Matching criteria were sex, age at time of enrolment (± 3 y), 
study centre, date of blood collection (± 3 mo), time of day of blood collection 
(± 2 h), and fasting status at the time of blood collection (< 3, 3-6, and > 6 
h since last meal). Matched controls were unavailable for 11 cases and these 
individuals were excluded from analyses. Casesets including participants with 
missing blood samples (n=110), no information on follow-up (n=6) or smoking 
history (n=16), or including cases with other morphology codes than 8120 and 
8130 (n=78) were also excluded. The current study included 848 pairs of first 
primary UCC cases and their matched controls.
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Laboratory assays
Aliquots of plasma were extracted from the central biorepository at IARC and 
the local centres of Denmark and Sweden. The frozen plasma was shipped in dry 
ice to the National Institute for Public Health and the Environment (Bilthoven, 
Netherlands) for analysis. Samples were analysed for retinol, α-tocopherol and 
α-tocopherol with high-performance liquid chromatography using a HPLC 
column (250 x 4.6 mm, ChromSpher 5-µm C18, Varian Association) with UV 
detection at 325 nm for retinol and fluorescence detection (ex 225 em 325 nm) 
for tocopherols. Tocol was used as internal standard.27 The limit of sensitivity 
of the method is 0.09, 0.05 and 0.06 µmol/L for retinol, α- and α-tocopherol, 
respectively. No peaks were under the limit of detection. For quality control, 
one control sample with concentrations similar to the mean concentrations in 
controls was added to each batch of samples to assess interbatch reproducibility. 
There were 25 batches. Coefficients of variation for these quality-control 
samples were 4.0% for retinol, 4.1% for α-tocopherol and 3.7% for α-tocopherol. 
To minimize the influence of batch-to-batch variation, cases were analysed in 
the same analytic batch as their matched controls. Laboratory technicians were 
blinded to the case-control status of the samples, and biochemical analyses 
were done in one laboratory, with avoidance of between-laboratory method 
variability. Plasma retinol and tocopherols have been estimated to be stable for 
several years at different storage temperatures.28
Statistical analysis
Odds ratios (OR) and 95% confidence intervals (95% CI) for UCC risk in relation to 
plasma concentrations and dietary intakes were calculated by using conditional 
logistic regression models stratified by the case-control sets. By using incidence 
density sampling design, the estimated OR is an unbiased approximation of the 
incidence rate ratio.29 ORs were calculated by using quartiles with cutoff points 
that were based on the distribution of retinol and tocopherols in the control 
subjects. We derived probability values for a linear trend across quartiles 
from regression models using the median plasma levels within quartiles as a 
continuous variable, thereby taking the unequal distances of the quartiles into 
account.30 The data were also analysed as continuous variables. Plasma and 
dietary values of retinol and tocopherols were log-2 transformed to improve 
normality. The OR of these log-2 transformed values corresponds to the UCC 
risk associated with a doubling of the plasma concentration or dietary intake. 
All analyses were controlled for smoking status (never, former, current), duration 
of smoking (years), and lifetime intensity of smoking (cigarettes/day). Energy 
intake, alcohol intake, physical activity, BMI, occupational history, educational 
level, and dietary supplement intake were not included in the analysis because 
none of these factors affected the α estimates of the plasma variables by more 
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than 10%. The primary sources of retinol are animal foods (particularly liver, 
dairy products, eggs and fish oils). Foods rich in α-tocopherol include margarine, 
almonds, spinach and vegetable oils, while α-tocopherol is found in many seeds 
and nuts.31 To evaluate whether the associations were driven by specific foods 
containing retinol and/or tocopherols, we adjusted the final models one by one 
for each of these foods. As previous findings suggest a reduced UCC risk, in 
particular aggressive UCC, with higher concentrations of the sum of plasma 
carotenoids in the same study population20, the final models were further 
adjusted for the sum of plasma carotenoids. Plasma carotenoids were measured 
by using reverse-phase HPLC, which has been described in detail previously.20 
Analyses were also performed for non-aggressive and aggressive UCC as 
separate endpoints. 
Because smoking and vitamin C could have modified the investigated 
associations, joint effects were determined for tertiles of plasma retinol or 
tocopherols in combination with smoking status (never, former, current) or 
log-2 transformed plasma vitamin C (< 28.05, 28.05-43.07, ≥ 43.07 µmol/L) 
in relation to UCC risk. Plasma vitamin C was measured by using a colorimetric 
assay.20 The combined category of low plasma retinol or tocopherols with 
never smokers or low plasma vitamin C was chosen as reference. We used 
tertiles of plasma retinol and tocopherols instead of quartiles because of 
power considerations. The statistical interaction on a multiplicative scale was 
tested by introducing a product term between plasma retinol or tocopherols 
(continuous), and smoking status or plasma vitamin C (continuous). Analyses 
of joint effects were controlled for smoking status, duration of smoking, and 
lifetime intensity of smoking. Similar models were used to test for interactions 
with alcohol intake and BMI. To evaluate whether preclinical disease may have 
influenced results, analyses were repeated after exclusion of cases along with 
their matched controls who were diagnosed within 2 y after recruitment (n=134 
pairs). All statistical analyses were performed using SAS software (version 9.2, 
SAS Institute Inc, Cary, NC, USA). For all analyses, 2-sided p-values <0.05 were 
considered statistically significant.
RESULTS 
On average, cases were more likely to smoke, reported somewhat lower intakes 
of fruit, higher intakes of dairy products and dietary retinol than the controls. 
While plasma α- and α-tocopherol concentrations were somewhat lower 
among controls compared to cases, no differences were seen in plasma retinol 
concentrations (Table 1). Median follow-up for UCC cases was 5.2 years (range 
0.06 to12.08 years).
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Table 1. Baseline characteristics of the study population of urothelial cell carcinomas andcontrols.1
Cases 
(n= 848)
Matched controls1  
(n= 848)
General characteristics
Men (n, %) 627 (74) 627 (74)
Women (n, %) 221 (26) 221 (26)
Age at recruitment (y) 58.6 ± 7.42 58.5 ± 7.4
BMI (kg/m2) 26.6 ± 4.0 26.4 ± 3.8
Physically active (n, %)3 350 (42) 356 (42)
Smoking status9
Never smokers (n, %) 164 (20) 330 (39)
Former smokers (n, %) 308 (36) 297 (35)
Lifetime number of cigarettes (cig/day) 10.1 ± 10.0 10.0 ±10.2
Smoking duration (y) 25.3 ± 13.8 21.6 ± 12.9
Age at start smoking (y) 17.8 ± 5.7 19.0 ± 6.7
Time since quitting smoking (y) 13.7 ± 11.5 17.1 ± 12.1
Current smokers (n, %) 376 (44) 221 (26)
Lifetime number of cigarettes (cig/day) 14.0 ± 9.3 11.7 ± 8.8
Smoking duration (y) 38.7 ± 9.9 36.1 ± 11.6
Age at start smoking (y) 17.9 ± 5.9 19.6 ± 7.9
Exposure to occupational carcinogens (n, %)4 
Heavy metals 169 (12) 160 (11)
Aromatic amines 134 (9) 116 (8)
Polycylic Aromatic Hydrocarbons (PAH) 115 (8) 94 (6)
Environmental tobacco smoking exposure 38 (3) 38 (3)
Educational level (n, %)
None and primary school 387 (46) 338 (40)
Technical/professional school 201 (24) 235 (28)
Secondary school 95 (11) 86 (10)
University degree 148 (18) 167 (20)
Not specified 14 (1) 16 (2)
Plasma concentrations micronutrients 
(median, 5th - 95th percentile)
Retinol (μmol/L) 2.2 (1.1-3.7) 2.2 (1.2-3.7)
α-tocopherol (μmol/L) 25.6 (15.7-45.8) 24.9 (16.2-44.4)
γ-tocopherol (μmol/L)9 4.0 (1.4-10.1) 3.9 (1.3-9.8)
Dietary factors 
Total energy (kcal/d) 2262.9 ± 661.0 2280.1 ± 712.8
Energy from fat (kcal/d) 782.9 ± 285.5 785.8 ± 296.7
Energy from non-fat (kcal/d) 1480.0 ± 442.0 1494.3 ± 481.2
Alcohol consumption (g/day) 19.1 ± 22.6 17.5 ± 21.3
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Table 1. Continued.
Cases 
(n= 848)
Matched controls1  
(n= 848)
Red and processed meat (g/day) 96.3 ± 56.5 94.2 ± 61.5
Fresh fruits (g/day)9 196.1 ± 165.1 217.4 ± 188.0
Nuts and seeds (g/day) 3.0 ± 10.0 2.7 ± 7.0
Total vegetables (g/day) 173.1 ± 144.1 178.6 ± 125.0
Vegetable oils (ml/day) 10.5 ± 15.3 10.1 ± 15.2
Dairy products (g/day)9 345.2 ± 272.4 341.9 ± 247.6
Dietary vitamin E intake (mg) 11.4 ± 5.4 11.7 ± 5.6
Dietary retinol intake (μg)9 1086.1 ± 1201.2 991.9 ± 875.2
Cases only
Age at diagnosis 63.2 ± 7.7
Time from blood draw to diagnosis (y) 4.6 ± 2.8
Urothelial cell carcinomas (n,%)5
Aggressive6 400 (47)
Non-aggressive7 382 (45)
Unknown8 66 (8)
1 Controls were matched to cases by gender, age at baseline, study centre, date and time of 
blood collection, and fasting status. 
2 Mean ± SD (all such values).
3 Cambridge Physical Activity Index incorporates occupational and non-occupational physical 
activity. 
4 Information on exposure to carcinogens at the job is not available for Umea (Sweden), Nor-
way, Naples (Italy), Utrecht (The Netherlands) and France. 
5 The group “urothelial cell carcinomas” includes transitional cell papillomas and carcinomas 
(morphology codes 8120 and 8130, and behaviour coded as ‘uncertain whether benign or 
malignant’, ‘carcinoma in situ’ and/or as ‘malignant’), but excludes inverted papillomas (8121/1). 
6 The category “aggressive urothelial cell carcinomas” includes all stage T1 or higher, all CIS or 
all WHO 1973 grade 3 carcinomas (including Ta grade 3)
7 The category “non-aggressive urothelial cell carcinomas” includes all stage Ta grade 1 or Ta 
grade 2 carcinomas. 
8 66 urothelial cell carcinomas cannot be classified as aggressive or non-aggressive urothelial 
cell carcinomas, because of lacking information on stage and/or grade. 
9  Baseline characteristics differ significantly between cases and controls (p < 0.05). 
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Increased plasma α-tocopherol levels were positively associated with total UCC 
risk (OR for highest compared with lowest quartile 1.63; 95%CI: 1.15-2.31, 
P-trend=0.003) (Table 2). When stratified by prognostic subgroups of UCC, we 
found an increased risk of aggressive UCC with increasing α-tocopherol levels 
(OR 3.27; 95%CI: 1.85-5.81, P-trend=0.0001 comparing the highest quartile 
with the lowest quartile of plasma α-tocopherol). Plasma α-tocopherol was not 
associated with non-aggressive UCC risk (OR for highest compared with lowest 
quartile 0.95; 95%CI: 0.58-1.57, P-trend=0.94) (Table 2). The final model of the 
abovementioned associations between α-tocopherol and UCC risk was further 
adjusted for the sum of plasma carotenoids. These risk estimates were slightly 
stronger for total UCC (OR after log2-transformation 1.34; 95%CI: 1.01-1.78) 
and for aggressive UCC (OR after log2-transformation 2.49; 95%CI: 1.58-3.94) 
(data not shown). No significant associations were observed between levels 
of retinol, α-tocopherol and the risk of UCC, although a suggestive positive 
association for retinol and aggressive UCC was observed. With correction for 
main food sources of retinol and/or tocopherols, the observed associations 
remained (data not shown). These positive and null associations persisted after 
exclusion of cases diagnosed during the first two years of follow-up (data not 
shown). 
No association was found between dietary intake of retinol (OR highest vs. 
lowest quartile 1.00; 95%CI: 0.71-1.41, P-trend=0.89), dietary intake of vitamin 
E (OR highest vs. lowest quartile 0.83; 95%CI: 0.60-1.16, P-trend=0.27) and 
UCC risk (Table 3). 
When joint effects of smoking status and plasma α-tocopherol were evaluated, 
an effect of α-tocopherol was mainly seen in never smokers. In the highest 
tertile of α-tocopherol, smoking does not seem to have any effect anymore 
(P-interaction=0.04) (Table 4). Although the interaction on a multiplicative scale 
between plasma α-tocopherol and vitamin C on risk of UCC was not significant 
(P-interaction=0.33), the highest UCC risk was seen among those subjects with 
increasing plasma α-tocopherol levels in combination with lower vitamin C 
levels (OR 1.60; 95%CI: 1.00-2.57). The lowest UCC risk was seen in subjects 
with lower plasma α-tocopherol levels in combination with higher vitamin C 
levels (OR 0.57; 95%CI: 0.35-0.95) (Table 4). Smoking status or plasma vitamin C 
levels did not modify the associations between retinol and α-tocopherol and risk 
of UCC. In addition, the associations between plasma retinol and tocopherols 
and risk of UCC were not modified by alcohol intake, sex or BMI (P-interaction 
> 0.05).
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DISCUSSION 
In this large prospective study, higher concentrations of plasma α-tocopherol 
were associated with an increased risk of UCC, in particular the risk of aggressive 
UCC. The positive association between α-tocopherol and UCC was most clearly 
seen in never smokers. 
To date, only few prospective studies have examined associations between 
blood levels of retinol and/or tocopherols and bladder cancer risk. A case-control 
study nested within a cohort of Japanese-American men including 111 incident 
cases of bladder cancer reported a statistically non-significant increase in risk 
associated with higher serum retinol, but not with tocopherol concentrations.11 
Although our findings are consistent with two other prospective studies in the 
US and Finland which suggested an increased risk of bladder cancer associated 
with circulating concentrations of α-tocopherol12,13, these studies had small 
sample sizes (10-40 cases) and may therefore have lacked power to reach 
statistical significance. Two case-control studies on blood concentrations of 
retinol, tocopherols and bladder cancer risk found inconsistent results. One 
case–control study in the US that included 386 cases showed that higher plasma 
α-tocopherol and retinol levels were inversely associated with bladder cancer 
risk, while an increased bladder cancer risk was suggested with higher levels 
of plasma α-tocopherol.9 Another case–control study in the US with 84 cases 
found no association for plasma retinol and tocopherols and bladder cancer 
risk.10 However, in case-control studies results may be biased by changes in 
blood levels after diagnosis. 
Intervention studies that involved retinol (the CARET trial)32 or α-tocopherol 
(the ATBC and SELECT trial)33,34 supplements and examined bladder cancer as 
secondary endpoint showed no association with risk. These large randomized 
controlled trials had a relatively small number of cases (40-50 cases), and 
therefore may have lacked statistical power to detect any significant difference 
in bladder cancer risk. The null effect of pharmacological doses of retinol and 
α-tocopherol on bladder cancer risk in trials is difficult to compare with the 
positive association with plasma levels seen in our study, because circulating 
blood concentrations of retinol and tocopherols reflect both dietary and 
supplement intake. Whereas observational studies observe the effect of 
micronutrients in the general population, clinical trials can only examine the 
effect of a specific intervention, in a specific population, over a relatively short 
period of time. 
There are several proposed mechanisms by which tocopherols may influence 
carcinogenesis. Oxidative damage to DNA, proteins, and lipids may play 
an important role in the pathogenesis of cancer. Antioxidant vitamins may 
scavenge reactive oxygen and nitrogen species and thus delay or prevent 
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oxidative damage. In addition, the potential involvement in important processes 
of carcinogenesis, such as promoting immune system enhancement and the 
induction of tumour cell apoptosis, implies that tocopherols may play specific 
roles beyond that of its antioxidant function.3 Because the possible role of 
tocopherols in the prevention of cancer is often hypothesized, our findings are 
rather unexpected. The mechanism of tumour promotion by tocopherols is at 
present unknown, but may be related to increased formation of α-tocopherol 
radicals which, when not efficiently scavenged by other antioxidants, may 
act as reactive radical species themselves.7 In line with the hypothesis that 
higher concentrations of vitamin C regenerate α-tocopherol and inhibit the 
pro-oxidant activity of α-tocopherols6,8, we did see a suggestion of a stronger 
positive association of UCC risk with higher plasma levels of α-tocopherol in 
combination with lower plasma levels of vitamin C. Vitamin C is considered 
to be a powerful antioxidant as well but plasma vitamin C was not associated 
with UCC risk in the same study population.20 Further, it has been postulated 
that smokers with increasing levels of α-tocopherol may have a higher cancer 
risk.6 Increased blood concentrations of tocopherols may behave as pro-
oxidants especially under conditions of increased oxidative damage caused by 
cigarette smoking. Modelling the effects of plasma α-tocopherol jointly with 
smoking status showed that at higher blood levels of α-tocopherol an increased 
risk was mainly seen in never smokers. Interestingly, in the highest tertile of 
α-tocopherol levels, smoking does not seem to have any effect anymore. Thus, 
we cannot exclude a detrimental role of α-tocopherol in the absence nor in 
the presence of smoking. Given that smoking is the predominant risk factor 
for the development of UCC35, also confirmed in this study population36, these 
findings should further reinforce recommendations for smoking prevention 
and cessation. The observed associations should be interpreted with caution 
because we conducted multiple comparisons and because residual confounding 
by smoking cannot be excluded. 
Due to the relatively large number of cases in our study, we were able to analyse 
prognostic subgroups of UCC according to tumour aggressiveness. To our 
knowledge, previous studies have limited their analyses to total bladder cancer, 
and therefore, any differences in associations according to stage and grade of 
bladder cancer may be missed. In the current study, the increased UCC risk 
with higher levels of α-tocopherol was particularly driven by aggressive UCC. 
Aggressive, high-grade bladder tumours frequently show defects in the TP53 
and RB tumour suppressor genes. In vitro and animal studies have demonstrated 
that tocopherols can increase the expression of tumour suppressor p53, and can 
lead to accumulation of the tumour cells in G1 of the cell cycle and inhibition of 
tumour cell proliferation.37,38 However, this argues for a protective rather than 
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a risk-increasing role of tocopherols by control of tumour growth. Although 
there seems to be a biologically plausible role for the pro-oxidant activity of 
tocopherols, it is unclear why the risk of UCC is mainly found among aggressive 
bladder tumours and will require further study. 
Our results showed that the positive associations remained unchanged 
when the results were adjusted for several lifestyle factors (data not shown). 
The observed associations could also not be explained by adjusting for 
the consumption of major foods contributing retinol and/or tocopherols. 
Though, positive associations seen in observational studies may reflect other 
unmeasured lifestyle factors associated with both higher plasma concentrations 
of tocopherols and higher risk of UCC. Thus, higher plasma concentrations of 
tocopherols may just be a marker of an unhealthy diet and/or lifestyle. In our 
study, participants with higher plasma concentrations of tocopherols tended 
to have an unhealthy lifestyle (data not shown). On the other hand, adjusting 
for plasma carotenoids, which may be a marker for a more healthy diet, 
strengthened the positive association between plasma α-tocopherol and UCC 
risk for which we do not have a clear explanation. In addition, it is possible that 
exposure to potential risk factors may have changed during follow-up, which 
could lead to residual confounding. We could not take changes in dietary and 
lifestyle factors into account, as replicate measurements of these factors were 
not available in our study. 
The strengths of our study include its prospective design, a relatively large 
number of incident UCC cases, the wide range in plasma concentrations of 
micronutrients, and the collection of blood samples before cancer diagnosis. 
On the other hand, the results should be interpreted in light of several 
limitations. Retinol and tocopherols are transported in blood as part of 
lipoprotein complexes and plasma levels may depend on the type and amount 
of fat consumed. Optimally, plasma levels of retinol and tocopherols should 
therefore be adjusted for blood lipids and it is possible that the impossibility to 
adjust for blood lipids might have confounded our results. Although we were 
not able to present lipid-adjusted results because this information is lacking 
in our study, we did adjust for several lifestyle factors, including dietary fat 
consumption, that influence blood lipids. Also, adjustment for plasma lipids 
measured in another EPIC study on gastric cancer using the same biomarkers 
did not result in any appreciable changes in risk estimates.39 It seems unlikely 
that this would explain the positive association. The use of dietary supplements 
also could affect plasma levels of micronutrients. No substantial change in risk 
estimates was observed by simple adjustment for dietary supplement use (data 
not shown). Unfortunately, information about the specific type of supplement 
and frequency of use was not available in our study. Our analyses were based 
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on single measurements of plasma retinol and tocopherol concentrations at 
baseline. On this basis, we assumed that plasma levels were stable in persons 
during follow-up. Blood concentrations may differ over time because of day-
to-day variation and long-term changes within persons, which may lead to an 
attenuation of the associations. The stability of plasma retinol and tocopherols 
over time has been estimated in a subsample of the two Dutch cohorts within 
EPIC. Over 2 to 5 y, the intraclass correlation coefficients (ICC) was 0.17 for 
α-tocopherol, 0.44 for α-tocopherol and 0.41 for retinol.40 This suggests that 
a single measurement is not fully able to capture long-term intake and body 
stores. 
In conclusion, higher levels of plasma α-tocopherol may be associated with the 
risk of UCC, in particular aggressive UCC risk. Residual confounding by smoking 
or other factors cannot be excluded. Confirmation of these results in other 
prospective settings with multiple measurements of blood levels is warranted. 
FUNDING
This work has been supported by the European Commission: Public Health and 
Consumer Protection Directorate 1993-2004; Research Directorate-General 
2005-.”; Ligue contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de 
l’Education Nationale, Institut National de la Santé et de la Recherche Médicale 
(INSERM) (France); German Cancer Aid, German Cancer Research Center, 
Federal Ministry of Education and Research (Germany); Danish Cancer Society 
(Denmark); Health Research Fund (FIS) of the Spanish Ministry of Health, The 
participating regional governments and institutions (Spain); Cancer Research 
UK, Medical Research Council (United Kingdom); Hellenic Health Foundation, 
Stavros Niarchos Foundation and the Hellenic Ministry of Health and Social 
Solidarity; Italian Association for Research on Cancer, National Research 
Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), 
Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention 
Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund 
(WCRF), Dutch Cancer Society (KWF), Statistics Netherlands (The Netherlands); 
Swedish Cancer Society, Swedish Scientific Council, Regional Government of 
Skane (Sweden); Helga study - Nordforsk center of excellence programme in 
food and nutrition (Norway). The study sponsors had no role in the design, 
collection, analysis or interpretation of the data, nor in writing or submitting 
the manuscript.
Plasma retinol and tocopherols and risk of urothelial cell carcinomas
127
REFERENCES
1. Debier C, Larondelle Y. Vitamins A and E: metabolism, roles and transfer to offspring. Br J 
Nutr. 2005;93:153-174.
2. Zou C, Liebert M, Grossman HB, et al. Identification of effective retinoids for inhibiting 
growth and inducing apoptosis in bladder cancer cells. J Urol. 2001;165:986-992.
3. Dutta A, Dutta SK. Vitamin E and its role in the prevention of atherosclerosis and 
carcinogenesis: a review. J Am Coll Nutr. 2003;22:258-268.
4. Kanai K, Kikuchi E, Mikami S, et al. Vitamin E succinate induced apoptosis and enhanced 
chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo. Cancer Sci. 
2010;101:216-223.
5. Yu W, Jia L, Park SK, et al. Anticancer actions of natural and synthetic vitamin E forms: 
RRR-alpha-tocopherol blocks the anticancer actions of gamma-tocopherol. Mol Nutr Food 
Res. 2009;53:1573-1581.
6. Kontush A, Finckh B, Karten B, et al. Antioxidant and prooxidant activity of alpha-tocopherol 
in human plasma and low density lipoprotein. J Lipid Res. 1996;37:1436-1448.
7. Rietjens IM, Boersma MG, Haan L, et al. The pro-oxidant chemistry of the natural 
antioxidants vitamin C, vitamin E, carotenoids and flavonoids. Environ Toxicol Pharmacol. 
2002;11: 321-333.
8. Chan AC. Partners in defense, vitamin E and vitamin C. Can J Physiol Pharmacol. 1993;71: 
725-731.
9. Liang D, Lin J, Grossman HB, et al. Plasma vitamins E and A and risk of bladder cancer: a 
case-control analysis. Cancer Causes Control. 2008;19:981-992.
10. Hung RJ, Zhang ZF, Rao JY, et al. Protective effects of plasma carotenoids on the risk of 
bladder cancer. J Urol. 2006;176:1192-1197.
11. Nomura AM, Lee J, Stemmermann GN, et al. Serum vitamins and the subsequent risk of 
bladder cancer. J Urol. 2003;170:1146-1150.
12. Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-
carotene, retinol, and subsequent bladder cancer. Cancer Res. 1989;49:6144-6148.
13. Knekt P, Aromaa A, Maatela J, et al. Serum micronutrients and risk of cancers of low 
incidence in Finland. Am J Epidemiol. 1991;134:356-361.
14. Knowles MA. Molecular pathogenesis of bladder cancer. Int J Clin Oncol. 2008;13:287-
297.
15. Wallerand H, Bakkar AA, de Medina SG, et al. Mutations in TP53, but not FGFR3, in 
urothelial cell carcinoma of the bladder are influenced by smoking: contribution of 
exogenous versus endogenous carcinogens. Carcinogenesis. 2005;26:177-184.
16. Serretta V, Morgia G, Altieri V, et al. Preliminary report of a multicentric study on 
environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from 
Gruppo Studi Tumori Urologici Foundation. Urol Int. 2006;77:152-158.
Chapter 6
128
17. Jiang X, Castelao JE, Yuan JM, et al. Cigarette smoking and subtypes of bladder cancer. Int 
J Cancer. 2012;130:896-901.
18. Sturgeon SR, Hartge P, Silverman DT, et al. Associations between bladder cancer risk 
factors and tumor stage and grade at diagnosis. Epidemiology. 1994;5:218-225.
19. Hayes RB, Friedell GH, Zahm SH, et al. Are the known bladder cancer risk-factors associated 
with more advanced bladder cancer? Cancer Causes Control. 1993;4:157-162.
20. Ros MM, Bueno-de-Mesquita HB, Kampman E, et al. Plasma carotenoids and vitamin 
C concentrations and risk of urothelial cell carcinoma in the European Prospective 
Investigation into Cancer and Nutrition. Am J Clin Nutr. 2012;96:902-910.
21. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and 
Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5:1113-
1124.
22. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective 
Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26 Suppl 1: S6-S14.
23. Slimani N, Deharveng G, Unwin I, et al. The EPIC nutrient database project (ENDB): a first 
attempt to standardize nutrient databases across the 10 European countries participating 
in the EPIC study. Eur J Clin Nutr. 2007;61:1037-1056.
24. Buchner FL, Bueno-de-Mesquita HB, Ros MM, et al. Consumption of vegetables and fruit 
and the risk of bladder cancer in the European Prospective Investigation into Cancer and 
Nutrition. Int J Cancer. 2009;125:2643-2651.
25. Kiemeney LA, Thorlacius S, Sulem P, et al. Sequence variant on 8q24 confers susceptibility 
to urinary bladder cancer. Nat Genet. 2008;40:1307-1312.
26. Richardson DB. An incidence density sampling program for nested case-control analyses. 
Occup Environ Med. 2004;61:e59.
27. Steghens JP, van Kappel AL, Riboli E, et al. Simultaneous measurement of seven carotenoids, 
retinol and alpha-tocopherol in serum by high-performance liquid chromatography. J 
Chromatogr B Biomed Sci Appl. 1997;694:71-81.
28. Key T, Oakes S, Davey G, et al. Stability of vitamins A, C, and E, carotenoids, lipids, and 
testosterone in whole blood stored at 4 degrees C for 6 and 24 hours before separation of 
serum and plasma. Cancer Epidemiol Biomarkers Prev. 1996;5:811-814.
29. Knol MJ, Vandenbroucke JP, Scott P, et al. What do case-control studies estimate? 
Survey of methods and assumptions in published case-control research. Am J Epidemiol 
2008;168:1073-1081.
30. Jansen MC, Bueno-de-Mesquita HB, Feskens EJ, et al. Quantity and variety of fruit and 
vegetable consumption and cancer risk. Nutr Cancer. 2004;48:142-148.
31. Traber MG, Sies H. Vitamin E in humans: demand and delivery. Annu Rev Nutr. 1996;16: 
321-347.
32. Bruemmer B, White E, Vaughan TL, et al. Nutrient intake in relation to bladder cancer 
among middle-aged men and women. Am J Epidemiol. 1996;144:485-495.
Plasma retinol and tocopherols and risk of urothelial cell carcinomas
129
33. Mettlin C, Graham S. Dietary risk factors in human bladder cancer. Am J Epidemiol. 
1979;110:255-263.
34. Kolonel LN, Hinds MW, Nomura AM, et al. Relationship of dietary vitamin A and ascorbic 
acid intake to the risk for cancers of the lung, bladder, and prostate in Hawaii. Natl Cancer 
Inst Monogr. 1985;69:137-142.
35. Riboli E, Gonzalez CA, Lopez-Abente G, et al. Diet and bladder cancer in Spain: a multi-
centre case-control study. Int J Cancer. 1991;49:214-219.
36. Nomura AM, Kolonel LN, Hankin JH, Yoshizawa CN. Dietary factors in cancer of the lower 
urinary tract. Int J Cancer. 1991;48:199-205.
37. Wakai K, Takashi M, Okamura K, et al. Foods and nutrients in relation to bladder cancer 
risk: a case-control study in Aichi Prefecture, Central Japan. Nutr Cancer. 2000;38:13-22.
38. Garcia-Closas R, Garcia-Closas M, Kogevinas M, et al. Food, nutrient and heterocyclic 
amine intake and the risk of bladder cancer. Eur J Cancer. 2007;43:1731-1740.
39. Holick CN, De Vivo I, Feskanich D, et al. Intake of fruits and vegetables, carotenoids, folate, 
and vitamins A, C, E and risk of bladder cancer among women (United States). Cancer 
Causes Control. 2005;16:1135-1145.
40. Garcia R, Gonzalez CA, Agudo A, et al. High intake of specific carotenoids and flavonoids 
does not reduce the risk of bladder cancer. Nutr Cancer. 1999;35:212-214.
41. Zeegers MP, Goldbohm RA, van den Brandt PA. Are retinol, vitamin C, vitamin E, folate 
and carotenoids intake associated with bladder cancer risk? Results from the Netherlands 
Cohort Study. Br J Cancer. 2001;85:977-983.
42. Michaud DS, Pietinen P, Taylor PR, et al. Intakes of fruits and vegetables, carotenoids and 
vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. Br J 
Cancer. 2002;87:960-965.
43. Brinkman MT, Karagas MR, Zens MS, et al. Minerals and vitamins and the risk of bladder 
cancer: results from the New Hampshire Study. Cancer Causes Control. 2010;21:609-619.
44. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for 
intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer 
Inst. 1996;88:1550-1559.
45. Virtamo J, Edwards BK, Virtanen M, et al. Effects of supplemental alpha-tocopherol and 
beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland). 
Cancer Causes Control. 2000;11:933-939.
46. Mazdak H, Zia H. Vitamin e reduces superficial bladder cancer recurrence: a randomized 
controlled trial. International journal of preventive medicine. 2012;3:110-115.
47. Boffetta P. Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl. 
2008;218:45-54.
48. Bjerregaard BK, Raaschou-Nielsen O, Sorensen M, et al. Tobacco smoke and bladder 
cancer-in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 
2006;119: 2412-2416.
Chapter 6
130
49. Chen CS, Squire JA, Wells PG. Reduced tumorigenesis in p53 knockout mice exposed in 
utero to low-dose vitamin E. Cancer. 2009;115:1563-1575.
50. Schwartz JL, Antoniades DZ, Zhao S. Molecular and biochemical reprogramming of 
oncogenesis through the activity of prooxidants and antioxidants. Ann N Y Acad Sci. 
1993;686:262-278.
51. Jenab M, Riboli E, Ferrari P, et al. Plasma and dietary carotenoid, retinol and tocopherol 
levels and the risk of gastric adenocarcinomas in the European prospective investigation 
into cancer and nutrition. Br J Cancer. 2006;95:406-415.
52. Comstock GW, Burke AE, Hoffman SC, et al. The repeatability of serum carotenoid, 
retinoid, and tocopherol concentrations in specimens of blood collected 15 years apart. 
Cancer Epidemiol Biomarkers Prev. 2001;10:65-68.
53. Leenders M, Ros MM, Sluijs I, et al. Reliability of selected antioxidants and compounds 
involved in one-carbon metabolism in two dutch cohorts. Nutr Cancer. 2013;65:17-24.
Plasma retinol and tocopherols and risk of urothelial cell carcinomas
131

Reliability of selected 
antioxidants and compounds 
involved in one-carbon 
metabolism in two Dutch ohorts
Nutr Cancer. 2013, 65(1), 17–24
7
ABSTRACT 
Many epidemiological studies assess nutritional status based on single 
blood measurements, without verifying if these remain reliable over repeated 
measurements. This study assessed the reliability over a period of 2 to 5 yr of 
plasma carotenoids, vitamin C, retinol, tocopherols, and serum compounds 
involved in 1-carbon metabolism in a subsample of Dutch participants of 
European Prospective Investigation into Cancer and Nutrition (EPIC). Blood 
samples from 38 men from MORGEN-EPIC and 35 women from Prospect-
EPIC were collected between 1993 and 1997 and again after 2 to 5 yr. The 
reliability of plasma carotenoids, retinol, vita- min C, and tocopherols, and of 
serum folate, homocysteine, and vitamins B6 and B12 was estimated using an 
intraclass correlation coefficient (ICC). Serum homocysteine and vitamin B12 
were highly reliable biomarkers, with ICCs of 0.91 and 0.75, respectively. 
All other analysed biomarkers had a slight or fair reliability over several years 
(ICCs ranged from 0.17 to 0.56). Most examined biomarkers showed reliability 
values that may lead to considerable attenuation of the risk estimate when used 
as exposure assessment in a risk model. If multiple measurements are not 
available, the risk estimates can be adjusted for the regression dilution using the 
ICC as adjustment coefficient.
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INTRODUCTION 
Biomarkers are indicators of a biological status and are commonly used in 
epidemiology to provide accurate measures that can be correlated to dietary 
intake. Nutritional biomarkers can provide more accurate estimates of nutrient 
status for nutrients with inadequate food composition data and are more proximal 
assessments of nutrient status when compared to dietary assessment methods1, 
but the use of biomarkers in risk models can be limited by measurement error. 
This error can be caused randomly (i.e., biological variation and sampling errors) 
or systematically (analytical variability).2
The reliability of exposure estimates concerns the extent to which a 
measurement of this estimate remains stable over repeated measurements.3,4 
Random measurement error causes unreliable measures and this “regression 
dilution” may attenuate risk estimates toward their null value.5 By increasing 
time between measurements, the reliability of biomarkers may decrease because 
changes in behaviour (e.g., change in diet), health status6, or environment (e.g., 
smoking or seasonal variation), causing an increased within-subject variance and 
corresponding decreased reliability.7 The reliability of biomarkers can be improved 
by using average measures at 1 time point8 and using repeated measures over 
time. When multiple measurements are not available, the intraclass correlation 
coefficient (ICC) can function as attenuation coefficient to correct risk estimates 
for underestimation by regression dilution.9
Many prospective epidemiological studies examine associations between 
chronic disease risk and prediagnostic exposure to dietary factors, such as 
vegetables, fruits, or antioxidants.10,11 Biomarkers that are commonly used 
for dietary assessment of these factors include carotenoids, vitamin C, retinol, 
tocopherols, and compounds involved in the 1-carbon metabolism (OCM) 
pathway (e.g., B-vitamins). However, many studies base nutritional status on 
single blood measurements, without taking its long-term reliability into account. 
Previous studies generally observed a moderate short-term reliability (ranging 
from 2 wk. to 1 yr) for selected antioxidants, with correlations around 0.6–0.7, 
and even stronger correlations for homocysteine, vitamin B12, and folate.12–20 
However, these studies were performed over a time period not representative 
of most longitudinal studies and were performed in the United States, where a 
larger between- subject variation may exist than in Europe because of a higher 
use of dietary supplementation21,22 and fortification23. In addition, most studies 
did not calculate an ICC14–16 or adjust analyses14–20, which removes part of the 
heterogeneity in biomarker levels between the subjects and generally results in a 
decreased reliability.24 Therefore, the aim of this study is to assess the reliability 
over a period of 2 to 5 yr and calculate corresponding ICCs of plasma carotenoids, 
vitamin C, retinol, tocopherols, and serum compounds involved in OCM (folate, 
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homocysteine, and vitamins B6 and B12) in a subsample of Dutch participants of 
the European Prospective Investigation into Cancer and Nutrition (EPIC).
METHODS 
Study population
This study includes subjects from the 2 Dutch contributions to EPIC, Prospect-
EPIC, and MORGEN-EPIC.25,26 The Prospect-EPIC cohort follows over 17,000 
women living in the city of Utrecht and its surroundings who participated in 
the national breast cancer screening program, aged 49–70 yr at baseline.27 The 
MORGEN-EPIC includes 23,100 men and women from a random sampling 
of the population in 3 towns in the Netherlands (Amsterdam, Doetinchem, 
and Maastricht), aged 20–59 yr at baseline.28,29 The design of this study was 
based on a previous study.30 Participants provided blood samples and data on 
diet, lifestyle, disease history, and anthropometrics at 2 different examination 
points. Participants from MORGEN-EPIC were recruited between May 1993 
and February 199428,29, and 487 participants from Doetinchem were invited 
for a second examination, approximately 5 yr later. From Prospect-EPIC, 700 
women were recruited between 1993 and 1997 and were invited for a second 
examination after 2–4 yr. Both blood samples were collected in the same season 
(±2 months of first sample).
Participants were included if they were aged 40–65 yr (MORGEN-EPIC) or 50–
65 yr (Prospect-EPIC) at the time of the first sample, with no history of diabetes, 
cancer, heart infarct, or cerebrovascular accident. In addition, smoking status 
(current, former, never for Prospect-EPIC; ≥1 cigarette per mo, <1 cigarette per 
mo, former, never for MORGEN-EPIC), alcohol intake (≥1 consumption per wk., 
<1 consumption per wk., ever, never for MORGEN-EPIC; drinker, non-drinker for 
Prospect-EPIC), weight (within 5 kg of first sample), energy intake (within same 
quartile as first sample), and vitamin supplement use (yes, no) had to be similar 
within 1 person for both time points. Smoking categories were dichotomized by 
combining former and never smokers and participants that smoke <1 cigarette per 
month (latter for MORGEN-EPIC only). For Prospect-EPIC, females were excluded 
if they were pregnant in the last six months before a sampling point. To represent 
categories of gender, only men were selected from the MORGEN-EPIC cohort to 
compare results with the Prospect-EPIC study. In total, 37 men from MORGEN-
EPIC and 35 females from Prospect-EPIC satisfied all conditions. Two serum and 
plasma measurements were available for, respectively, 27 and 28 participants 
from Prospect-EPIC. In MORGEN-EPIC, 34 participants had 2 available plasma 
antioxidant and serum folate measurements, 33 had 2 serum homocysteine 
and vitamin B6 measurements, and 35 had 2 vitamin B12 measurements. All 
participants gave informed consent before study inclusion. The Prospect-EPIC 
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study was approved by the Institutional Review Board of the University Medical 
Center Utrecht, and the EPIC-MORGEN project was approved by the Medical 
Ethical Committee of TNO, Netherlands.
Blood collection and biomarker assessment
Nonfasting venous blood samples were obtained from each participant, using 3 
× 10 mL Safety-Monovettes tubes (Sarstedt, Tilburg, the Netherlands), that is, 
1 whole blood for serum and 2 citrated for plasma. Filled syringes were kept 
at 5–10αC, protected from light, and transferred in cool boxes to the Cryo-
laboratory of the National Institute for Public Health and the Environment 
(RIVM), Bilthoven, the Netherlands. Blood was separated into 0.5 ml fractions 
(serum, plasma, red cells, and buffy coat for DNA extraction) and stored in heat-
sealed straws at −196αC under liquid nitrogen. Biomarker assessment took 
place at the RIVM biochemistry laboratory. The serum and plasma samples 
for, respectively, 29 and 31 participants from EPIC-MORGEN and 15 and 16 
participants from Prospect-EPIC were analysed in the same batch to minimize 
batch-to-batch variations. For the remaining subjects, the second sample was 
measured a day (or in 1 case, 2 days) after the first sample in a different batch. 
High-performance liquid chromatography (HPLC) using an HPLC column (250 × 
4.6 mm, ChromSpher 5 µm C18, Varian Assoc., Middelburg, the Netherlands) was 
used to determine plasma concentrations of carotenoids (lutein, zeaxanthin, α- 
crytoxanthin, lycopene, α-carotene, α-carotene, cantaxanthin) (at 450 nm), retinol 
(at 325 nm), and tocopherols (α-tocopherol and α-tocopherol) (with fluorescence) 
as previously described.31 Cantaxanthin concentrations were close to or below 
the limit of detection (20 nmol/L) for most samples and were therefore not used 
in the present study. The sum of carotenoids was calculated by adding the six 
individual carotenoid concentrations. An LX20-Pro autoanalyzer (Beckman-
Coulter, Woerden, the Netherlands) was used to determine plasma vitamin 
C concentrations, using a coloric assay as previously described32, and serum 
homocysteine concentrations with an enzyme cycling assay using diagnostic 
reagents of Dialab (Vienna, Austria). Two samples for vitamin C and α-carotene, 
and 3 samples for zeaxanthin were found under the limit of detection (20 nmol/L) 
and were set at the detection limit. Folate and vitamin B12 concentrations were 
determined in serum using an Access-2 immunoanalyzer. Serum vitamin B6 
was determined by reversed-phase HPLC analysis with fluorescence detection 
using a kit of Chromsystems (Munich, Germany), HPLC equipment from Varian 
Assoc. (Middelburg, the Netherlands), and a fluorescence detector from Jasco 
(Separations, H.I., Ambacht, the Netherlands). One control sample with a 
concentration similar to the mean was added to each batch of samples to assess 
between-batch reproducibility. The inter-assay coefficients of variation were 
14.6% for α-carotene, 6.3% for α-carotene, 4.4% for α-cryptoxanthin, 10.1% for 
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lycopene, 7.8% for lutein, 10.5% for zeaxanthin, 4.7% for vitamin C, 4.0% for 
retinol, 4.1% for α-tocopherol, 3.7% for α-tocopherol, 6.1% for folate, 3.4% for 
homocysteine, 3.5% for vitamin B6, and 7.2% for vitamin B12.
Data analyses
Differences in biomarker levels and changes in daily energy intake (MJ/day), 
age (yr), weight (kg), and body mass index (BMI; kg/m2) at both time points 
were examined with Wilcoxon signed rank tests and percent changes. Also, 
frequencies of current smoking (yes, no), vitamin supplement use (yes, no), and 
hormone therapy use (yes, no) were compared. Spearman’s rank correlation 
coefficients were used as non-parametric measure to assess the correlation of 
biomarkers be- tween the samples. Although it does not take into account both 
within-subject and between-subject variation, Spearman’s rank correlation does 
give an indication of the reliability.33
ICCs were computed to assess the reliability of the biomarkers over 2–5 yr 
and were calculated using a 2-way random effects model for single measures.8 
This model was used because all biomarkers were measured at the same time 
points, therefore causing a systematic error between both measurements for all 
biomarkers (2-way model), which was considered to be random (random effects).9 
Because epidemiological studies tend to use the ranking of participants instead 
of absolute values, a consistency measure, which concerns ranking only and 
ignores absolute values, was used.8 Following Shrout’s reliability definitions34, 
the reliability was considered virtually none (ICC: <0.1), slight (ICC: 0.1–0.4), fair 
(ICC: 0.4–0.6), moderate (ICC: 0.6–0.8), or substantial (ICC: >0.8). ICCs were 
computed unadjusted and adjusted for the duration between the time points (yr), 
smoking status (yes, no), age (yr), BMI (kg/m2), energy intake (MJ/day), vitamin 
supplement use (yes, no), and hormone therapy use (yes, no) (latter for women 
only). ICCs can function as attenuation coefficients to adjust risk estimates of 
corresponding biomarkers for regression dilution. Because risk models are often 
adjusted for various factors, ICCs may represent the reliability for these models 
better if they are adjusted accordingly.9 BMI was included in the models instead 
of weight, because it may be more informative on health status. Alcohol intake 
and serum LDL concentration were not included because these did not affect the 
reliability estimates. Adjusted analyses were also stratified by gender. Season was 
not included, because most measures for women (24 of all 28) were obtained in 
spring and summer, whereas most measures for men (26 of all 35) were obtained 
in autumn and winter. Therefore, any variance due to season may have been 
caused by gender differences or vice versa.
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RESULTS 
Median absolute percentage differences between both samples ranged between 
0% and 20% for most biomarkers. After 2 to 5 yr, male homocysteine levels 
increased significantly and α-tocopherol, lycopene, and sum of carotenoid levels 
decreased in women (Table 1). Spearman correlations of plasma biomarkers 
(carotenoids, tocopherols, retinol, and vitamin C) ranged from 0.33 for zeaxanthin 
to 0.60 for α-cryptoxanthin (Table 2). Correlations of serum biomarkers ranged 
from 0.51 for folate to 0.73 for vita- min B12. Adjustment for the time between 
the 2 measurements did not materially change the Spearman correlations. 
Crude ICCs of plasma carotenoids ranged from 0.37 for zeaxanthin to 0.54 for 
α-cryptoxanthin in the total study population. Other plasma biomarkers showed 
ICCs of 0.55 for vitamin C, 0.50 for retinol, 0.43 for α-tocopherol, and 0.52 for 
α-tocopherol. The ICC for serum vitamin B6 and folate was, respectively, 0.41 
and 0.52, but higher ICC values for vitamin B12 and homocysteine were found 
(0.76 and 0.90, respectively). ICCs for most biomarkers, except for homocysteine, 
α- and α-carotene, and sum of carotenoids, decreased after adjustment for 
covariates and duration between the measurements. Most notably, the ICC for 
vitamin B6 in women decreased from 0.23 to 0.00. After adjustments, biomarker 
reliability in women ranged from 0.00 for vitamin B6 and α-tocopherol to 
0.65 for vitamin B12. In men, reliability ranged from 0.17 for folate to 0.94 for 
homocysteine (Table 3).
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Table 1. Medians and 25-75th percentiles for biomarkers and continuous covariates for MORGEN- EPIC and Pros-
pect-EPIC, at times 1 and 2, and correspondent Wilcoxon signed-rank p-values and % differences; frequencies 
(numbers and percentages) for binary variables, at times 1 and 2.
Men 
(MORGEN-EPIC)
Biomarker n Time 1, 
Median
25-75% Time 2, 
Median
25-75% p Median  
percent change
Folate (nmol/L) 34 8.82 7.38-10.46 9.06 7.04-11.56 0.54 2.72
Homocysteine (μmol/L) 33 14.84 12.41-17.28 16.73 15.04-20.03 0.00 12.74
Vitamin B6 (μg/L) 33 31.90 21.70-53.30 36.30 28.50-49.40 0.13 13.79
Vitamin B12 (pmol/L) 35 273.00 212.00-352.00 249.00 204.00-318.00 0.05 -8.79
Vitamin C (μmol/L) 34 33.44 24.09-40.37 38.61 29.04-45.32 0.10 15.46
Retinol (μmol/L) 34 2.40 1.90-2.70 2.45 2.00-2.70 0.80 2.08
α-tocopherol (μmol/L) 34 25.10 20.80-29.60 23.70 20.10-30.00 0.37 -5.58
γ-tocopherol (μmol/L) 34 5.15 3.80-8.20 5.70 4.10-7.90 0.62 10.68
Lutein (μmol/L) 34 331.90 262.80-395.80 328.60 242.90-499.90 0.38 -0.99
Zeaxanthin (μmol/L) 34 91.60 74.30-112.10 94.50 69.10-134.30 0.52 3.17
β-cryptoxanthin (μmol/L) 34 302.40 174.90-381.80 248.05 168.50-482.00 0.56 -17.97
Lycopene (μmol/L) 34 440.70 333.90-664.30 512.25 359.70-689.30 0.24 16.24
α-carotene (μmol/L) 34 95.45 57.70-156.20 112.20 83.50-152.90 0.19 17.55
β-carotene (μmol/L) 34 438.75 352.60-674.20 545.30 365.80-850.30 0.05 24.28
Sum of carotenoids (μmol/L) 34 1843.4 1421.8-2350.2 2021.3 1464.9-2384.3 0.10 9.65
Age (years) 35 52 47-59 57 52-64
Weight (kg) 35 80.6 77.3-87.1 80.9 77.0-87.6 1.00
BMI (kg/m2) 35 25.8 24.4-26.8 25.8 24.6-26.7 0.97
Energy (kJ) 35 10856 9534-14102 10274 9308-12545 0.47
Hormone use (yes, no) 35 - -
Vitamin use (yes, no) 35 6 / 29 17% 6 / 29 17%
Smoking (yes, no) 35 7 / 28 20% 7 / 28 20%
EPIC = European Prospective Investigation into Cancer and Nutrition 
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Table 1. Continued
Women 
(Prospect-EPIC)
Biomarker n Time 1, 
Median
25-75% Time 2, 
Median
25-75% p Median  
percent change
Folate (nmol/L) 27 8.64 5.95-12.69 8.62 7.09-11.16 0.21 -0.23
Homocysteine (μmol/L) 27 14.70 12.75-17.71 14.26 12.27-16.34 0.67 -2.99
Vitamin B6 (μg/L) 27 38.54 26.84-49.27 39.50 28.02-54.74 0.42 2.49
Vitamin B12 (pmol/L) 27 276.00 210.00-355.00 285.00 211.00-394.00 0.33 3.26
Vitamin C (μmol/L) 28 47.91 31.85-57.48 42.35 34.87-51.21 0.37 -11.60
Retinol (μmol/L) 28 2.07 1.78-2.46 1.82 1.50-2.26 0.06 -12.33
α-tocopherol (μmol/L) 28 21.17 16.31-24.29 16.16 14.34-20.72 0.06 -23.66
γ-tocopherol (μmol/L) 28 4.46 3.07-5.94 3.10 2.18-4.17 0.00 -30.58
Lutein (μmol/L) 28 338.28 286.69-420.87 309.89 238.29-412.27 0.23 -8.39
Zeaxanthin (μmol/L) 28 103.10 81.34-136.00 99.97 73.98-148.98 0.71 -3.04
β-cryptoxanthin (μmol/L) 28 345.23 222.48-459.40 362.36 247.80-446.49 0.95 4.96
Lycopene (μmol/L) 28 512.15 388.93-713.68 400.88 289.01-579.07 0.01 -21.73
α-carotene (μmol/L) 28 92.49 73.55-136.44 110.26 59.53-134.64 0.77 19.21
β-carotene (μmol/L) 28 658.02 549.30-776.86 550.10 455.17-767.08 0.06 -16.40
Sum of carotenoids (μmol/L) 28 2151.8 1850.9-2435.1 2001.1 1421.8-2284.9 0.04 -7.00
Age (years) 28 54 53-58 57 55-61
Weight (kg) 28 68.8 61.3-78.5 69.0 62.8-77.5 0.95
BMI (kg/m2) 28 24.6 22.3-28.4 24.8 22.8-28.2 0.95
Energy (kJ) 28 7757 6517-9075 7774 6178-8404 0.61
Hormone use (yes, no) 28 7 / 21 25% 11 / 17 39%
Vitamin use (yes, no) 28 10 / 18 36% 10 / 18 36%
Smoking (yes, no) 28 7 / 21 25% 7 / 21 25%
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DISCUSSION 
Over 2–5 yr, serum homocysteine and vitamin B12 were highly reliable biomarkers, 
but most other analysed biomarkers had a slight or fair reliability. In the present 
study, ICCs for plasma vitamin C, carotenoids, and tocopherols ranged between 
0.17 and 0.56, whereas previous studies reported correlations over 0.6.12–14,17 
Previously reported ICCs of compounds involved in OCM were close to 1.18–20 
Although in our total study population the ICC of serum homocysteine and vitamin 
B12 showed a moderate and substantial reliability, biomarkers for serum folate 
and vitamin B6 showed a fair and slight reliability. Reliability was also assessed 
for natural log transformed values, a common transformation in risk models, but 
this did not materially change the ICC of most biomarkers (Supplemental Table 1).
The present study differs from previous studies as most previous studies13,15–20 
were performed with less time between the measurements (2 wk.–1 yr). One 
previous study14 collected samples 15 yr after each other and, although only an 
indication of reliability, found Spearman’s rank correlations for serum carotenoids 
and tocopherols, similar to our ICCs. This suggests that reliability decreases with 
a longer time between measurements. In addition, most previous studies14,16–20 
did not calculate or adjust ICCs, which causes a lower reliability due to removal of 
heterogeneity between the subjects.24
The use of nonfasting samples in this study may have in- creased the within-
subject variance, because some biomarkers (e.g., water-soluble vitamins) respond 
quickly to a short-term intake.1,35 Most previous studies12,13,15,16,18,20 made use 
of fasting samples, but this difference does not explain the lower reliability for 
biomarkers in our study that are more robust to fasting status (e.g., fat-soluble 
vitamins). Another difference is that previous studies were performed in the 
United States, where a larger variance in exposure to sources of the selected 
biomarkers may exist than in Europe due to, for example, fortification (folate 
fortification causes a larger variation in folate and homocysteine levels).23
Changes in diet may explain the larger within-subject variation in our study. 
Additional analyses in the EPIC-MORGEN cohort showed that ICCs were slightly 
higher in participants with minimal changes in reported energy intake (<10%) 
between sampling points but did not improve in individuals with minimal changes 
in reported nutrient intake (dietary vitamin B6, B12, C, retinol, and α-carotene) 
(data not shown).
A strong influence of processing and storage on the within-subject variance 
is unlikely because reliability in the EPIC-Prospect cohort was not better than 
for EPIC-MORGEN, although storage time was shorter and, because of a strict 
adherence to the cold chain prior to processing, processing time between blood 
collection and storage was restricted to less than 24 h, and samples were stored 
at −196αC. Previous studies reported stable carotenoid, retinol, and tocopherol 
biomarker levels at long-term storage with temperatures under −70αC.37,38
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Differences between the 2 cohorts may have been caused by differences in 
gender or season. The slight and fair reliability of carotenoids may have been 
caused by the fact that postmenopausal women have lower carotenoid levels 
than pre-menopausal women36, but this does not explain the equally low reliability 
in men. In addition, the proportion of women that experienced menopausal 
changes is probably low as the median age at the time of the first sample was 55. 
Differences between the cohorts may also be explained by differences in season, 
for which we could not control because most measurements within the cohorts 
were performed in the same season.
Several limitations of the study need to be discussed. First, single measures of 
biomarkers were used for both sampling times for all participants. Using averages 
of multiple measurements will generally result in a higher reliability8,39 and reduce 
random error in the laboratory assay. Within-person variance was minimized by 
selecting participants with similar values for covariates at both sampling times, 
because such covariates are often controlled for in risk models. It should be noted 
that this is likely to cause an underestimation of the within-person variance (and 
therefore overestimation of the ICC) for persons that did change behaviour over 
time. Systematic analytical measurement error is unlikely to be a major factor as 
most samples were analysed within the same batch.
Second, the study was performed among Dutch subjects and therefore results 
might not be applicable to the overall European population. However, this study 
is the first (and therefore the most applicable) to calculate reliability of these 
biomarkers in a European population. Selection criteria were used to avoid 
possible confounding on the reliability of the analysed biomarkers, but excluding 
participants may have further limited the generalizability of the study, except in 
risk models that contain the same covariates. Preferably, assessment of biomarker 
reliability should be extended to other European regions. A strength of the study 
was the time between the 2 measurements, which was longer than most previous 
studies. Therefore, our findings will be more relevant for studies with a long time 
between exposure and outcome.
Because of the high within-subject variance, using a single measure of a low-reliable 
biomarker as exposure assessment in a disease-biomarker model may attenuate 
risk estimates. In these cases, it is desirable to use averages of replicate measures 
to improve reliability and prevent attenuation of the risk estimate. However, for 
biomarkers with virtually no reliability (such as α-tocopherol and vitamin B6) even 
this cannot prevent the possible attenuation.34 If multiple repeated samples are 
not available, the risk estimate can be adjusted for attenuation by dividing the 
risk estimate by the ICC9, for example, attenuation adjustment of the association 
observed for plasma vitamin C and gastric cancer risk within EPIC [odds ratio 
(OR) for highest vs. lowest quartile 0.55; 95% confidence interval (95% CI): 
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0.31–0.97]40, using the adjusted ICC for vitamin C results in an adjusted OR 
of 0.30 (95%CI: 0.06–0.95). However, it should be noted that the adjustment 
of risk estimates can only be validly achieved when the ICC is obtained from a 
representative sample of the population studied.
In summary, the present study assessed the reliability of commonly used biomarkers 
in a European population. Serum homocysteine and vitamin B12 showed high 
ICCs, but most other analysed biomarkers had a slight or fair reliability over 2–5 
yr. Prospective studies that use slightly or fairly reliable biomarkers can reduce 
random analytical measurement error by using average measures of repeated 
samples. If multiple samples are not available, the risk estimates can be adjusted 
for the regression dilution, using the ICC as adjustment coefficient.
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ABSTRACT
Results from previous studies investigating the association between fluid 
intake and urothelial cell carcinomas (UCC) are inconsistent. We evaluated this 
association among 233,236 subjects in the European Prospective Investigation 
into Cancer and Nutrition (EPIC), who had adequate baseline information on 
water and total fluid intake. During a mean follow-up of 9.3 years, 513 first 
primary UCC occurred. At recruitment, habitual fluid intake was assessed by 
a food frequency questionnaire. Multivariable hazard ratios were estimated 
using Cox regression stratified by age, sex and centre and adjusted for energy 
intake, smoking status, duration of smoking and lifetime intensity of smoking. 
When using the lowest tertile of intake as reference, total fluid intake was not 
associated with risk of all UCC (HR 1.12; 95%CI: 0.86–1.45, P-trend=0.42) 
or with risk of prognostically high-risk UCC (HR 1.28; 95%CI: 0.85–1.93, 
P-trend=0.27) or prognostically low-risk UCC (HR 0.93; 95%CI: 0.65–1.33, 
P-trend=0.74). No associations were observed between risk of UCC and 
intake of water, coffee, tea and herbal tea and milk and other dairy beverages. 
For prognostically low-risk UCC suggestions of an inverse association with 
alcoholic beverages and of a positive association with soft drinks were seen. 
Increased risks were found for all UCC and prognostically low-risk UCC with 
higher intake of fruit and vegetable juices. In conclusion, total usual fluid intake 
is not associated with UCC risk in EPIC. The relationships observed for some 
fluids may be due to chance, but further investigation of the role of all types of 
fluid is warranted.
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INTRODUCTION 
More than 90% of bladder cancers arise from the urothelium. Urothelial cell 
carcinoma (UCC) is the second most common malignancy of the genitourinary 
tract.1 UCC shows widely different characteristics in histopathology and 
clinical behaviour. It has been proposed that there are two major groups 
of urothelial cell tumours that develop via different molecular pathways. The 
low grade, papillary tumours are characterized by activating mutations in the 
HRAS and FGFR3 oncogenes and chromosome 9 aberrations; the high grade 
solid tumours are characterized by structural and functional defects in the 
TP53 and RB tumour suppressor genes.2
Tobacco smoking3 and occupational exposure to carcinogens like aromatic 
amines and polycyclic aromatic hydrocarbons (PAHs),4 family history5 and 
specific low-penetrance susceptibility, such as NAT2 and GSTM1,6 are the main 
risk factors for UCC. However, the occurrence of UCC is not fully explained 
by these risk factors. With regard to dietary factors, it is postulated that 
the intake of fluid may influence the risk of bladder cancer. Several potential 
mechanisms exist for a role of total fluid intake in the development of bladder 
cancer. The urogenous contact hypothesis suggests that high fluid intake 
may reduce the exposure to carcinogens by diluting the urine and reducing the 
contact time through increased micturition.7 Conversely, a high intake of fluids 
could also increase the risk of UCC if fluids contain contaminants that are 
bladder carcinogens. Bladder wall extension associated with a high intake of 
fluids or a lower miction frequency may allow the carcinogens in the urine to 
come into contact with the deeper layers of the bladder urothelium.8 In 2007, 
an international panel of experts concluded that evidence for an association 
of total fluid intake in relation to bladder cancer risk is limited.9 A recent 
review reported a probable association between total fluid intake and bladder 
cancer; however, studies on total fluid intake showed inconsistent findings.10
The role of fluid volume intake is further complicated because of the possibility 
that specific fluids may have an effect as well. Possible opposing mechanisms 
to explain the role of specific types of beverages in carcinogenesis have been 
postulated. For example, the intake of alcoholic beverages and coffee may 
dilute metabolites in the urine. The diuretic effect of alcohol may increase 
the frequency of voiding and reduce contact of carcinogens with the bladder 
epithelium.11 On the other hand, the intake of alcoholic beverages could be 
harmful because the primary breakdown product of ethanol in the body, 
acetaldehyde, has been shown to cause damage to the DNA, which makes 
alcohol a plausible bladder carcinogen.12 Caffeine, which i s contained in 
coffee, has been suggested to contribute to the increased risk of bladder 
cancer, although IARC concluded that caffeine is not classifiable as to its 
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carcinogenicity to humans.13 Coffee consumption is correlated with smoking 
habits, and the positive findings in some studies might be the result of 
residual confounding by smoking. Conversely, coffee might have a possible 
protective effect by acting as an antimutagenic through formation of complex 
compounds.14 Disinfection byproducts and arsenic in drinking water may 
be potential carcinogens and could increase the risk of bladder cancer.15,16 
Antioxidants in green tea and fruit and vegetable juices have been suggested 
to decrease the risk of bladder cancer.17 Milk and other dairy foods contain 
calcium and bioactive compounds, which may also have a protective role.9 
Dietary factors may differentially affect the risk of low and high grade bladder 
tumours. To our knowledge, only one epidemiological study on suspected 
dietary risk factors did evaluate high and low grade tumours separately. 
Coffee consumption, the only dietary risk factor evaluated thus far, was not 
associated with tumour stage and grade.18
The aim of this study is to examine the association between self-reported total 
and specific fluid intake and the risk of prognostically low- and high-risk UCC 
(defined on stage and grade), within the European Prospective Investigation 
into Cancer and Nutrition (EPIC).
MATERIAL AND METHODS
Study participants
EPIC is a multicentre cohort study designed to examine the association between 
nutrition and cancer. Participants, mostly aged between 25 and 70 years, were 
enrolled in 1992 to 2000 by 23 centres in 10 European countries: Denmark 
(Aarhus and Copenhagen), France, Germany (Heidelberg and Potsdam), Greece, 
Italy (Florence, Varese, Ragusa, Turin, and Naples, The Netherlands (Bilthoven 
and Utrecht), Norway, Spain (Asturias, Granada, Murcia, Navarra, and San 
Sebastian), Sweden (Malmö and Umea) and the United Kingdom (Cambridge 
and Oxford). Eligible subjects were invited to participate in the study, and those 
who accepted gave informed consent and completed questionnaires on their 
diet, lifestyle and medical history. A total of 521,448 subjects participated in the 
study. The methods of recruitment for EPIC and the design of the study have 
been described in detail elsewhere.19 Participants with a history of cancer at 
recruitment (n=23,633) and participants with missing follow-up data (n=3,448) 
were excluded for analysis. 
This study includes participants from the following centres: France, The 
Netherlands (Bilthoven, Utrecht), Germany (Heidelberg, Potsdam), Sweden 
(Malmö) and Denmark (Aarhus, Copenhagen). Data on water intake was not 
collected in the other centres, and participants through these centres were, 
therefore, not included in this study (n=256,140). We further excluded 
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participants with missing dietary questionnaire data (n=233), and participants 
with missing lifestyle questionnaire data (n=37). Data for participants in the top 
and bottom 1% of the ratio of energy intake to estimated energy requirement 
calculated from age, sex and body weight were also excluded to reduce the 
effect of implausible extreme values (n=4,721). After these exclusions, the 
study cohort comprised 67,914 men and 165,322 women.
Diet and lifestyle questionnaires
Usual dietary intake during the year before recruitment was measured by 
country-specific validated dietary questionnaires designed to reflect local 
dietary patterns and high compliance rates of completion. The habitual dietary 
assessment methods were all based on general methodology of food frequency 
questionnaires. In The Netherlands and Germany self-administered dietary 
questionnaires, containing up to 260 food items, estimating individual average 
portion size were used. In France, interviewer-administered questionnaires 
similar to the dietary questionnaires, but structured by meals, were used. 
Semiquantitative food frequency questionnaires with the same standard 
portion assigned to all participants were used in Denmark. In Malmö (Sweden), 
a nonquantitative food frequency questionnaire was combined with a 14-day 
record on hot meals.19 Information on validity of the food questionnaires has 
been published previously.20
Habitual total fluid intake was calculated by adding the intake of different 
beverages. Intake of total fluid includes alcoholic beverages, milk and other 
dairy beverages, coffee, tea, herbal tea, water (excluding water as ingredient of 
meals), fruit and vegetable juices and soft drinks. All fluid items were assessed in 
the five participating countries; however, data on the intake of dairy beverages 
(except milk) was not available in Sweden (Malmö), and data on the intake of 
herbal teas was not assessed in Denmark. Chicory/coffee substitute and bouillon 
were not included in the total fluid intake variable because these variables were 
only assessed in two countries and contribute little to total fluid intake. Several 
centres validated the food frequency questionnaire for specific beverages 
against 12-times repeated 24-hour dietary recalls. The correlation coefficients 
for the relative validity of reported consumption of alcoholic beverages varied 
from 0.74 to 0.94.21,22 The German food frequency questionnaire validated 
also coffee and tea (correlation coefficient is 0.70) and soft drinks (correlation 
coefficient is 0.67).22 The Dutch food frequency questionnaire was validated 
for non-alcoholic beverages; the correlation coefficient was 0.74.21 So, the 
questionnaires seem adequate for ranking individuals according to intake of 
several beverages. 
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Baseline information on other lifestyle variables was obtained from standardized 
questionnaires including questions on education, occupation, medical history, 
physical activity and smoking. Data on occupational history was only available 
for a subset of the cohort [not in Utrecht (The Netherlands) and France]. 
Occupational history focused on 52 selected jobs that have been previously 
linked to the risk of developing cancer. This data is used to examine the effect 
of occupational exposure on the Cox regression models. We focused on the 
following carcinogenic exposures: heavy metals (present in foundries, in metal 
industries and in occupations related to welding, turning and electroplating); 
aromatic amines (present in, e.g., dye production, textile and leather dying and 
hairdressers); PAHs (associated with refineries, asphalt work, the transport 
sector and car repair stations); environmental tobacco smoking (particularly 
elevated for workers in bars and restaurants). The scores were treated as 
dichotomous variables (yes/no).
Endpoints
The follow-up was based on population-based cancer registries [The 
Netherlands, Sweden (Malmö) and Denmark] or on a combination of methods 
including health insurance records, cancer and pathology registries and active 
follow-up through study participants and their next-of-kin (Germany and 
France). For centres covered by cancer registries follow- up ended at: December 
2003 (Bilthoven and Denmark); December 2004 (Utrecht and Malmö); June 
2005 (France). For Germany, the end of follow-up was considered to be the last 
known contact date, the date of diagnosis or the date of death, whichever came 
first. Mortality data were also collected through cancer registries at the regional 
or national level.
For the current analysis, participants were followed up from study entry until 
a diagnosis of first primary UCC [code C67 according to the ICD-Oncology 
(ICD-0-third edition)], death, emigration or end of the follow-up period. Only 
the urothelial cell papillomas and carcinomas (morphology codes 812–813), 
further referred to as UCC, were included in the analysis. Bladder cancer with 
morphology codes 8980 (carcinosarcoma), 9590 (malignant lymphoma), 9671 
(malignant lymphoma, lymphoplasmacytic) and 8121 (inverted papillomas) 
and with behaviour coded as benign (5th digit of the morphology code is 
zero) were censored at time of diagnosis. Pathology reports of the UCC cases 
were collected from each centre. Information on morphology, TNM stage and 
differentiation grade of UCC was extracted from the reports. We stratified UCC 
into two prognostic risk groups; high-risk UCC was defined as: all T1 and higher, 
all CIS and all WHO Grade 3 (poorly differentiated) carcinomas and low-risk 
tumours were defined as: all Ta Grade 1 (well differentiated) and Ta Grade 2 
(moderately differentiated) carcinomas; 93% of the cases could be classified 
into prognostically high- or low-risk UCC.
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Statistical methods
Cox proportional hazard models were used to analyse the association between 
total and specific fluid intake and UCC. Analyses were also performed using 
low-risk and high-risk urothelial bladder cancer as separate endpoints. Age was 
used as the primary time variable in the models. Time at entry was defined 
as age at recruitment and exit time as age at diagnosis, age at death or age 
at the end of the follow-up, whichever came first. All analyses were stratified 
by age at recruitment (in 1-year categories) to control for length of follow-up 
and by gender and centre to control for country effects, such as follow-up 
procedures and questionnaire design. Cases diagnosed after censoring date 
were considered as noncases.
Total fluid intake and the specific fluid variables (alcoholic beverages, milk and 
other dairy beverages, coffee, tea, herbal tea, water, fruit and vegetable juices 
and soft drinks) estimated from the dietary questionnaire were calculated in 
millilitre per day. Values within the extreme 0.5 percentiles of total fluid intake 
were considered unreliable and were replaced by the cutpoint (below the 0.5 
percentile and above the 99.5 percentile). We did not perform this procedure 
for values below the 0.5 percentile and above the 99.5 percentile of subgroups 
of fluid intake, i.e., low extreme values are possible if participants did not 
consume or consume a specific beverage in a very low amount. High extreme 
values were also possible if participants did not drink a variety of beverages. The 
data were analysed using categorical variables, by sex-specific tertiles, and as 
continuous variables (increment of 100 mL/d). To calculate the p value for trend 
across tertiles, the median of each tertile was assigned to participants, and this 
variable was entered as a continuous term in the Cox regression models.
All analyses were controlled for smoking status (current, former and never), 
duration of smoking (in years), lifetime intensity of smoking (cigarettes/d) and 
energy intake from fat and nonfat sources. Consumption of fruits and vegetables 
(excluding juices), processed meat, alcohol, physical activity and BMI were not 
included in the analysis as these did not change the α estimate of the fluid 
variables by more than 10%. Analyses were stratified by smoking status and 
gender. Models stratified for smoking status were adjusted for duration and 
lifetime intensity of smoking (only for former and current smokers). Statistical 
interaction on a multiplicative scale was tested by introducing a product term 
between total fluids (continuous) and smoking status, gender and country.
Linear regression calibration was used to improve comparability of dietary 
data across the participating centres and to correct for systematic over- and 
underestimation of dietary intake.23 The 24-h diet recall measurements were 
regressed on dietary questionnaire values for total fluid intake and subgroups of 
fluid intake. Zero consumption values in the main dietary questionnaires were 
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included in the regression calibration models. Data were weighted by day of the 
week and season of the year on which the 24-h diary was collected. Country 
and sex-specific calibration models were used to obtain individual calibrated 
values of dietary exposure for all participants. Cox regression models were then 
applied using the calibrated values for each individual on a continuous scale. The 
standard error of the de-attenuated coefficient was calculated with bootstrap 
sampling (n=10 repetitions) in the calibration and disease models consecutively. 
Categorical models were based on observed values while continuous models 
were based on observed and calibrated values. All analyses were conducted 
using SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
A total of 233,236 participants contributed 2.10 million person-years at risk 
with a mean follow-up of 9.3 years. Table 1 shows the frequency of UCC and 
the corresponding number of person-years included in the analysis according 
to country and gender. During follow-up, 513 participants were diagnosed with 
a first primary UCC. Of these cancers, 32 UCC cases could not be classified as 
prognostically high- or low-risk UCC because information on stage and grade 
was lacking; 210 UCC cases were classified as high-risk tumours and 271 cases 
as low-risk tumours. 
Calibrated median values of total fluid intake and sub- groups of fluid intake 
by gender and country are shown in Table 2. In men, the median calibrated 
intake of total fluid is 2,230 mL/d. In women, the median calibrated total fluid 
intake is 1,751 mL/d. The average of the individual percentages for water intake 
and for coffee consumption contributing to total fluid intake is 33% and 24%, 
respectively. For the other types of fluids, averages of the individual percentages 
contributing to total fluid intake are 16% (tea and herbal tea), 10% (alcoholic 
beverages), 9% (milk and other dairy beverages), 4% (fruit and vegetable juices) 
and 4% (soft drinks). Baseline characteristics by tertiles of total fluid intake 
and gender are shown in Table 3. Both men and women with higher reported 
total fluid intake were somewhat heavier in weight and longer in stature, were 
more likely to smoke, were more physically active and reported higher intakes 
of energy, fruit and vegetables and red meat. Participants with higher reported 
consumption of total fluids reported higher consumption of the different types 
of fluids with the exception of the consumption of tea and fruit and vegetables 
juices that declined with higher intake of total fluids (only in men). 
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The risks of UCC by sex-specific tertiles of total fluid intake by smoking status 
are presented in Table 4. There was no evidence of an association between total 
fluid intake and risk of all UCC: the multivariable-adjusted hazard ratio (HR) for 
the highest versus lowest tertile is 1.12 [95% confidence interval (CI) 0.86–
1.45]. We did find a weakly increased risk with increments of 100 mL/d of total 
fluid intake (observed HR 1.01; 95%CI: 1.00–1.02, calibrated HR 1.02; 95%CI: 
0.99–1.04), which was slightly stronger in men than in women. But, there was 
no statistically significant difference in risks between men and women (P-value 
interaction >0.05). No significant association was found between total fluid 
intake and prognostically high-risk UCC (HR for the highest versus lowest tertile 
is 1.28; 95%CI: 0.85–1.93) or for prognostically low-risk UCC (HR for the highest 
versus lowest tertile is 0.93; 95%CI: 0.65–1.33; Table 4). We found no effect of 
an increment of total fluid intake with 100 mL/d on either prognostically low- 
or high-risk UCC. Total fluid intake was not associated with risk of UCC in the 
different subgroups of smoking status with variables modelled as categorical 
or continuous. Consequently, the interaction of smoking status and total fluid 
intake was not statistically significant (P for interaction=0.34) (Table 4). There 
was no heterogeneity of between geographic regions on the effect of total 
fluid intake on risk of overall and prognostically high- and low-risk UCC (P for 
heterogeneity >0.05) (data not shown). 
To evaluate whether preclinical disease may have influenced results, we 
conducted additional analyses after exclusion of cases that were diagnosed 
within 2 years after recruitment. Exclusion of the first 2 years of follow-up 
did not change the results (data not shown). To explore possible confounding 
by exposure to occupational carcinogens, analyses were further adjusted for 
occupational history in a subset of the cohort [Denmark, Germany, Bilthoven 
(The Netherlands) and Malmö (Sweden)]. Associations between fluid intake and 
UCC remained similar when exposure to occupational carcinogens was added 
to the model (data not shown). In the analysis of specific types of beverages, 
no association was found between intake of water, coffee, tea and herbal tea, 
and milk and other dairy beverages and risk of UCC with variables modelled 
as categorical or continuous (Table 5). The intake of alcoholic beverages was 
inversely associated with prognostically low-risk UCC (HR 0.71; 95%CI: 
0.51–0.98 comparing the highest tertile with the lowest; P-trend=0.02); this 
association was not confirmed in the analysis of the continuous intake variable. 
When stratified by smoking status, we found an inverse association between 
alcoholic beverages and prognostically low-risk UCC for current smokers 
only (observed HR for 100 mL/d increase in intake 0.95; 95%CI: 0.91–1.00). 
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However, this association attenuated when calibrated data were used (calibrated 
HR for 100 mL/d increase in intake 0.95; 95%CI 0.90–1.01). The interaction of 
smoking status and alcoholic beverages was not statistically significant (P for 
interaction=0.52; data not shown). 
The intake of fruit and vegetable juices was positively associated with all UCC 
and prognostically low-risk UCC (HR for high versus low tertile of intake 1.32; 
95%CI: 1.05– 1.66; P=0.02, and 1.53; 95%CI: 1.12–2.09; P=0.01, respectively). 
This association was also observed in the analysis based on the continuous 
intake variable [observed HR for 100 mL/d increase in intake 1.10 (95%CI: 
1.04–1.17), for all UCC and 1.12 (95%CI: 1.05–1.20) for prognostically low-risk 
UCC]. Risk estimates remained statistically significant using calibrated instead 
of observed consumption data. When stratified by smoking status, we found an 
association between fruit and vegetable juices and all UCC and prognostically 
low-risk UCC for current smokers only (observed HR for 100 mL/d increase 
in intake 1.09; 95%CI: 1.01–1.19 and 1.10; 95%CI: 1.00–1.21, respectively). 
This association attenuated when calibrated data were used. The interaction of 
smoking status and fruit and vegetable juices was not statistically significant (P 
for interaction=0.61) (data not shown). Exclusion of the first 2 years of follow-
up did not change the results (data not shown). 
A weak association was found between soft drinks as a continuous variable 
and all UCC (observed HR 1.04; 95%CI: 1.00–1.08, calibrated HR 1.06; 95%CI: 
1.01–1.12) and prognostically low-risk UCC (observed HR 1.07; 95%CI: 1.02–
1.11, calibrated HR 1.09; 95%CI: 1.02–1.16), but this association was not 
confirmed in the analysis of the categorical intake variable. No differences were 
found when stratified by smoking status (P for interaction for both all UCC and 
prognostically low-risk UCC is >0.05).
DISCUSSION
In this cohort study, there was no evidence of an association between total 
fluid intake and risk of UCC. Associations were not different when stratified by 
gender and smoking status. Results suggesting positive and inverse associations 
with intake of specific beverages should be interpreted with caution because 
they may have resulted from residual confounding and chance.
Our null finding for total fluid intake is in line with two other prospective 
cohort studies: The Netherlands Cohort Study24 and the Adventist Health 
Study25 did not find an association between fluid intake and bladder cancer 
risk. One cohort study, the Health Professionals Follow-Up Study, found a 
protective effect of higher fluid intake in men.26 This cohort has similar study 
design characteristics, and an explanation for the contrasting outcome with our 
findings is not clear. Four case-control studies reported no association,27,28–30 
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whereas other case-control studies did find a positive8,31–36 or an inverse 
association.37,38 Inconsistencies between studies that examined the association 
between total fluid intake and bladder cancer risk may arise from the fact that 
most studies included relatively few participants and, thereby, lacked power 
to detect significant observations. Also, information bias in these studies is a 
plausible explanation of the results of previous studies. The type of beverages 
that contribute to total fluid intake varied between studies, and differences in 
exposure assessment could also have led to inconsistent results. Most of the 
beverages are water based, and water can contain a great number of chemicals. 
A recent pooled analysis based on six case-control studies found a positive 
association between tap water and bladder cancer, but no effect was seen for 
fluid intake other than tap water.39 These findings suggest that contaminants in 
tap water such as disinfection byproducts may be responsible for the excess risk 
and could explain the apparently inconsistent results in epidemiological studies. 
We were not able to examine the effect of water source on UCC risk because 
information about the source of water is not available in our study. In addition, 
in the countries included in this study, there may be very little variability in the 
source of water. 
Some authors argued against using total fluid intake and suggest that the daily 
number of urinary voids is etiologically relevant, because frequency of voiding 
is directly related to the intensity and duration of urothelium flattening.40 The 
few studies7,41,42 that examined the effect of increased urination frequency on 
bladder cancer risk found conflicting results. Because volume of fluid intake is 
strongly correlated with urine volume,43 we believe that fluid intake and urine 
volume may be used interchangeably.
Our study suggested an inverse association between low-risk UCC and 
alcoholic beverages as a categorical variable only. This finding should be 
interpreted with caution because no effect was seen in the analysis of 
the continuous intake variable. The association between alcoholic beverages 
and prognostically low-risk UCC was attenuated when the intake of alcoholic 
beverages modelled as categorical variable were further adjusted for consumers 
(yes or no) and other specific beverages. The effect of alcoholic beverages 
became nonsignificant when the association is examined in the whole EPIC 
cohort (HR for low-risk UCC high versus low tertile of intake 0.89; 95%CI: 
0.69–1.15). A recent review by Pelucchi and La Vecchia11 concludes that there 
is no association between alcohol intake and bladder cancer risk, although 
findings were not always consistent and low- and high-risk bladder cancers 
were not distinguished.
We observed a positive association between the intake of fruit and vegetable 
juices and the risk of UCC. This association remains statistically significant 
for both all UCC and prognostically low-risk UCC when fruit and vegetable 
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juices were analysed in the whole EPIC cohort (HR continuous 1.09; 95%CI: 
1.03–1.15 and HR continuous 1.11; 95%CI: 1.04–1.19, respectively). However, 
we found no significant association between fruit and vegetable juices and 
all UCC (HR for the highest versus lowest tertile is 1.10; 95%CI: 0.94–1.30) 
or for prognostically low-risk UCC (HR for the highest versus lowest tertile is 
1.21; 95%CI 0.94–1.54) in the whole EPIC cohort. Only few studies26,29,38 
have examined the relation between juices and bladder cancer risk. One 
cohort study26 and one case-control study29 reported an increased risk for 
juices, whereas another case-control study38 found an inverse association 
between fruit drinks and bladder cancer risk. However, the associations were 
not statistically significant. The increased UCC risk in our study among those 
consuming fruit and vegetable juices could be explained by a low urine pH due 
to vitamin C in fruit and vegetable juices. Rothman et al.44 found that low urine 
pH was associated with higher DNA adduct levels in exfoliated urothelial cells. 
However, a case-control study did not find an association between urine pH and 
UCCs45. Furthermore, added anti- oxidants may explain our results, because 
in vitro some antioxidants may prevent the natural process of cell death.46 
In the Danish EPIC cohort, Roswall et al.47 found an increased, although not 
significant, risk between dietary vitamin C and urothelial carcinomas. In our 
study, however, the association did not change when the models for fruit 
and vegetables juices were further adjusted for dietary intake of vitamin C. The 
association between fruit and vegetable juices and the risk of UCC differed 
according to smoking status: an increased risk for current smokers only. In vitro 
studies showed that antioxidants, such as α-carotene, may also serve as a pro-
oxidant, depending on the amount of α-carotene and on the redox potential 
of the biologic environment in which it acts.48 α-Carotene may enhance DNA 
oxidative damage and modify p53-related pathways of cell proliferation and 
apoptosis in cultured cells when these cells are exposed to tobacco smoke 
condensate.49 However, confirmation in other studies is warranted.
We also found a weakly increased risk for soft drinks and all UCC and low-risk 
UCC. When the effect of soft drinks is examined in the whole EPIC cohort, 
the association remains statistically significant (HR continuous 1.03; 95%CI: 
1.00–1.07 for all UCC and HR 1.06; 95%CI: 1.02–1.11 for low-risk UCC). 
Of five case control studies28,29,34,35,38 examining the association between 
soft drinks and bladder cancer, four28,34,35,38 observed a slightly increased risk 
in the highest level of intake; however, these results were not statistically 
significant. A cohort study that examined the risk of soft drinks and bladder 
cancer found no association.26 Because of the possible carcinogenic effect of 
artificial sweeteners on bladder cancer that have been reported from animal 
studies in rats, artificial sweeteners in juices and soft drinks might increase 
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the risk of bladder cancer. However, a meta-analysis50 of case control studies 
found no evidence of an association between saccharin and bladder cancer, 
and it is, therefore, unlikely that the increased risk is attributable to artificially 
sweeteners in soft drinks or juices. For drinking of water, coffee, tea and herbal 
tea and milk and other dairy beverages, we did not see associations with UCC 
risk. Results from other studies that have evaluated the relation between 
specific types of beverages and UCC are inconsistent. Although our results 
on alcohol, juices and soft drinks are in line with the few other observational 
studies, residual confounding cannot be excluded. Moreover, we con- ducted 
multiple comparisons and chance findings can thus not be excluded.
There are limitations in this study. Fluid intake may have changed during follow-
up and resulted in exposure misclassification, but we do not expect that middle-
aged participants, the majority of the EPIC study participants, changed their 
fluid consumption over the years. We excluded centres that did not assess 
drinking water intake, because water intake is an important component of total 
fluid intake. In our study, a third of the total fluid intake was water. Also, the 
quantity of reported drinking water intake in the study population was very 
similar to the volume of drinking water intake that was measured in other 
studies.30,37 Although we did not include all centres in this study, we still 
had a relatively large sample size, and our study is one of the largest cohorts 
investigating the association between total fluid intake and bladder cancer 
risk thus far. Despite the large cohort size, there is limited power for testing 
heterogeneity over smoking status because the number of cases is small 
when stratified by smoking status. Other strengths of EPIC relate to the 
cohort design that mainly precludes recall bias, the availability of an extensive 
set of potential confounders and the possibility to distinguish low- from high-
risk urothelial bladder cancers.
In conclusion, results from our study do not support that total fluid intake 
is associated with UCC risk or with prognostically low- and high-risk UCC. 
Observed associations between alcoholic beverages, fruit and vegetables juices 
and soft drinks and the development of bladder cancer may be due to chance 
and merit further prospective investigations.
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ABSTRACT
Background 
Several studies have suggested an increased risk of bladder cancer among 
hairdressers, who are occupationally exposed to hair dyes. There has also been 
concern about a possible increased risk of bladder cancer among users of hair 
dyes. However, the association between personal hair dye use and bladder 
cancer risk remains inconclusive. 
Objective 
In this study, we examined associations between personal use of permanent 
and temporary hair dyes and bladder cancer risk in a population-based case–
control study involving 1,385 cases (n=246 women) and 4,754 controls (n=2,587 
women). 
Methods 
Participants filled out a questionnaire with regard to history of personal hair dye 
use and risk factors for bladder cancer. Unconditional logistic regression was 
used to calculate odds ratios (OR) and 95% confidence intervals (CI), adjusted 
for age, smoking status, duration of smoking and intensity of smoking. 
Results 
Analyses were restricted to women as less than 5% of all men in the study ever 
used hair dyes. About 50% of the women ever used hair dyes. Use of tempo-
rary hair dyes (OR 0.77; 95%CI: 0.58–1.02) or use of permanent hair dyes (OR 
0.87; 95%CI: 0.65–1.18) was not associated with bladder cancer risk. No clear 
association between hair dyes and bladder cancer risk was found when dye use 
was defined by type, duration or frequency of use, dye colour, or extent of use. 
Also, results were similar for aggressive and non-aggressive bladder cancer. Age, 
educational level, and smoking status did not modify the association between 
hair dye use and bladder cancer risk. 
Conclusions 
The present study does not support an association between personal hair 
dye use and bladder cancer risk. Also, various types of hair dye, intensity of 
exposure to hair dyes or dye colour do not appear to be important factors for 
bladder cancer development. 
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INTRODUCTION 
Occupational exposure to hair dyes has been associated with an increased risk 
of bladder cancer.1,2 The International Agency for Research on Cancer (IARC) 
concludes that hairdressers and barbers are ‘‘probably’’ at greater risk of bladder 
cancer because of their exposure to hair dyes.3 This has raised concerns that 
personal use of hair dyes may also increase the risk of bladder cancer.4 Personal 
hair dyes are widely used. It has been estimated that over one-third of women 
above the age of 18 and over 10% of men above the age of 40 in Europe and 
North America use some type of hair dye.5 
Small amounts of 4-aminobiphenyl (4-ABP), a recognized urinary bladder 
carcinogen which is banned since the mid-1950s from the US market and since 
1998 from the European market6, were identified in commercial hair dyes yet. 
The amount of 4-ABP found in hair dyes varies, and frequent use of hair dyes may 
result in considerable exposure to 4-ABP over time.7 These and other aromatic 
amines and related nitro-compounds in hair dyes are known to be mutagenic in 
vitro3,8 and carcinogenic in animal models.9 Small amounts of these substances 
are absorbed through the skin during normal use.10 Oxidation of aromatic amines 
to N-hydroxyarylamine is thought to be required for carcinogenic potency.11, 12 
Hair dyes comprise a complex group where oxidative (permanent) dyes differ 
in composition compared to non-oxidative (semi-permanent and temporary) 
dyes, although carcinogenic agents have been found in each type of hair dye. 
Permanent dyes consist of primary intermediates (e.g., p-phenylenediamines, 
p-aminophenols) and couplers (e.g., m-aminophenols, m-hydroxyphenols) that, 
in the presence of peroxide, form the dye by a chemical reaction. Non-oxidative 
hair dyes include colored compounds that stain hair directly. Semi-permanent 
hair dyes resist several shampooings, while temporary dyes wash out after one 
shampooing.4, 13 
The possible association between personal hair dye use and bladder cancer 
risk has been examined in several epidemiological studies.14–24 Overall, these 
studies did not show an association with bladder cancer risk. However, most 
studies on bladder cancer risk associated with personal hair dye use suffer from 
methodological difficulties. Several studies did not collect information on type 
and colour of hair dyes. This may have led to attenuation of the risk estimate 
because permanent dyes (particularly dark dyes) are considered to pose a 
greater risk than other types of hair colouring products. Small sample sizes 
in most studies limited the statistical power to detect an effect if one exists. 
In addition, some studies14, 15, 18 examined only death rates of bladder cancer 
instead of incidence rates, which is inappropriate since most bladder cancers 
(approximately 75%) involve only the superficial layers of the bladder and can 
be cured either with chemotherapy or surgical removal of the bladder. 
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Despite the majority of studies reporting null associations, personal hair dye 
use has led to discussions about its impact on human health. A case–control 
study from California found an increased risk of bladder cancer in long-term (15 
years and more) users of permanent hair dyes among women22, which was more 
pronounced among exclusive users and women with the N-acetyltransferase-2 
(NAT2) slow acetylator phenotype. Also, a recent study from New England 
found that women who used permanent dyes and had a college degree had an 
increased risk of bladder cancer and that the risk was more pronounced among 
exclusive users of permanent hair dyes who also had the NAT2 slow acetylation 
phenotype.24 
Because of the widespread use of hair dyes, a small increase in risk of bladder 
cancer may have a large public health impact. The aim of the present study was 
to investigate associations between personal use of permanent and temporary 
hair dyes and bladder cancer risk in a case–control study from the Netherlands. 
METHODS 
Study population 
Patients diagnosed with bladder cancer between 1975 and 2009 under the age 
of 75 years registered by the population-based cancer registry in the eastern 
part of the Netherlands were invited to participate in a study on genes and 
environment as potential risk factors for bladder cancer (The Nijmegen Bladder 
Cancer Study, NBCS). Patients were requested to fill out a detailed questionnaire 
on lifestyle and medical factors and to donate a blood sample for DNA isolation. 
The response rate for cases was 62%. All cases were histologically confirmed. 
For the current analysis, only cases with urothelial cell carcinoma (morphology 
ICD-O-3 codes 8120 and 8130) were included (n=1,501). Data on tumour stage 
and grade were obtained through the cancer registry. According to Kiemeney et 
al.25, we classified urothelial cell carcinomas with regard to risk of progression 
into aggressive and non-aggressive tumours. Patients with high-risk of 
progression (aggressive UCC) were defined as TNM stage Tis or T1 and higher 
or WHO 1973 differentiation grade 3 or WHO/ISUP 2004 high grade. Patients 
with low-risk of progression (non-aggressive UCC) were defined as having TNM 
stage Ta in combination with WHO 1973 differentiation grade 1 or 2 or WHO/
ISUP 2004 low grade. 
Controls were recruited for the Nijmegen Biomedical Study (NBS), a population-
based survey conducted in 2002 by the Department of Epidemiology and 
Biostatistics in collaboration with the Department of Clinical Chemistry of the 
Radboud University Medical Centre. 21,756 age-and sex-stratified randomly 
selected inhabitants of the munici pality of Nijmegen, The Netherlands, 
received an invitation to fill out a postal questionnaire on, for example, lifestyle 
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and medical history, and to donate two tubes of blood. The response to the 
questionnaire was 43% (n=9,350). The NBS participants who gave consent 
for further research and were still alive in 2008 were contacted again with 
an invitation to fill out an additional detailed lifestyle questionnaire that also 
contained questions on personal hair dye use. In total, 5,613 (60%) participants 
completed this questionnaire. Control participants who had a prior history of 
cancer (except non-melanoma skin cancer) at the time of recruitment were 
excluded (n=303). A detailed description of the design and study population 
has been reported previously.26, 27 The study protocols of the NBCS study and 
the NBS were approved by the Institutional Review Board of the Radboud 
University Medical Centre, and all participants gave written informed consent. 
Assessment of personal hair dye use 
Participants were asked about ever use of temporary and permanent hair dyes 
separately. In addition, information on duration of use (years), frequency of use 
(times per year), extent of use (part or entire scalp), and colour of the most 
frequently used dye was collected for each type of hair dye product used. 
Specific colours were classified as brown, black, blond, red, and other colours. 
Permanent hair dye was defined as a hair colour that does not wash out (but 
grows out) and temporary dye as a hair colour that washes out over time. 
Participants with missing data on hair dye use (20 cases and 97 controls) and 
smoking variables were excluded (96 cases and 459 controls). 
Statistical analysis 
Unconditional logistic regression models were used to estimate odds ratios 
(OR) and 95% confidence intervals (95% CI) for the association between 
type of personal hair dye use (temporary or permanent dyes, both temporary 
and permanent dyes, exclusive temporary or exclusive permanent dyes) and 
bladder cancer. All analyses were adjusted for age at time of completing the 
questionnaire (continuous), smoking status (never, ever), duration of smoking (in 
years), and intensity of smoking (cigarettes/day). Participants who never smoked 
during their life were defined as never smokers. If participants quitted smoking 
cigarettes, cigars, or pipe before completing the questionnaire, we defined 
them as former smokers. Current smokers were defined as participants who 
smoked cigarettes, cigars, or pipe at the time of completing the questionnaire. 
It is likely that some former smokers returned to smoking and that some current 
smokers stopped smoking just after being diagnosed with bladder cancer. 
Since the smoking status could have changed, we classified participants into 
never and ever (former and current) smokers. Because additional adjustment 
for height, weight, occurrence of bladder cancer in first-degree relatives and 
educational level (primary school, secondary school, technical, and professional 
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school, and university degree) did not change the α estimate by more than 10%, 
these factors were not included in the final analyses. Risks of bladder cancer 
were also evaluated by duration (≤10 or >10 years), frequency (≤5 times or 
>5 times a year, and ≤40 times or >40 times during lifetime), colour (brown, 
black, blond, red, and other colours), and extent of use (part or entire scalp). 
Separate analyses were performed for non-aggressive and aggressive urothelial 
bladder cancer. Additional stratified analyses were performed on age (≤65 
and >65 years of age), educational level (as a proxy for quality of answers to 
the questions), and smoking status (never, ever). In order to increase power, 
we classified educational level into no college degree (primary and secondary 
school) and at least a college degree (technical and professional school, and 
university degree). Statistical interaction on a multiplicative scale was tested 
by introducing a product term between hair dye use and age, educational level, 
or smoking status. The reference group for analyses of temporary hair dyes 
consisted of subjects who had never used temporary hair dyes. The reference 
group for analyses of permanent hair dyes consisted of subjects who had never 
used permanent hair dyes. An additional analysis was conducted to evaluate 
whether the use of another reference category (never used any type of hair 
dye) would yield different results. In the current study, hair dye use appeared 
to be rare among men: less than 5% of both male cases and controls had ever 
used hair dyes. Therefore, analyses were restricted to women. The study sample 
size of 246 female cases and 2,587 controls was estimated to provide 80% 
power at the significance level of 5% to detect odds ratios of <0.68 or >1.25 
in the category of hair dye users as compared to never users. Naturally, for the 
subgroup analyses, the power to detect associations was smaller. All statistical 
analyses were performed in SAS (SAS system for Windows, version 9.2, SAS 
institute, Cary, NC). 
RESULTS
The present study included 1,385 bladder cancer cases (1,139 men and 246 
women) and 4,754 controls (2,167 men and 2,587 women). On average, cases 
were much older, more likely to report bladder cancer in the first- degree family, 
had a lower level of education and were more likely to be former or current 
smokers than the controls. Among former and current smokers, cases had 
smoked for a longer period and smoked more cigarettes per day than controls. 
Temporary and permanent hair dyes were used more frequently by controls 
than by cases (Table 1). Female users of hair dyes were somewhat younger, 
reported more frequently a higher educational level and the percentage of users 
that reported to be former or current smoker was slightly higher compared to 
non- users (Table 2).
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The risks of bladder cancer by personal hair dye use in women are presented 
in Tables 3 and 4. Compared to women who never used temporary hair dyes, 
the OR for temporary hair dye use was 0.77 (95%CI: 0.58–1.02) (Table 3). 
Use of permanent dyes was not associated with bladder cancer risk either (OR 
0.87; 95%CI: 0.65–1.18) (Table 3). Among women using both types of personal 
hair dye (permanent and temporary), the OR was 0.72 (95%CI: 0.27–1.26) 
compared to women who never used any type of hair dye (Table 4). Compared 
to women who never used any type of hair dye, the ORs for exclusive use 
of temporary hair dyes or permanent hair dyes were 0.71 (95%CI: 0.47–1.09) 
and 0.84 (95%CI: 0.57–1.26), respectively (Table 4). No clear association was 
found between hair dyes and bladder cancer risk when dye use was defined 
by duration of use, frequency of use (number of times a year or times during 
lifetime), dye colour, or extent of use (entire hair or only part of hair). We found 
no differences in risks of aggressive and non-aggressive bladder cancer (Tables 
3 and 4). When analyses were stratified by age, educational level, or smoking 
status, risk estimates were not different over the strata (Table 5).
Personal hair dye use and the risk of bladder cancer
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DISCUSSION 
In this case–control study, personal hair dye use was not associated with bladder 
cancer risk. This finding did not clearly differ by type of hair dye, duration, or 
frequency of use, dye colour, or extent of use. 
Our findings are consistent with most previous epidemiological studies14–24 that 
have generally reported no association between hair dye use and bladder cancer 
risk. Similarly, a few meta-analyses have been conducted.28–30 The interpretation 
of findings from the meta analysis by Hunchareck and Kupelnick30 differs from 
that of Takkouche et al.29 Although both papers evaluated nearly the same set 
of studies, Hunchareck and Kupelnick30 suggest an increased bladder cancer 
risk exists, while Takkouche et al.29 concludes that there is no association. In 
the meta-analysis by Hunchareck and Kupelnick sensitivity analyses to examine 
the influence of hair dye types, colour, and study design found the risk of 
developing bladder cancer increased by 22–50% among those using permanent 
hair dye products versus those who do not. The most recent meta-analysis by 
Kelsh et al.28 reported associations in individual studies ranging from 0.8 to 1.5, 
with a meta-relative risk of 1.01 (95%CI: 0.89–1.14). Thus, the overall results 
are not yet converging. 
In contrast with nearly all other studies, the study of Gago-Dominguez et al.22 
suggested an increased bladder cancer risk of permanent hair dye use (OR 1.5; 
95%CI: 0.97–2.3), which was more pronounced among females having used 
hair dyes more than 12 times per year for more than 15 years (OR 3.3; 95%CI: 
1.3–8.4). Although no overall association between hair dyes and bladder 
cancer was found in a recently published study from New England, increased 
risks were observed in certain subgroups.24 The New England study found that 
women who used permanent dyes and had at least a college degree had an 
increased risk of bladder cancer (OR 3.3; 95%CI: 1.2–8.9). Our study, however, 
showed no evidence that the lack of association between hair dyes and bladder 
cancer risk was modified by educational level. On the other hand, our risk 
estimates are not robust because of the small number of female cases exposed 
to hair dyes in some subgroups, resulting in limited statistical power. Also, the 
New England study found, similar to the California study31, that the risk was 
more pronounced among exclusive users of permanent hair dyes who had the 
NAT2 slow acetylation phenotype (OR 7.3; 95%CI: 1.6–32.6). By contrast, a 
previous study from Spain, the Spanish Bladder Cancer Study, failed to confirm 
an increased risk of bladder cancer in a population of personal hair dye users 
and found no increased risk in NAT2 slow acetylators.16 As data on specific 
genetic polymorphisms involved in the metabolism of aromatic amines was not 
available in the current study, we were not able to examine the influence of 
genetic susceptibility on the risk of bladder cancer associated with hair dye use. 
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In the present study, we found no gradient in risk with longer duration of 
hair dye use (i.e., more than 10 years). A consideration with respect to the 
interpretation of the pre vious studies is that the numerous chemicals used 
in hair dyes have varied over time. After the 1980s, several aro matic amines 
(e.g., 2,4-diaminotoluene, 2,4-diaminoanisole and 4-ABP) were banned as hair 
dye ingredients after they were found to be carcinogenic in rodents.32 It is 
therefore important to examine the time period of dye use because hair dye 
formulations that occurred around 1980s may be more carcinogenic than newer 
dyes formulated in response to concern about potential cancer risk. Although 
we collected detailed information on duration of hair dye use, we have no 
information about year at first dye use. On the other hand, the presence of 
the most common permanent hair dye ingredient, p-phenylenediamine has 
remained unchanged for the last 50 years even though animal data support its 
carcinogenicity.33 Also, a few new ingredients were introduced during the last 20 
years.3 Bladder cancer has very long latency times, so that effects of historical 
exposure to aromatic amines in hair dyes may still be observed decades later. 
This study may suffer from several limitations inherent to case–control study 
designs. Information on hair dye use was assessed after the diagnosis of bladder 
cancer and is therefore sensitive to recall bias. Due to the media attention for 
this topic, it is possible that cases reported personal hair dye use differently from 
controls, although it is more likely that this would have resulted in inflated odds 
ratios. Another limitation of the study is the relatively low response rate among 
controls, possibly leading to selection bias. A short telephone questionnaire was 
completed by 100 non-respondent controls to evaluate whether they differed 
from the participating controls. Compared to non-respondents, respondents 
were somewhat more highly educated and were more likely to have a paid job 
(data not shown). Because users of hair dyes among the controls are somewhat 
higher educated (Table 2), it is possible that we overestimated hair dye use in 
the general female population that may explain part or all of the observed odds 
ratios. On the other hand, additional adjustment for educational level did not 
change the results. 
One of the strengths of this study is the information collected about various 
types of hair dyes (i.e., permanent and temporary dyes). Hair dyes differ in 
level of suspected carcinogenic chemicals, that is, permanent hair dyes have 
a higher content of aromatic amines.32 Nevertheless, we found no substantial 
difference in risks between types of hair dye. Although we evaluated different 
types of hair dyes separately, the category of temporary dyes could also be 
further separated into water-soluble dyes that withstand only one shampooing 
(temporary dyes) and semi-permanent dyes that are usually synthetic and 
persist longer than temporary dyes (4–5 shampooings), because these types 
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of products vary slightly in composition. Combining the temporary and semi-
permanent dyes may have lead to inability to detect an increased risk for one or 
the other type. In addition, we stratified the analyses by hair dye colour, because 
dye colours differ in chemical properties, that is, in general dark dyes contain 
higher concentrations of aromatic amines than lighter shades.32 A few studies17, 
19 did suggest an increased bladder cancer risk among long-term users of dark 
dyes. The low prevalence of exposure to dark hair dyes in most populations 
may explain the discrepancies in these results. We collected information on 
hair dye colour, but were unable to present associations between black dye 
use and bladder cancer risk because none of the cases reported black hair dye 
use. We did not find any association for blond, brown, and red hair dye use. 
It is important to note, however, that these findings were also based on small 
numbers of cases. 
CONCLUSION 
We did not confirm an increased risk of bladder cancer with use of hair dyes in 
this population. We observed no association between temporary or permanent 
hair dye use and bladder cancer risk among women. The lack of association 
was not affected by duration or frequency of use, dye colour, or extent of use. 
Because hair dye use is most frequently used by women while bladder cancer 
is more prevalent among men, it is difficult to study the role of hair dye. In our 
analyses, the number of female cases is fairly small which affects the power of 
the study to detect small increases in risk. Residual confounding by smoking 
or selection bias can also not entirely be excluded. Further investigations with 
larger sample sizes, focussing on subgroups that may be more prone to the 
toxic effects of hair dyes, may be needed to obtain a definitive answer to the 
question. However, because both the risk and the etiological fraction induced 
by hair dyes are probably small, it may be better to focus on yet unidentified 
bladder cancer factors.
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This thesis aimed to investigate the role of fruit and vegetables, nutritional 
biomarkers of fruit and vegetables, and other dietary and lifestyle related factors 
in the development of urothelial cell carcinomas of the bladder (UCC) using 
data from the European Prospective Investigation into Cancer and Nutrition 
(EPIC) and the Nijmegen Bladder Cancer Study (NBCS). This chapter discusses 
the main findings of this thesis, puts these results into a broader context, and 
provides suggestions for further research.  
MAIN FINDINGS OF THIS THESIS
The main findings of this thesis are summarized in Table 1. In the EPIC cohort, 
we did not observe an association between total fruit and/or vegetable 
consumption and risk of bladder cancer. The null association remained when 
stratified by prognostic subgroups of bladder cancer according to tumour 
aggressiveness. Higher plasma levels of the sum of carotenoids and higher 
serum levels of folate were inversely associated with the risk of UCC, whereas 
higher levels of plasma α-tocopherol were associated with an increased risk of 
UCC. When stratified by prognostic subgroups of UCC, stronger associations 
for sum of carotenoids, α-carotene, α-tocopherol and folate were found for 
aggressive UCC. For non-aggressive UCC, a decreased risk was only observed 
for plasma lutein. No associations were observed between circulating levels 
of other individual carotenoids (α-carotene, α-cryptoxanthin, lycopene and 
zeaxanthin), vitamin C, retinol, α-tocopherol, homocysteine, vitamin B6, and 
vitamin B12 and risk of UCC. Finally, total fluid intake and the use of personal 
hair dyes (NBCS) were also not associated with UCC risk. 
In conclusion, this large prospective study did not point to a protective effect 
of self-reported total fruit and/or vegetable consumption. On the other hand, 
it provides suggestive evidence for an etiologic role for some micronutrients 
in the development of bladder cancer. Some of these bioactive compounds in 
fruits and vegetables may influence the risk of developing the aggressive form 
of bladder cancer in particular. 
INTERPRETATION OF STUDY RESULTS
Fruit and vegetables 
The role of fruit and vegetables in bladder cancer development has long been 
debated. Most of the evidence of a protective effect of vegetables and fruit 
on bladder cancer was derived from case–control studies, while most cohort 
studies provided weaker or no evidence.1 Our null results are consistent with 
previous prospective studies. The discrepancies may be related to recall and 
selection biases in case-control studies. However, cohort studies tend to be 
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more affected by misclassification, which may explain their tendency to show 
no association more often than case-control studies.2 Overall, there has been 
limited evidence that fruit and vegetables are associated with reduced risk of 
most types of cancer studied. The few significant inverse associations observed 
have been in respiratory and digestive cancers.1 In the EPIC study, for instance, 
the relative risk for a 200 g per day increment in fruit and vegetable consumption 
was 0.92 (95%CI: 0.90-0.95) for cancers associated with smoking, and 0.98 
(95%CI: 0.97-1.00) for other cancers.3 It may be that fruit and vegetables protect 
against the carcinogenic effect of tobacco smoking, but it is also possible that 
these results are due to residual confounding. In the EPIC study a higher intake 
of fruits and vegetables was associated with other lifestyle variables which may 
have contributed to a lower cancer risk. 
Table 1. Summary of main findings of the studies described in this thesis.
All urothelial 
cell carcinomas
Aggressive  
urothelial cell carcinomas
Non-aggressive  
urothelial cell carcinomas
Fruit and vegetables - - -
Plasma α-carotene - - -
Plasma β-carotene - ↓ -
Plasma β-cryptoxantin - - -
Plasma lycopene - - -
Plasma lutein - - ↓
Plasma zeaxanthin - - -
Sum of plasma carotenoids ↓ ↓ -
Plasma vitamin C - - -
Serum folate ↓ ↓ -
Serum homocysteine - - -
Serum vitamin B6 - - -
Serum vitamin B12 - - -
Plasma retinol - - -
Plasma α-tocopherol ↑ ↑ -
Plasma γ-tocopherol - - -
Total fluid intake - - -
Personal hair dye use - - -
Increased intake or blood concentrations were inversely (↓), positively (↑) or not (-) associated 
with the risk of urothelial cell carcinomas.
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Biomarkers of fruits and vegetables
The population study described in this thesis is the first prospective study of 
this size investigating circulating blood concentrations of specific nutritional 
biomarkers in relation to bladder cancer. We observed that participants with 
increasing levels of carotenoids had a 19% reduction in risk of UCC with each 
doubling of plasma levels of the sum of carotenoids. As carotenoids are widely 
distributed in fruits and vegetables, the sum of circulating carotenoids may be 
the most consistent marker of fruit and vegetable intake.4, 5 In our studies we 
measured the major carotenoids available in plasma and were therefore able to 
sum the separate carotenoids. As specific compounds in fruits and vegetables 
may be responsible for anticarcinogenic activities, we also studied the role 
of individual carotenoids. A suggestive inverse association between plasma 
α-carotene and lutein, and UCC was seen (Chapter 4). In addition to carotenoids, 
higher serum levels of folate may also decrease the risk of UCC (Chapter 5). 
Previously, the associations of bladder cancer with nutritional biomarkers 
have been investigated in a few, relatively small observational studies. Case-
control studies showed inverse associations for blood levels of lutein6, α- 
and α-carotene6, lycopene6 and folate7, while no association was found for 
retinol and tocopherols6. Prospective studies showed inverse associations for 
α-carotene, lutein plus zeaxanthin and a suggestion for an increased risk of 
α-tocopherol8, 9, however, no association was found for α-carotene8, 9, lycopene9 
retinol and α-tocopherol10. In case-control studies results may be biased by 
changes in blood levels after diagnosis, while previous prospective studies had 
small sample sizes and may therefore have lacked power to reach statistical 
significance.
Circulating blood levels of nutritional biomarkers have been linked to risk of 
multiple cancer sites in several prospective cohorts. Within the EPIC study, the 
relationship with selected nutritional biomarkers has been assessed for cancers 
from the upper aero-digestive tract, lung, gastric, pancreas, colorectal, breast, 
prostate and kidney (Table 2). Although these studies did not provide consistent 
evidence of an inverse or positive association for specific markers, it seems 
that carotenoids may play an etiological role in various types of cancers, those 
to date identified including gastric, colorectal, pancreas, breast and bladder 
cancer. These studies support the thought that using biomarkers of fruits and 
vegetables is a relevant method to provide a more clear picture of the role of 
fruits and vegetables in cancer prevention. 
Fruit and vegetables versus biomarkers
Blood carotenoids are well correlated with each other because of the overlap 
of sources of specific carotenoids and thus no single fruit or vegetable group 
is completely specific to a certain carotenoid. Nevertheless, in spite of this 
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overlap, we have noticed some interesting relationships between levels 
of certain carotenoids and folate, specific fruits and vegetables and UCC 
incidence. For instance, findings about the role of fruit and vegetables in the 
entire EPIC cohort (Chapter 3) suggest that consumption of root and leafy 
vegetables, which have a high α- and α-carotene, lutein and folate content, 
were more strongly associated with a decreased risk of UCC than other types 
of vegetables. Regarding other potential biomarkers for fruit and vegetables, 
blood concentrations of α-cryptoxanthin and vitamin C are better predictors 
of fruit than of vegetable intakes. In this thesis we observed no association for 
plasma vitamin C, α-cryptoxanthin (Chapter 4) nor for fruit intake (Chapter 3). 
It seems that the possible bladder cancer-preventing effects may be exerted 
via mechanisms specific to carotenoids and folate that are present in several 
subgroups of vegetables, although we cannot exclude that other bioactive 
compounds in fruits and vegetables are also responsible for this effect. 
Biological considerations
One of the most common hypotheses of the health benefits of fruits and 
vegetables is attributed to antioxidant nutrients, such as vitamin C and E, 
and carotenoids, to prevent DNA damage by neutralizing free radicals and 
oxidants and thus preventing subsequent development of cancer. 27, 28 Other 
proposed mechanisms for their anticarcinogenic activity include gap junction 
communication between cells, cell growth regulation, modulating gene 
expression and immune response.29, 30 The exact mechanism that links folate 
with human health is thought to involve the one-carbon metabolism metabolic 
pathways. Altered folate metabolism causes ineffective DNA synthesis 
and diminished levels of folate may result in misincorporation of uracil into 
DNA, leading to chromosome breaks and disruption of DNA repair. Another 
hypothesis for folate insufficiency refers to the alteration of gene expression 
through changes in methylation pattern of DNA and histones.31 There is, 
however, no evidence that synthetic antioxidants are beneficial in humans32, 
33 and it is plausible that the benefit of a diet rich in fruit and vegetables is 
due to the complex mixture of biological compounds present in whole foods. 
This is the first study that identifies a potential role of dietary habits involved 
in different (proposed) bladder cancer pathways due to our ability to stratify 
the analysis into aggressive and non-aggressive bladder tumours. We found 
indications that the effect of nutritional biomarkers was particular seen 
for the aggressive form of bladder cancer. In chapters 4-6 we discussed the 
potential mechanisms of nutrients on the development of aggressive bladder 
tumours. Regarding α–carotene it is suggested that this nutrient may inhibit the 
development of aggressive bladder carcinogenesis through pathways related to 
cancer cell proliferation.34 The mechanism of tumour promotion by tocopherols 
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may be related to increased formation of α-tocopherol radicals which, when 
not efficiently scavenged by other antioxidants, may act as reactive radical 
species themselves35. As the p53 tumour suppressor gene that is mutated in 
the aggressive form of bladder cancer appears to be susceptible to the DNA 
damaging and hypomethylating effects of folate deficiency, it suggests that 
folate affects aggressive bladder carcinogenesis through DNA methylation.36 
However, the precise mechanisms underlying the association with aggressive 
bladder cancer remain undisclosed. Although there are several mechanisms by 
which micronutrients may influence carcinogenesis, it is unclear to what extent 
carotenoids, folate and tocopherols itself are responsible for the decreased or 
increased risks observed. To further understand whether vitamins and other 
micronutrients may play a role in the prevention of bladder cancer, more 
experimental (animal) and epidemiological studies are needed to clarify the 
mechanism of action.
METHODOLOGICAL CONSIDERATIONS 
The strengths and limitations of the study design of the EPIC cohort are 
extensively discussed in the previous chapters. In brief, the most important 
strengths of this prospective study include its very large size, multiple 
populations with large variations in exposure and outcome, standardized data 
collection, long follow-up with large numbers of end points, and the availability 
of blood samples. This chapter highlights additional methodological issues. 
Dietary intake assessment of fruit and vegetables 
Accurate ranking of dietary intake is essential to understand the association 
between diet as a modifiable risk factor and bladder cancer risk. The Food 
Frequency Questionnaire (FFQ) is the most commonly used and feasible dietary 
method to assess habitual dietary intake in large-scale epidemiological studies 
because it is less expensive than other dietary assessment methods, easy to 
apply and has a low burden on the participant. Self-reporting by FFQ relies 
on the participant’s ability to recall or record food intake sufficiently accurate. 
Although the FFQ is useful to a certain extent for ranking individual intakes, it 
may be less suitable to estimate the quantity of food intake because the list of 
food items is limited and fixed.37 Moreover, in EPIC, a mix of (semi-) quantitative 
food frequency questionnaires was used tailored to the local situation. In 
order to account for systematic over- and underestimation of dietary intake, 
a statistical approach has been developed to improve comparability of dietary 
data across the participating centres within the EPIC cohort.38 The dietary 
data were calibrated using a multivariable linear calibration model in which, 
for example, fruit and vegetable intakes obtained from the 24h recall were 
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regressed on that from the FFQ. However, this method does not entirely solve 
the problem of misclassification as errors in measurement of the 24h recall 
and the dietary questionnaire are correlated, and thus we cannot exclude the 
impact of such measurement errors. In addition, we do not know whether 
we have measured usual diet in the relevant time window on the road to 
clinical manifestation of the cancer. So, although our null findings for total 
fruit and vegetable consumption may indeed be real, it is also possible that 
methodological problems in adequately measuring diet may have attenuated 
our risk estimates towards the null.
Nutrients measured by dietary questionnaires and in blood samples
Dietary biomarkers are thought to more accurately assess nutritional intake/
status than self-reported dietary assessment methods.39 Interestingly, in our 
studies we observed quite similar risk estimates for dietary intake of α-carotene 
and folate and blood concentrations of both biomarkers. Although it seems that 
determination of these nutrients from dietary questionnaires could provide 
a quantitative measure of intake of these nutrients, we have to keep in mind 
that most food composition tables contain values for only few carotenoids 
(for example in the EPIC cohort only α-carotene is available in the nutrient 
database) and assessing dietary intake of other specific carotenoids and the 
sum of carotenoids is therefore not possible. 
With regard to folate status, the present study provides information on the 
level of dietary folate intake in European countries before voluntary folate 
fortification and folic acid supplement use was widespread. Our measurement 
of circulating folate seems, therefore, mainly determined by naturally occurring 
folate. Furthermore, in the EPIC cohort the assessment of dietary intake of folate 
in the food composition tables is very detailed due to recent improvement of the 
quality and completeness of folate data in the European Nutrient Database.40 As 
circulating blood concentrations reflect both dietary and supplemental intakes, 
in a population where folate fortification and folic acid supplementation is 
commonly used, self-reported dietary intake of folate may be a less accurate 
measure of folate status than that of blood folate concentrations. 
On the other hand, for dietary vitamin E and plasma tocopherols we did not 
find comparable risk estimates. Indeed, higher concentrations of plasma 
α-tocopherol were associated with an increased risk of UCC, whereas higher 
dietary intakes of vitamin E were not associated with UCC (Chapter 6). The lack 
of an association between dietary vitamin E and UCC risk may be explained by 
biases in the assessment of dietary intake and errors in the food-composition 
table from which dietary vitamin E were derived. Further, vitamin E includes 
several forms of tocopherols (α, α, α and α) and dietary vitamin E derived from 
the food composition table is a combination of these individual tocopherols. 
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On the other hand, the bioavailability of tocopherols can very substantially 
depending on the cooking method used or the metabolism of tocopherols that 
can affect their blood concentrations. Although α- and α-tocopherol are the 
predominant forms in plasma, it is difficult to compare individual plasma levels 
with dietary levels. 
Freedman et al.41 proposed to combine measurements of nutritional biomarkers 
with information from self-reported instruments to strengthen the analysis of a 
diet-disease relationship. They have demonstrated this approach in an analysis 
of the association between lutein and zeaxanthin intakes and nuclear cataracts. 
In their example, the odds ratio for the serum level (0.69) was stronger than 
for the reported dietary intake using an FFQ (0.77) and the estimated odds 
ratio using the combined FFQ-biomarker measure was slightly stronger than for 
serum alone (0.66). The gains in statistical power for detecting a diet-disease 
association are, however, modest. 
Stability of a single measurement 
It is possible that dietary intake may have changed during follow-up and that a 
single food frequency questionnaire or blood sample measured at baseline may 
not perfectly represent long-term intake. Longer term changes of the exposure 
of interest within persons may lead to underestimation of the strength of the 
association due to regression dilution.41, 42 This raises concerns of whether 
multiple measurements are necessary. Replicate measurements of the 
exposure variables incorporate changes over time and reduce within-subject 
variation. In the future, more valid methods have to be applied that will allow 
a better characterization of diets over longer time periods. Combining newly 
designed food frequency questionnaires with repeated 24h recalls are the most 
promising option as this takes into account day-to-day and seasonal variation 
if repeatedly applied. Data collection for a newly designed (web-based) second 
dietary examination for assessing usual frequencies in combination with one 
or two 24-hour dietary recalls for better assessing usual quantity of intake is 
considered in EPIC, but more discussions will take place in 2013. 
In biomarker studies we have to keep in mind that the exposure assessment of 
blood levels is based on a single measurement, a snap-shot in time. To examine 
to which extent our risk estimates may have been attenuated by regression 
dilution, the stability of nutritional biomarkers, as described in this thesis 
(Chapter 6), has been estimated in a subsample of the two Dutch cohorts within 
EPIC.43 Serum homocysteine and vitamin B12 were highly stable biomarkers over 
time, whereas most other analysed biomarkers had a moderate or poor stability. 
The intra-class correlation coefficient (ICC), which is the proportion of the total 
variance (within-subject + between-subject) due to between-subject variance, 
was used to adjust risk estimates for attenuation by regression dilution.44 For 
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example, taking the observed ICC (0.46 for the sum of carotenoids) into account, 
the de-attenuated IRR (IRR=0.64) for the sum of plasma carotenoids was 0.39. 
The de-attenuated risk for the sum of plasma carotenoids may thus well be 
substantially lower than the uncorrected measures. These results indicate that 
the true association is likely to be much stronger. The higher the attenuation 
coefficient, the closer the regression coefficients of the disease model are to 
the true but unknown coefficients. It is, however, important to recognize that 
the stability of repeated measures was examined in a selected sample of the 
Dutch EPIC participants (n=65) and that the attenuation factor may be different 
in the different EPIC study populations. Supervised by the EPIC Oxford centre, 
analyses in six study centres of the EPIC cohort on the stability of several 
B-vitamins and other exposure biomarkers are ongoing in a dataset including 
more than 1000 participants. This data will allow us to correct relative risks for 
regression dilution across European countries, although this will still not be fully 
representative of the whole EPIC cohort.
Confounding by smoking
Residual confounding by smoking remains of particular concern in our studies, 
because cigarette smoking, although substantially less strong as in lung cancer, 
is still clearly associated with both bladder cancer and the level of circulating 
nutrients. Theoretically, the possible relationship of nutritional biomarkers with 
bladder cancer might be best investigated in people who have never smoked. 
In our studies we observed that the effect of concentrations of carotenoids and 
folate were more prominent in current smokers (Chapter 4 and 5), while for 
α-tocopherol we cannot exclude a detrimental role of α-tocopherol regardless 
of smoking status (Chapter 6). However, bladder cancer in never smokers is 
a rare disease and the data from our studies may not be sufficient to draw 
conclusions. Although we adjusted for self-reported smoking status, smoking 
intensity and smoking duration as good as possible, it is possible that the 
observed associations in our studies reflect incomplete control of smoking. 
Cotinine levels can be used as an indicator of more recent smoking behaviour 
levels as cotinine, the main metabolite of nicotine, is considered the most 
accurate measure of smoking intensity at the time of blood collection. However, 
a recent study in EPIC45 using plasma cotinine levels as biomarkers for smoking 
exposure in relation to the risk of pancreatic cancer, found no reason for an 
underestimation of the relation between self-reported smoking behaviour and 
pancreatic cancer risk. Thus, the self-reported smoking status seems adequate 
to reflect smoking behaviour, but it is still possible that residual confounding 
exists. 
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Verification of bladder cancer diagnosis
In our studies we evaluated the role of selected foods and nutrients in relation to 
different pathological features of UCC to take into account the heterogeneous 
nature of bladder tumours. UCC cases were classified as aggressive and 
non-aggressive based on stage and grade. Information on stage and grade 
was, however, not always collected in population cancer registries and thus 
not included in the EPIC database. In order to provide detailed pathology 
information about stage and grade for each defined bladder cancer case, we 
collected pathology reports of all cases identified in the EPIC cohort. Although 
not a real revision of slides or tissue, the revision of the pathology data available 
in the IARC bladder cancer dataset lead to improvement of the original data as 
more than 90% of the cases were classified into aggressive or non-aggressive 
UCC. Although the collected data on stage and grade obtained from pathology 
reports offers the opportunity to classify bladder tumours by aggressiveness, it 
still suffers from interobserver variability between different uro-pathologists in 
different countries. An appropriate classification of cancer subtypes is significant 
for epidemiological research to better identify important relationships between 
risk factors and bladder tumour types. To improve characterization and identify 
different subsets of bladder cancer, future studies should include molecular 
profiles. The Dutch part of the EPIC cohort is involved in a so-called Rainbow 
project, funded by the Biobanking and Biomolecular Research Infrastructure 
(BBMRI). This project focusses on the collection of tumour material for several 
cancer types, including bladder cancer. Molecular characterizing of tumour 
tissue by tumour microarrays will be linked to Dutch cohort studies for molecular 
epidemiology. 
FUTURE DIRECTIONS OF EPIDEMIOLOGICAL RESEARCH
The relationship between fruit and vegetable consumption measured at the 
start of the study and the occurrence of bladder cancer has been investigated 
extensively during the last decades. In future analyses, we therefore recommend 
to study the impact of repeated dietary measurements and changes in dietary 
intake and lifestyle factors on risk of bladder cancer. To attain conclusive evidence 
to confirm or refute effects of dietary factors on risk of bladder cancer, further 
unravelling the effects of diet on bladder cancer risk is of great public health 
importance. It is therefore important to participate in consortia to increase the 
sample size and thus statistical power for analyses. The BLEND consortium on 
diet and bladder cancer, coordinated by the University of Maastricht, is a good 
example of collaboration between many study centres worldwide, including the 
EPIC cohort.
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Epidemiological studies with nutritional biomarkers are sparse in bladder 
cancer research and results from the reliability study suggest that a single 
measurement is not fully able to capture long-term intake and body stores 
and stability decreases with a longer time between measurements. Therefore, 
confirmation of the observed associations in other large prospective studies 
with multiple measurements of blood levels is required. It is therefore of major 
concern to maintain the use of valuable data of ongoing population cohorts 
and their biobanks to continue epidemiological research on diet and cancer. For 
the EPIC cohort and the few other large-scale European cohorts combined in 
an European Cohort Consortium it is crucial to have a suitable call in Horizon 
2020, the EU program for Research and Innovation, to apply for funding for a 
second dietary examination and a second blood sample. 
Gene-environment interactions
To further explore the role of folate in bladder cancer aetiology, analyses of diet 
and or nutritional biomarkers should preferably include data on specific genetic 
polymorphisms. Folate metabolism impaired by the genetic variants (C667T and 
A1298C) of MTHFR could change DNA methylation patterns. As shown in the 
EPIC cohort by Eussen et al., plasma folate concentrations were lower among 
healthy participants with the MTHR 677TT genotype compared with CC and 
CT genotypes.46 Partly in line with this finding, one case-control study from the 
United States observed an increased risk for those with the MTHFR 677CT/TT 
genotypes and those with a low folate intake, but did not find significant effects 
of the MTHFR 1298 polymorphism on bladder cancer risk.47 
Although an increased bladder cancer risk was found among those with a low 
folate intake, authors found stronger associations for CT/TT. While a case-
control study conducted in Spain reported an increased bladder cancer risk 
with low folate intake, they did not find an interaction with MTHFR gene.48 
It is a clear drawback that previous case-control studies were based on folate 
measurements taken after diagnosis and these findings need confirmation 
in large population based studies. As data on MTHFR is available within the 
bladder cancer case-control study nested within EPIC, using more recent data on 
follow-up with larger number of cases we propose to examine the relationship 
between folate and bladder cancer risk stratified by genetic variants (e.g. C667T, 
A1298C, T1317C and G1793A) of MTHFR.  
Another approach to further investigate the pathway through which folate 
and other one-carbon metabolism components are involved in bladder 
carcinogenesis is to apply structural equation modelling (SEM). SEM allows 
simultaneous estimation of linear relations where a variable can be the outcome 
in one equation and the predictor in another, as well as allowing estimation 
using latent variables (factors estimated by correlation matrix). A recent study 
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on lung cancer in EPIC49 applied SEM to measure four mechanisms in the one-
carbon metabolism related to lung cancer risk. They showed that the folate cycle 
(in which folate acts as a crucial carrier of methyl groups and involves several 
additional water-soluble B vitamins) was allowed to affect lung cancer indirectly 
through the methionine-homocysteine metabolism. In the investigation of the 
involvement of one-carbon metabolism, it is important to consider complex 
pathways (e.g. by applying SEM) rather than the effects of single vitamins or 
nutrients (e.g. using traditional multiple regression). In the use of a pathway 
approach the effects of polymorphisms related to one-carbon metabolism can 
be included as well. 
To provide new insights into the mechanism of antioxidants and the role of the 
oxidant-antioxidant balance in the pathogenesis of bladder cancer, it would also 
be of interest to investigate whether the observed associations for carotenoids 
and tocopherols in our studies were modified by variants in genes related to the 
antioxidant defense.
Single nutrient versus dietary/nutrient patterns
Like many epidemiological studies, this thesis reports on the role of individual 
foods and nutrients. Nevertheless, people do not consume nutrients or single 
foods, they eat meals that consist of certain combinations of foods and 
nutrients. Foods and nutrients could act synergistically or be metabolized 
jointly. Diet is a complex exposure variable and it needs multiple approaches to 
examine the relationship between diet and disease risk. The evidence base is 
strengthened when the results from multiple lines of research (i.e. biomarkers 
of nutrient intake, nutrients, foods, and dietary patterns) are consistent. 
Complementary to analyses of the role of individual foods or nutrients, dietary 
pattern analysis is useful to explore diet-disease relationships and to identify 
‘healthy’ eating patterns. Consumption of fruit and vegetables is often part 
of a healthy food pattern, replacing the consumption of less healthy foods. 
Dietary patterns identified in prior research were often defined as ‘Western’ 
and ‘prudent’ patterns. One case-control study conducted in Uruquay reported 
that adherence to the Western dietary pattern, characterized by high intakes of 
meat, fat, sweets and desserts, was associated with increased risk of bladder 
cancer. The prudent pattern, characterized by high intakes of fruit, vegetable, 
fish and poultry was not associated with risk of bladder cancer.50 Although 
there is evidence that the Mediterranean diet (e.g. high consumption of fruits, 
vegetables, olive oil, and fish, and low consumption of meat) may lower the risk 
of cancer incidence and mortality, in the EPIC cohort no clear association was 
observed between this type of diet and the risk of bladder cancer.51 However, 
there are many difficulties with studying dietary patterns. Based on a review 
published in 2002, there is an increasing discussion in literature on the different 
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techniques that can be used, the selection of food groups to be analysed, and the 
labelling of the food patterns.52 
In addition to analysing food patterns, the relatively new approach to identify 
nutrient patterns may be useful to capture bioactive compounds in biological 
mechanisms. Thus far, few studies have considered the role of combinations 
of nutrients on cancer risk. Two case-control studies from Uruguay and Italy 
examined nutrient-derived dietary patterns for multiple cancer sites (e.g. 
colorectal53, 54, head and neck55, 56, lung57, pancreas58, gastric59, breast and ovarian60 
cancer). They defined four or five major dietary patterns that explained about 80% 
of the total variance in nutrient intake in the study population. These findings 
seem to confirm that diets rich in animal origin are positively, and those rich in 
fruit and vegetables inversely related to cancer risk. Recently, in the EPIC cohort 
four nutrient-derived patterns were identified. Especially of interest to further 
explore the role of nutrients on bladder cancer risk are the nutrient patterns 
named “animal vs. plant nutrients”, which shows the contrast between diet rich 
in animal and plant source nutrients, and “the vitamins and minerals” pattern, 
which has high loadings of B-vitamins, vitamin C, α-carotene, retinol, phosphorus, 
potassium and magnesium.61 This approach may strengthen the research on 
nutrient consumption and related biomarkers and bladder cancer risk. 
CLINICAL IMPLICATIONS
The majority of bladder tumours (75%-80%) present as superficial (non-muscle-
invasive), tumours and do not penetrate beyond the epithelial basement 
membrane. These tumours are often multifocal and recurrent, well-differentiated 
(low-grade) and have limited potential to become muscle-invasive. Although, 
the prognosis of these tumours is very good62, 63, patients with a superficial type 
of bladder cancer suffer from recurrences of cancer which is a large burden for 
the patient and the health care system. The remaining bladder cancer patients 
present initially with bladder tumours invading the muscularis propria of the 
bladder or beyond. Muscle invasive tumours usually require radical cystectomy 
and have a poor survival.63 Despite improvements in diagnosis and treatment 
of bladder tumours, the risk of both recurrence and progression remains 
significant. For people who are living with a diagnosis of cancer or those who 
have recovered from the disease it is important to know if there are specific 
nutrition and lifestyle changes they can make to reduce their risk of bladder 
cancer progression or recurrence. 
As tobacco use remains the most common modifiable causative factor, cessation 
of smoking is the most important advice for patients. Studies have suggested 
that bladder tumours in patients who smoked demonstrated higher histological 
grade and stage64-66, and leading to higher mortality from the disease.67 
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In a 2010 published report it has been shown that urological patients’ awareness 
of smoking as a risk factor for bladder cancer is lower than their awareness 
regarding other smoking-related disease entities.68 Counselling patients 
regarding the risk of tobacco is an important role for urologists.69 
To date, most studies focused on dietary and lifestyle changes as ways of 
preventing bladder cancer in the first place. As bladder cancer, in particular non-
muscle invasive bladder cancer, is often treated as a chronic disease requiring 
lifelong surveillance and the number of bladder cancer survivors is growing, it 
would be of interest to investigate whether foods and nutrients are important 
for patients diagnosed with bladder cancer and those that survive the disease. 
In a recent randomized clinical trial of lifestyle modifications, a telephone-
based dietary counselling intervention was tested in patients with non-invasive 
bladder cancer. This novel intervention shows an increased vegetable intake 
and α-carotene concentrations after 6 months.70 We highly recommend 
research on the association between eating habits and the risk of recurrence or 
progression of bladder cancer stratified by tumour aggressiveness. As scientific 
evidence is not yet clear enough to make any specific recommendations for 
cancer survivors as a whole, or for those who are survivors of bladder cancer, 
the WCRF/AICR advice survivors of cancer to follow the recommendations for 
cancer prevention, which include refraining from smoking, eating a healthy diet, 
being physically active and maintaining a healthy weight.1 
SOCIETAL IMPACT
The expected even larger burden of cancer among the general population in 
the near future provides a growing incentive to address this problem. Primary 
prevention through lifestyle and environmental interventions might offer the 
best option for reducing the occurrence of cancer worldwide. The incidence 
of bladder cancer was strongly associated with occupational exposure to 
aromatic amines used in the dye industry. With reduction of such workplace 
exposure, smoking is now the strongest environmental risk for bladder cancer, 
contributing to more than 50% of cases.71 Stopping smoking and avoiding 
exposure to second-hand smoke should be an effective method of decreasing 
the incidence of the disease. Although there exist several ways of support to 
help people quit smoking, it is still hard to quit smoking and only one in 10 
can successfully do so. Therefore it is of great importance to encourage people 
not to start smoking. Recently, the Dutch Cancer Society started a campaign 
focusing on the awareness of young people that not smoking is the standard 
nowadays. 
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In 2007, WCRF/AICR implemented recommendations for a healthy lifestyle for 
the prevention of cancer.1 Romaguera et al.72 reported that EPIC participants 
were 18% less likely to develop any type of cancer and a 16% reduction in 
risk of bladder cancer if they adhered to these recommendations on diet, 
nutrition, physical activity, and weight management. This thesis underpins the 
importance of a healthy diet; a decrease in risk of bladder cancer was seen among 
participants with higher blood concentrations of specific nutritional biomarkers, 
which could be achieved by an increased intake of fruit and vegetables. This 
finding corresponds with the recommendation of the WCRF/AICR public health 
policy to eat mostly foods of plant origin to prevent cancer. 
In the Netherlands, only 1-2% of the children met the recommendations for 
vegetables. In adults, this percentage increased with age; 3-4% of the young 
adults (19-30 years) and 9-14% of the adults older than 30 years complied 
with the recommendations for vegetable consumption. The guideline for fruit 
consumption was met by 3-26% in the different age groups. In young children (7-8 
years) and adults above 30 years 19-26% complied with the recommendations 
for fruit consumption.73 Low intakes of fruit and vegetables are still points for 
improvement in the diet, especially in children and young adults. Research to 
date has uncovered few definite effects and has resulted in confusing messages 
to the public. More systematic assessments of what combination of policies 
and actions can increase the intake of fruits and vegetables in the population 
are needed. The major challenge for prevention is improving the methods of 
communication of research results to the public to create awareness that a 
healthy lifestyle may help prevent cancer.
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Bladder cancer is a major public health problem in the Western world. Primary 
prevention through lifestyle and environmental interventions might offer the 
best option for reducing the occurrence of bladder cancer. It is clear that tobacco 
smoking and occupational exposure to carcinogens like aromatic amines and 
polycyclic aromatic hydrocarbons (PAHs), family history and specific low-
penetrance susceptibility, such as NAT2 and GSTM1 are important risk factors 
for UCC, but evidence for the relationship between diet and bladder cancer risk 
is very inconsistent. (Chapter 2) 
This thesis aimed to study the role of fruit and vegetables, nutritional biomarkers 
of fruit and vegetables, and other dietary and lifestyle factors in the development 
of UCC. We used data from the European Prospective Investigation into Cancer 
and Nutrition (EPIC). The EPIC cohort is a large multi-centre cohort study 
designed to investigate the relation between food, nutritional status, various 
lifestyle and environmental factors and the incidence of different forms of 
cancer. The total cohort consists of more than 500,000 people recruited in 23 
centers in 10 European countries. At enrolment, blood samples, demographic, 
lifestyle and dietary data have been collected from all participants. In addition, 
case-control data of the Nijmegen Bladder Cancer Study (NBCS) were used. 
The role of fruits and vegetables in bladder cancer development has long been 
debated. Fruits and vegetables have been hypothesized to have anticarcinogenic 
effects and may therefore reduce the risk of cancer. Many epidemiological 
studies have examined fruit and vegetable consumption in relation to UCC of the 
bladder, but results were inconsistent. Contradictory results may be explained 
because UCC is often considered to be one disease although it represents a 
heterogeneous group of tumours with different prognoses that develop through 
different molecular pathways. The low grade, low stage papillary tumours are 
characterized by activating mutations in HRAS and FGFR3 and by chromosome 
9 aberrations; the high grade solid muscle invasive tumours are characterized 
by structural and functional defects in TP53 and RB1. The association between 
fruit and vegetable consumption may vary by bladder tumour aggressiveness. 
In chapter 3 we described the relationship between fruit and vegetable 
consumption and the risk of aggressive and non-aggressive UCC in the EPIC 
cohort. After 8.9 years of follow-up, 947 UCC were diagnosed among 468,656 
participants. Total consumption of fruits and vegetables was not associated with 
UCC. An increase in leafy vegetables and grapes consumption was associated 
with a reduced risk of non-aggressive UCC, while the intake of root vegetables 
(HR 25g/day increase 0.88; 95%CI: 0.78-1.00 and HR 0.87; 95%CI: 0.77-0.97, 
respectively) was inversely associated with risk of aggressive UCC (HR 25g/day 
increase 0.87; 95%CI: 0.77-0.98). We concluded that our study did not confirm 
a protective effect of fruits and/or vegetable consumption on aggressive or 
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non-aggressive UCC. Higher consumption of certain subtypes of vegetables 
and fruits may reduce the risk of UCC.
Biomarkers, as indicators of dietary intake or nutritional status, offer an important 
opportunity for improving measurement of exposure as they do not rely on self-
reports of food intake. In chapters 4, 5 and 6 of this thesis, we investigated the 
association between blood levels of carotenoids, vitamin C, retinol, tocopherol 
and components of the one carbon metabolism and the risk of bladder cancer 
in a case-control study nested within the EPIC cohort. A total of 856 (for 
carotenoids and vitamin C), 824 (for folate, homocysteine, vitamin B6 and B12) 
or 848 (for retinol and tocopherols) patients with UCC were 1:1 matched to 
cohort members by incidence density sampling. Matching factors were sex, age 
at baseline, study centre, date and time of blood collection, and fasting status. 
Chapter 4 reports on circulating plasma concentrations of carotenoids and 
vitamin C. Higher concentrations of the sum of plasma carotenoids decreased 
UCC risk (IRR highest vs. lowest quartile 0.64; 95%CI: 0.44-0.93). Plasma 
α-carotene was inversely associated with the risk of aggressive UCC (IRR 0.51; 
95%CI: 0.30-0.88), while plasma lutein decreased the risk of non-aggressive 
UCC (IRR 0.56; 95%CI: 0.32-0.98). In chapter 5, serum compounds involved in 
one-carbon metabolism (folate, homocysteine, vitamin B6 and vitamin B12) in 
relation to bladder cancer were studied. Lower serum concentrations of folate 
may be associated with UCC (IRR highest vs. lowest quartile 1.37; 95%CI: 
0.98-1.30), in particular the risk of aggressive UCC (IRR 1.69; 95%CI: 1.04-
2.74). In chapter 6 we described the association between circulating plasma 
levels of retinol and tocopherols and the risk of UCC. Higher concentrations 
of plasma α-tocopherol were positively associated with UCC (IRR highest vs. 
lowest quartile 1.63; 95%CI 1.15-2.31), and in particular aggressive UCC (IRR 
3.27; 95%CI 1.85-5.81). No associations were observed between circulating 
levels of other individual carotenoids (α-carotene, α-cryptoxanthin, lycopene 
and zeaxanthin), vitamin C, retinol, α-tocopherol, homocysteine, vitamin B6, 
and vitamin B12 and risk of UCC.
Many epidemiological studies, including our biomarker studies, assess 
nutritional status based on single blood measurements. The reliability estimates 
concerns the extent to which a measurement of this estimate remain stable 
over repeated measurements. Blood concentrations may differ over time due 
to day-to-day variation and long-term changes within persons which may lead 
to attenuation of the associations. In chapter 7, we evaluated the stability of 
repeated measurements of blood concentrations of selected biomarkers 
(chapter 4-6) in a subsample of the Dutch participants of EPIC (EPIC-NL cohort). 
Blood samples were collected at baseline and after 2 to 5 years. The reliability of 
the biomarkers was estimated using an intraclass correlation coefficient (ICC). 
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Serum homocysteine and vitamin B12 were highly stable biomarkers, with ICCs 
of 0.91 and 0.75, respectively. Other analyzed biomarkers were less stable 
over several years (ICC ranged from 0.17-0.56). Results suggest that a single 
measurement is not fully able to capture long-term intake and body stores 
and stability decreases with a longer time between measurements. Therefore, 
confirmation of the observed associations in other large prospective studies 
with multiple measurements of blood levels is required.
With regard to other dietary factors, it is postulated that the intake of fluid 
may influence the risk of bladder cancer through several proposed mechanisms. 
Bladder cancer may be related to prolonged contact time of carcinogens with 
the urothelium. Higher fluid intake may play a protective role by diluting the 
urine or increasing the frequency of urination. Another opposite mechanism 
was proposed to explain the postulated increase in bladder cancer risk. A high 
intake of fluids could increase the risk if fluids contain contaminants that are 
bladder carcinogens. Bladder wall extension associated with a high intake of 
fluids or a lower miction frequency may allow the carcinogens in the urine to 
come into contact with the deeper layers of the bladder urothelium. Results 
from previous studies investigating the association between fluid intake 
and UCC are inconsistent. In chapter 8, we evaluated this association among 
233,236 subjects in EPIC, who had adequate baseline information on water and 
total fluid intake. During a mean follow-up of 9.3 years, 513 first primary UCC 
occurred. Total fluid intake was not associated with risk of UCC (HR highest vs. 
lowest tertile 1.12; 95%CI 0.86-1.45). Further, no associations were observed 
between risk of UCC and intake of water, coffee, (herbal) tea, milk and other 
dairy beverages.  
Besides nutritional factors that may influence bladder cancer risk, the use of hair 
dyes has been suggested as a risk factor for bladder cancer. Previous studies 
have suggested an increased risk of bladder cancer among hairdressers, who are 
occupationally exposed to hair dyes. There has also been concern about the possible 
increased risk of bladder cancer among users of hair dyes. In chapter 9 we report 
on the relation between personal hair dyes and development of bladder cancer 
risk. We used a population-based case-control study (NBCS), including 1,385 
bladder cancer cases (n=246 women) and 4,754 controls (n=2,587 women). 
As less than 5% of all men in the study ever used hair dyes, analyses were 
restricted to women. Use of temporary hair dyes (OR 0.77; 95% CI 0.58-1.02) 
or use of permanent hair dyes (OR 0.87; 95% CI 0.65-1.18) was not associated 
with bladder cancer risk. The lack of association was not affected by various 
types of hair dye, intensity of exposure to hair dyes or dye color. This study did 
not confirm an increased risk of bladder cancer with the use of hair dyes. 
In chapter 10 we discuss the main findings of this thesis, put these results into 
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a broader context, and provide suggestions for further research. In conclusion, 
this large prospective study did not point to a protective effect of self-reported 
total fruit and/or vegetable consumption. On the other hand, it provides 
suggestive evidence for an etiologic role for some micronutrients in the 
development of bladder cancer. The role of some of these bioactive compounds 
in fruits and vegetables may influence the risk of developing the aggressive 
form of bladder cancer in particular. In future analyses, we recommend to 
study the impact of repeated dietary and blood measurements and changes in 
dietary intake and lifestyle factors on risk of bladder cancer. To further explore 
the role of folate in bladder cancer etiology, analyses of diet and or nutritional 
biomarkers should preferably include data on specific genetic polymorphisms. 
Complementary to analyses of the role of individual foods or nutrients, dietary 
pattern analysis is useful to explore diet-disease relationships and to identify 
‘healthy’ eating patterns. To date, most studies focused on dietary and lifestyle 
changes as ways of preventing bladder cancer in the first place. We highly 
recommend research on the association between eating habits and the risk of 
recurrence or progression of bladder cancer stratified by tumor aggressiveness. 
Primary prevention through lifestyle and environmental interventions might 
offer the best option for reducing the occurrence of cancer worldwide. The 
major challenge for prevention is improving the methods of communication of 
research results to the public to create awareness that a healthy lifestyle may 
help prevent cancer.
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Blaaskanker is een groot probleem voor de volksgezondheid in de Westerse 
wereld. Primaire preventie door middel van leefstijl- en omgevingsinterventies 
levert een belangrijke bijdrage aan de vermindering van de incidentie van 
blaaskanker. De belangrijkste oorzaak van blaaskanker is het roken van 
sigaretten. Daarnaast is beroepsmatige blootstelling aan carcinogenen zoals 
aromatische aminen en polycyclische aromatische koolwaterstoffen (PAK) een 
belangrijke oorzaak. Wellicht speelt individuele genetische gevoeligheid ook 
een rol bij een deel van de blaaskankers. Tot op heden is nog niet bekend of 
een gezonde voeding, zoals een voeding rijk aan groenten en fruit, het risico 
op blaaskanker kan verlagen. Hoofdstuk 2 geeft een uitgebreid overzicht van de 
oorzakelijke factoren van blaaskanker.  
Dit proefschrift is gericht op het bestuderen van de rol van groenten en fruit, 
stoffen in het bloed die samenhangen met het eten van groenten en fruit en 
andere voedings- en leefstijlfactoren bij het ontstaan van blaaskanker. Voor de 
onderzoeken beschreven in dit proefschrift is gebruik gemaakt van de gegevens 
van de ‘European Prospective Investigation into Cancer and nutrition’ (EPIC) 
studie. De EPIC studie is een groot multicenter cohort, opgezet om de relatie 
tussen voeding, voedingsstatus, en diverse leefstijl- en omgevingsfactoren en 
het ontstaan van verschillende vormen van kanker te onderzoeken. Het totale 
cohort bestaat uit meer dan een half miljoen mensen, gerekruteerd door 23 
centra in 10 Europese landen. Bij de start van de studie zijn bij de deelnemers 
bloedmonsters afgenomen en demografische, leefstijl- en voedingsgegevens 
verzameld. Voor een additioneel onderzoek naar de relatie tussen het gebruik 
van haarverf en het risico op het ontstaan van blaaskanker is gebruik gemaakt van 
de ‘Nijmegen Bladder Cancer Study’ (NBCS). De NBCS is een patiënt-controle 
onderzoek, opgezet om genen en omgeving als potentiele risicofactoren voor 
blaaskanker te bestuderen. 
De mogelijk beschermende rol van groenten en fruit bij het ontstaan van 
blaaskanker is al jarenlang een punt van onderzoek en discussie. Een gangbare 
hypothese stelt dat groenten en fruit vele anti-carcinogene stoffen bevatten 
die verantwoordelijk zijn voor dit beschermend effect. Toch laten verschillende 
epidemiologische studies tegenstrijdige resultaten zien met betrekking tot 
een hoge inname van groenten en fruit in relatie tot het risico op blaaskanker. 
Een mogelijke verklaring hiervoor is dat blaaskanker ten onrechte vaak wordt 
beschouwd als één ziekte. Blaascarcinomen vormen namelijk een heterogene 
groep van tumoren met verschillende prognoses. De laaggradige, papillaire 
blaastumoren (niet-agressieve blaastumoren) worden gekarakteriseerd door 
mutaties in HRAS en FGFR3 oncogenen en door chromosoom 9 afwijkingen. 
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Hooggradige, solide spier-invasieve blaastumoren (agressieve blaastumoren) 
worden gekarakteriseerd door structurele en functionele defecten in TP53 en 
RB1 tumorsuppressorgenen. De relatie tussen de consumptie van groenten 
en fruit en het risico op blaaskanker kan mogelijk afhangen van de mate van 
agressiviteit van de blaascarcinomen. In hoofdstuk 3 is de relatie tussen de 
consumptie van groenten en fruit en het risico op agressieve en niet-agressieve 
vormen van blaaskanker in het EPIC cohort onderzocht.  In de 9 jaar na het 
begin van de studie zijn 947 patiënten gediagnosticeerd met blaaskanker. 
Van deze groep zijn 421 patiënten geclassificeerd met de agressieve vorm 
en 433 patiënten met de niet-agressieve vorm. Het eten van meer groenten 
en fruit blijkt niet gerelateerd aan het risico op de verschillende vormen van 
blaaskanker. Een hogere inname van groene bladgroenten en druiven hangt in 
ons onderzoek wel samen met een lagere kans op niet-agressieve blaaskanker 
(HR toename van 25 g/dag respectievelijk 0.88; 95% BI 0.78-1.00 en HR 0.87; 
95% BI: 0.77-0.97). De kans op agressieve blaaskanker wordt verlaagd bij een 
hogere inname van wortelachtige groenten (HR 0.87; 95% BI: 0.77-0.98). De 
mogelijk beschermende rol van de totale consumptie van groenten en fruit 
bij het ontstaan van verschillende vormen van blaaskanker wordt dus niet 
bevestigd in deze studie. De resultaten laten wel zien dat een toename van de 
consumptie van een aantal soorten groenten en fruit het risico op blaaskanker 
mogelijk kan verminderen. 
Het vastleggen van de inname van groenten en fruit met behulp van een 
voedselfrequentievragenlijst is de meest gebruikte methode in grote 
epidemiologische studies. De gebruikelijke inname van groenten en fruit is echter 
lastig te meten met een vragenlijst. Stoffen in het bloed die samenhangen met de 
voeding (biomerkers) worden gebruikt als indicatoren voor de voedingsinname 
of voedingsstatus, omdat deze niet gebaseerd zijn op zelfrapportage. In 
hoofdstuk 4, 5 en 6 van dit proefschrift wordt de relatie tussen bloedgehaltes 
van biomerkers die samenhangen met groenten en fruit (carotenoïden, vitamine 
C, retinol, tocoferolen en componenten van het koolstofmetabolisme) en het 
risico op blaaskanker onderzocht. Er is gebruik gemaakt van een patiënt-
controle studie, genest in het EPIC cohort. Een totaal van 856 patiënten 
gediagnosticeerd met blaaskanker (voor carotenoïden en vitamine C), 824 
(voor foliumzuur, homocysteïne, vitamine B6 en B12) en 848 (voor retinol en 
tocoferol) zijn 1 op 1 gekoppeld aan cohortdeelnemers zonder blaaskanker ten 
tijde van de vaststelling van de blaaskanker bij de patiënten (‘incidence density 
sampling’). Deze groepen zijn zoveel mogelijk gelijk wat betreft geslacht, leeftijd 
aan de start van de studie, deelnemend studiecentrum, datum en tijd van 
bloedafname en de status van vasten. Hoofdstuk 4 rapporteert de relatie tussen 
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plasmacarotenoïden en vitamine C en het ontstaan van blaaskanker. Een hogere 
concentratie in het bloedplasma van het totaal aan carotenoïden is gerelateerd 
aan een lager risico op blaaskanker (IRR hoogste versus laagste kwartiel 0.64; 
95% BI: 0.44-0.93). Een hogere waarde van plasma α-caroteen was geassocieerd 
met een lager risico op het krijgen van agressieve blaaskanker (IRR hoogste 
versus laagste kwartiel 0.51; 95% BI: 0.30-0.88), terwijl een hogere waarde 
van plasma luteïne het risico op niet-agressieve blaaskanker verlaagde (IRR 
hoogste versus laagste kwartiel 0.56; 95% BI: 0.32-0.98). Hoofdstuk 5 beschrijft 
de relatie tussen serumwaarden van foliumzuur, homocysteïne, vitamine B6 
en vitamine B12 en het risico op blaaskanker. Een lagere serumwaarde van 
foliumzuur verhoogde het risico op blaaskanker (IRR hoogste versus laagste 
kwartiel 1.37; 95% BI: 0.98-1.30) met name het risico op de agressieve vorm 
van blaaskanker (IRR 1.69; 95% BI: 1.04-2.74). In hoofdstuk 6 is de relatie 
tussen plasmawaarden van retinol en tocoferolen en het risico op blaaskanker 
beschreven. Een hogere waarde van plasma α-tocopherol was gerelateerd aan 
een grotere kans op blaaskanker (IRR hoogste versus laagste kwartiel 1.63; 95% 
BI 1.15-2.31), voornamelijk de agressieve vorm van blaaskanker (IRR 3.27; 95% 
BI 1.85-5.81). Er zijn in EPIC geen associaties gevonden tussen bloedwaarden 
van andere individuele carotenoïden (α-caroteen, α-cryptoxanthine, lycopeen 
and zeaxanthine), vitamine C, retinol, α-tocoferol, homocysteïne, vitamine B6, 
en vitamine B12 en het risico op blaaskanker.
In de meeste epidemiologische studies, inclusief onze eigen biomerkerstudies, 
wordt de voedingsstatus bepaald op basis van een eenmalige meting in het 
bloed. Bloedconcentraties van biomerkers kunnen in de tijd verschillen. Deze 
kunnen variëren van dag-tot-dag en over een langere termijn. Bij het gebruik 
van een enkele meting kan dit leiden tot een afzwakking van de gevonden 
associaties. Door het gebruik van herhaalde metingen wordt er rekening 
gehouden met veranderingen in de tijd. In hoofdstuk 7 wordt de stabiliteit van 
herhaalde metingen van bloedconcentraties van de geselecteerde biomarkers 
(hoofdstuk 4-6) geëvalueerd bij een deel van de Nederlandse deelnemers van 
het EPIC cohort (EPIC-NL). Bloedmonsters zijn aan het begin van de studie en 
na 2 tot 5 jaar verzameld. De stabiliteit van de biomerkers is uitgedrukt in een 
‘intraclass correlation coefficient’ (ICC). De resultaten van dit onderzoek laten 
zien dat serumwaarden van homocysteïne en vitamine B12 stabiele biomerkers 
zijn over de tijd (ICC = 0.91 en 0.75, respectievelijk). De andere geanalyseerde 
biomerkers waren minder stabiel over de verschillende jaren, de ICCs variëren 
van 0.17 tot 0.56. De resultaten duiden erop dat een eenmalige meting de 
inname en lichaamsvoorraden van deze biomerkers op langere termijn niet 
goed representeert. Bovendien vermindert de stabiliteit van deze biomerkers 
bij een langere tijd tussen de metingen. 
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De inname van vocht beïnvloedt mogelijk ook het risico op blaaskanker. Eerdere 
studies vonden echter geen consistent bewijs voor deze hypothese. Daarom is 
in hoofdstuk 8 het verband tussen vochtinname en het ontstaan van blaaskanker 
onderzocht. Voor dit onderzoek is gebruik gemaakt van deelnemers uit het EPIC 
cohort voor wie informatie over water- en totaal vochtinname bekend is (n = 
233,236). In de studie werden na 9 jaar 513 patiënten gediagnosticeerd met 
blaaskanker. Een hogere totale vochtinname was niet gerelateerd aan het risico 
op blaaskanker (HR hoogste versus laagste tertiel 1.12; 95% BI 0.86-1.45). Ook 
werden er geen associaties gevonden tussen het risico op blaaskanker en de 
inname van water, koffie, (kruiden)thee, melk en andere zuiveldranken. 
Naast voedingsfactoren wordt ook het gebruik van haarverf in verband gebracht 
met blaaskanker. Eerder uitgevoerde studies suggereren een verhoogd risico 
op blaaskanker bij kappers die beroepsmatig blootgesteld zijn aan haarverf. Er 
heerst ook bezorgdheid over een mogelijk verhoogd risico op blaaskanker bij 
gebruikers van haarverf. In hoofdstuk 9 is de relatie tussen persoonlijk gebruik 
van haarverf en het ontstaan van blaaskanker gerapporteerd. Dit is onderzocht 
in de NBCS, een patiënt-controle onderzoek waaraan 1,385 blaaskanker 
patiënten (n=246 vrouwen) en 4,754 controle deelnemers (n=2,587 vrouwen) 
hebben deelgenomen. De analyses zijn beperkt tot vrouwen omdat in deze 
studie het percentage mannen die ooit haarverf gebruikt hebben minder dan 5% 
was. Het gebruik van kleurspoeling (OR 0.77; 95% BI 0.58-1.02) en het gebruik 
van haarverf (OR 0.87; 95% BI 0.65-1.18) is niet gerelateerd aan het risico op 
blaaskanker. Verschillende types haarverf, intensiteit van de blootstelling aan 
haarverf of de kleur van de haarverf hadden geen invloed op deze associaties. 
Met deze studie hebben wij niet kunnen aantonen dat het gebruik van haarverf 
de kans op blaaskanker verhoogt.
In hoofdstuk 10 worden de belangrijkste bevindingen van dit proefschrift 
besproken. Daarnaast worden de resultaten in een breder perspectief geplaatst 
en worden suggesties voor verder onderzoek gedaan. Samenvattend kan 
gesteld worden dat deze grote prospectieve studie geen overtuigend bewijs 
levert voor een beschermend effect van het totaal aan zelf-gerapporteerde 
consumptie van groenten en fruit op het ontstaan van blaaskanker. Mogelijk 
spelen specifieke soorten groenten wel een rol. Ook suggereren deze studies 
een etiologische rol van een aantal stoffen in het bloed waarvan de concentratie 
ten dele samenhangt met het eten van groenten en fruit bij het ontstaan van 
blaaskanker. 
Mogelijkheden voor vervolgonderzoek zijn het bestuderen van de impact van 
herhaalde metingen van voeding en bloedwaardes, en van verandering van 
voedingsinname en leefstijlfactoren op het risico van blaaskanker. Bij nader 
onderzoek naar de rol van foliumzuur in de etiologie van blaaskanker is het 
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van belang om specifieke erfelijke variaties in genen die betrokken zijn bij 
de omzetting van foliumzuur in de analyses mee te nemen om de causaliteit 
van gevonden associaties te versterken. In aanvulling op het onderzoek 
naar de rol van individuele voedingsmiddelen en nutriënten is het relevant 
om voedingspatronen te analyseren om mogelijk ‘gezonde’ eetpatronen te 
identificeren. Tot nu toe richten de meeste studies zich op voedings- en 
leefstijlveranderingen bij het ontstaan van blaaskanker. Gezien de verwachte 
toename van het aantal patienten gediagnosticeerd met blaaskanker en van 
hen die de ziekte hebben overleeft is het van belang tevens onderzoek te 
doen naar het verband tussen eetgewoontes en het risico op het terugkeren 
en/of progressie van blaaskanker. Primaire preventie door leefstijl- en 
omgevingsinterventies blijft de beste manier om de incidentie van kanker 
wereldwijd te verminderen. Daarom is noodzakelijk dat de communicatie over 
de onderzoeksresultaten effectiever en gerichter wordt zodat het publiek zich 
bewust wordt van het feit dat een gezonde leefstijl kan helpen de kans op 
kanker aanzienlijk kan verminderen. 
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Mijn familie en vrienden wil ik bedanken voor alle belangstelling. Lieve Agnetha 
en Annemarie, bedankt voor jullie interesse, steun en gezelligheid. Ik hoop weer 
vaker bij onze theeavondjes aanwezig te zijn! 
Verder dank aan Oom Mart, Sander en Anja. Fijn dat ik vorig jaar in alle rust (en 
met goede koffie) een tijdje bij jullie op kantoor heb kunnen werken aan mijn 
proefschrift. 
Tenslotte dank aan mijn ouders en broer. Vol trots heb ik altijd gekeken hoe 
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